,PageNo,Text
0,page_0,"Cli nic al Tri al Pr ot oc ol TI T L E P A G E D oc u me nt N u m ber: c 1 9 5 5 8 8 0 8 - 0 6 E u dr a C T N o.: E U Tri al N o: N ot a p plica ble. BI Tri al N o.: 1 1 9 9- 0 3 2 4 BI I n vesti g ati o n al Pr o d uct(s): Ni nte da ni b Title: St u d y of P ul m o nar y Re ha bilitati o n I n Ni nte da ni b Treate d Patie nts wit h I P F: I m pr o ve me nts i n Acti vit y , E xercise E n d ura nce Ti me, a n d Q o L L a y Title: St u d y of p ul m o nar y re ha bilitati o n i n patie nts wit h I di o pat hic P ul m o nar y Fi br osis (I P F) Cli nic al P h ase: I V Cli nic al Tri al Le a der : C o or di n ati n g I n vesti g at or: St at us: Fi nal Pr ot oc ol ( Re vise d Pr ot oc ol base d o n Gl o bal A me n d me nt 2) Versi o n a n d D ate: Versi o n: 3. 0 D ate: 1 6 Dec 2 0 1 9 P a ge 1of 1 0 3 Pr o priet ar y c o nfi de nti al i nf or m ati o n . 2 0 1 9 B oe hri n ger I n gel hei m I nter n ati o n al G m b H or o ne or m ore of its affili ate d c o m p a nies. All ri g hts reser ve d. T his d oc u me nt ma y n ot -i n f ull or i n part -be passe d o n, re pr o d uce d, p u blis he d or ot her wise use d wit h o ut pri or writte n per missi o n."
1,page_1,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 C LI NI C A L T RI A L P R O T O C O L S Y N O P SI S C o m p a n y n a me B oe hri n ger I n gel hei m Fi nis he d pr o d uct n a me O F E V Acti ve i n gre die nt n a m e: Ni nte da ni b Pr ot oc ol d ate 1 5 A u g 2 0 1 8 Re visi o n d ate 1 6 Dec 2 0 1 9 Tri al n u m ber 1 1 9 9- 0 3 2 4 Title of tri al: St u d y of P ul m o nar y Re ha bilitati o n I n Ni nte da ni b Treate d Patie nts wit h I P F: I m pr o ve me nts i n Acti vit y , E xercise E n d ura nce Ti me, a n d Q o L C o or di n ati n g I n vesti g at or: Tri al site(s): M ultice nter Cli nic al p h ase: I V O bjecti ve(s): Deter mi ne t he differe nce i n c ha n ge fr o m baseli ne i n 6 M W D w he n p ul m o nar y re ha bilitati o n ( P R) is a d de d t o sta ble u n derl y i n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) Deter mi ne t he differe nce i n c ha n ge i n Q ualit y of Life ( Q o L )w he n p ul m o nar y re ha bilitati o n ( P R) is a d de d t o sta ble u n derl y i n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) Deter mi ne if t here is a n e n d uri n g effect i n 6 M W D, Q o L a n d l u n g f u ncti o n fr o m p ul m o nar y re ha bilitati o n ( P R) w he n p ul m o nar y re ha bilitati o n ( P R) is a d de d t o sta ble u n derl yi n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) M e t h o d ol o g y: Multi -ce ntre, pr os pecti ve, ra n d o mise d, o pe n la bel cli nical trial N u m ber of p atie nts e ntere d: 2 9 0 ( 9 6 s u b -st u d y ) N u m ber of p atie nts o n e ac h tre at m e nt: 1 4 5 ( 4 8 s u b -st u d y ) Di a g n osis: I di o pat hic P ul m o nar y Fi br osis (I P F) acc or di n g t o A merica n T h oracic S ociet y ( A T S), E ur o pea n Res pirat or y S ociet y ( E R S), Ja pa nese Res pirat or y S ociet y (J R S), a n d Lati n A merica n T h oracic Ass ociati o n ( A L A T) criteria p u blis he d i n 2 0 1 1, c o nsiste nt wit h I N P U L SI S criteria I n cl usi o n M ai n i n -a n d e xcl usi o n criteri a A ge ≥ 4 0 y ears. F orce d Vital Ca pacit y ( F V C) ≥ 4 5 %of pre dicte d"
2,page_2,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 F E V 1/ F V C greater t ha n/e q ual t o . 7 a n d Car b o n M o n o xi de Diff usi o n Ca pacit y ( D L C O ) (c orrecte d f or he m o gl o bi n [ H g b]) 3 0 -7 9 % of pre dicte d C o nfir me d dia g n osis of I P F acc or di n g t o 2 0 1 1 A T S/ E R S/J R S/ A L A T g ui deli nes b y Hi g h Res ol uti o n C o m p ute d T o m o gra p h y ( H R C T )(c o nsiste nt wit h I N P U L SI S criteria) or l u n g bi o ps y ta ke n wit hi n 2 4 m o nt hs pri or t o pr o vi di n g I n f or me d C o nse nt Treate d o n a st a ble d ose of ni nte da ni b f or u p t o 3 0 m o nt hs . Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m ust be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. E xcl usi o n Maj or s ur ger y wit hi n 1 2 wee ks pri or t o ra n d o mizati o n or pla n ne d wit hi n 6 m o nt hs after scree ni n g w hic h c o ul d i nterfere wit h t he a bilit y t o partici pate i n p ul m o nar y re ha bilitati o n Acti ve or s us pecte d mali g na nc y or hist or y of mali g na nc y wit hi n 3 y ears pri or t o scree ni n g C urre ntl y e nr olle d i n or less t ha n 3 0 da y s si nce e n di n g a n ot her i nter ve nti o nal i n vesti gati o nal de vice or dr u g trial W o me n w h o are pre g na nt, n ursi n g, or w h o pla n t o bec o me pre g na nt i n t he trial Pre vi o us partici pati o n i n p ul m o nar y re ha bilita ti o n pr o gra m wit hi n 4 5 da y s pri or t o si g ni n g i nf or me d c o nse nt Test pr o d uct(s): ni nte da ni b d ose: 1 5 0 m g BI D m o de of a d mi nistr ati o n: oral C o m p ar at or pr o d ucts: N o ne d ose: N A m o de of a d mi nistr ati o n: N A D ur ati o n of tre at m e nt: 2 4 wee ks E n d p oi nts Pri m ar y E n d p oi nt oC ha n ge fr o m baseli ne i n 6 M W D at 1 2 wee ks Sec o n d ar y E n dp oi nts oC ha n ge fr o m baseli ne i n Q o L ( S G R Q, K BI L D, U C S D S O B Q) at 1 2 a n d 2 4 wee ks oC ha n ge fr o m baseli ne i n 6 M W D at 2 4 wee ks oC ha n ge fr o m baseli ne i n l u n g f u ncti o n ( F V C) at 1 2 wee ks a n d 2 4 wee ks usi n g eac h of"
3,page_3,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 •A bs ol ute c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d •Relati ve c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d •A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decrease b y > 5 %, i ncrease b y > 5 % , a n d c ha n ge wit hi n ≤ 5 •A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decrease b y > 1 0, i ncrease b y > 1 0, a n d c ha n ge wit hi n ≤ 1 0 oC ha n ge fr o m baseli ne i n dail y acceler o meter acti vit y fr o m baseli ne at 1 2 a n d 2 4 wee ks S afet y criteri a: Vital si g ns, p h ys ical e xa mi nati o n, wei g ht Cli nical la b orat or y tests ( h ae mat ol o g y , cli nical c he mistr y , a n d uri nal ys is) Re p orti n g of a d verse e ve nts 1 2 lea d electr ocar di o gra m St atistic al m et h o ds: T he pri mar y ( 6 M W D at 1 2 wee ks) will be a nal ys e d usi n g t he A nal y sis of C o varia nce m o del i ncl u di n g i nter ve nti o n as a fi xe d cate g orical c o variate a n d baseli ne 6 M W D as c o nti n u o us c o variate 6 M W D will be a nal y se d o n t he ori gi nal scale. all ot her assess me nts will be a nal y se d usi n g ori gi nal scales."
4,page_4,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 F or sec o n dar y e n d p oi nts, 1 2- wee k e n d p oi nts will be a nal ys e d usi n g si milar A N C O V A met h o d ol o g y as t he pri mar y e n d p oi nt. T he 2 4 -wee k e n d p oi nts will be a nal y ze d usi n g a mi xe d m o del wit h re peate d meas ures. Descri pti ve statistics will be s h o w n f or all efficac y a n d safet y e n d p oi nts ."
5,page_5,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 F L O W C H A R T *I nf or me d c o nse nt nee ds t o be si g ne d bef ore a n y pr oce d ure relate d t o t he st u d y ,all A Es a n d C o nc o mita nt Treat me nts occ urri n g after t he I nf or me d c o nse nt ha ve t o be rec or de d. 1H R C T will be acce pta ble if d o ne wit hi n 2 4 m o nt hs, if n ot a vaila ble patie nt will be se nt f or H R C T bet wee n Visit 1 a n d 2, or wit hi n 7 da ys of c o m pleti n g Visit 2. 2Patie nts will wear t he p h ysical acti vit y m o nit or a n d c o m plete t he e Diar y ( P R Oacti ve T o ol ) 2 4 h o urs e ver y d a y f or 1 wee k pri or t o Visits 1, 2, 5 a n d 7 . De vices will be dis pe nse d i n cli nic at Visits 0 a n d 1, a n d will be s hi p pe d t o patie nt or pic ke d u p fr o m cli nic at least 1 wee k pri or t o Visits 5 a n d 7. 3 e xercise testi n g ce nter. T he i ncre me ntal a n d practice tests ca n b ot h be d o ne at Visit 1. 5Access I R T t o ter mi nate if scree n fail at Visit 1 or bet wee n Visit 0 a n d Visit 1 .Scree ni n g I nter ve nti o n al Peri o d Tre at me nt Visit 0 1 2 3 4 5 6 7 ( E O T) Wee ks of tre at me nt - 2 - 1 0 3 6 1 2 1 8 2 4 6 D a y Ti m e wi n d o w At least 7 da ys bef ore visit 1 ≥ 7 d bef ore V 2 1 2 2 ± 3 4 3 ± 3 8 5 ± 3 1 2 7 ± 3 1 6 9 ± 7 I nf or me d c o nse nt X * De m o gra p hics/ baseli ne c o n diti o ns X Me dical hist or y X I n -/e xcl usi o n criteria X X X P h ysical e xa mi nati o n 7, vital si g ns X X X X X X X La b orat or y test X X X X X X X Pre g na nc y test X X X X X X X S pir o metr y ( F V C) X X X X S p O 2( peri p heral ca pillar y o x y ge n sat urati o n) X X X X D L C O X X X X H R C T se nt f or o utc o mes re vie w 1X1X1 1 2 -lea d electr ocar di o gra m ( E C G ) X X ( Practice) Si x -mi n ute wal k test X Si x mi n ute wal k test X X X I nstr uct Patie nt o n Acti vit y M o nit ori n g a n d P R Oacti ve t o ol ( e Diar y )2X X X X X Acti vit y M o nit ori n g ( D y na p ort) X X X X X S G R Q, K BI L D , U C S D S O B Q X X X X P R Oacti ve T o ol 2, 3 X X X X X Ra n d o misati o n X Sc he d ule p ul m o nar y re ha b da ys f or assi g ne d patie nts 6X Rec or d p ul m o nar y re ha b X X X IR T X X5X A d verse e ve nts , c o nc o mita nt treat me nts X X X X X X X C o ncl u de s u bject partici pati o n X"
6,page_6,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6Ti me bet wee n visits 2 a n d 3 ma y be e xte n de d f or u p t o 6wee ks t o all o w sc he d uli n g of t he o nset of p ul m o nar y re ha bilitati o n, t he treat me nt peri o d will be gi n o n t he first da y of p ul m o nar y re ha bilitati o n a n d all visits m o ve acc or di n gl y t o kee p t he sa me visit sc he d ule. 7Hei g ht a n d wei g ht t o be c ollecte d at Visit 1 o nl y ."
7,page_7,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T A B L E O F C O N T E N T S TI T L E P A G E ................................ ................................ ........................................................... 1 C LI NI C A L T RI A L P R O T O C O L S Y N O P SI S ................................ ..................................... 2 F L O W C H A R T ................................ ................................ ........................................................ 6 T A B L E O F C O N T E N T S ................................ ................................ ........................................ 8 A B B R E VI A TI O N S ................................ ................................ ................................................ 1 2 1. I N T R O D U C TI O N ................................ ............................................................... 1 5 1. 1 M E DI C A L B A C K G R O U N D ................................ ............................................. 1 5 1. 2 D R U G P R O FI L E ................................ ................................ ................................ 1 5 1. 3 R A TI O N A L E F O R P E R F O R MI N G T H E T RI A L ......................................... 1 5 1. 4 B E N E FI T - RI S K A S S E S S M E N T ................................ ..................................... 1 6 2. T RI A L O B J E C TI V E S A N D E N D P OI N T S ...................................................... 1 7 2. 1 M AI N O B J E C TI V E S, P RI M A R Y A N D S E C O N D A R Y E N D P OI N T S ........ 1 7 2. 1. 1 M ai n o bjecti ves ................................ ................................ .................................... 1 7 2. 1. 2 Pri m ar y e n d p oi nt(s)............................................................................................ 1 7 2. 1. 3 Sec o n d ar y e n d p oi nt(s) ................................ ........................................................ 1 7 3. D E S C RI P TI O N O F D E SI G N A N D T RI A L P O P U L A TI O N ......................... 1 9 3. 1 O V E R A L L T RI A L D E SI G N A N D P L A N ....................................................... 1 9 3. 2 DI S C U S SI O N O F T RI A L D E SI G N, I N C L U DI N G T H E C H OI C E O F C O N T R O L G R O U P( S) ................................ ...................................................... 1 9 3. 3 S E L E C TI O N O F T RI A L P O P U L A TI O N ....................................................... 1 9 3. 3. 1 M ai n di a g n osis f or tri al e ntr y ................................ ............................................ 2 0 3. 3. 2 I ncl usi o n criteri a................................................................................................. 2 0 3. 3. 3 E xcl usi o n criteri a ................................ ................................ ................................ 2 1 3. 3. 4 Wit h dr a w al of p atie nts fr o m t her a p y or assess me nts..................................... 2 1 3. 3. 4. 1 Wit h dra wal fr o m trial treat me nt ................................ ........................................... 2 2 3. 3. 4. 2 Wit h dra wal of c o nse nt f or trial partici pati o n ........................................................ 2 2 3. 3. 4. 3 Disc o nti n uati o n of t he trial b y t he s p o ns or ........................................................... 2 2 4. T R E A T M E N T S ................................ ................................ ................................... 2 4 4. 1 I N V E S TI G A TI O N A L T R E A T M E N T S ........................................................... 2 4 4. 1. 1 I de ntit y of t he i n vesti g ati o n al me dici n al pr o d ucts........................................... 2 4 4. 1. 2 Selecti o n of d oses i n t he tri al ................................ .............................................. 2 4 4. 1. 3 Met h o d of assi g ni n g p atie nts t o tre at me nt gr o u ps ........................................... 2 4 4. 1. 4 Dr u g assi g n me nt a n d a d mi nistr ati o n of d oses f or e ac h p atie nt...................... 2 4 4. 1. 5 Bli n di n g a n d pr oce d ures f or u n bli n di n g ........................................................... 2 5 4. 1. 5. 1 Bli n di n g................................................................................................................. 2 5 4. 1. 5. 2 U n bli n di n g a n d brea ki n g t he c o de ................................ ........................................ 2 5 4. 1. 6 P ac k a gi n g, l a belli n g, a n d re- s u p pl y ................................ ................................... 2 5"
8,page_8,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 4. 2 O T H E R T R E A T M E N T S, E M E R G E N C Y P R O C E D U R E S, R E S T RI C TI O N S ................................ ................................ ................................ 2 5 4. 2. 1 Ot her tre at me nts a n d e mer ge nc y pr o ce d ures .................................................. 2 5 4. 2. 1. 1 Ma na ge me nt of a d verse e ve nts relate d t o ni nte da ni b ........................................... 2 5 4. 2. 1. 2 Ma na ge me nt of ot her a d verse e ve nts ................................ .................................... 2 5 4. 2. 2 Restricti o ns.......................................................................................................... 2 5 4. 2. 2. 1 Restricti o ns o n c o nc o mita nt treat me nt ................................ .................................. 2 5 4. 2. 2. 2 C o nc o mita nt treat me nts all o we d ................................ ........................................... 2 6 4. 2. 2. 3 Restricti o ns o n diet a n d life st y le ................................ .......................................... 2 6 4. 2. 2. 4 Restricti o ns re g ar di n g w o me n of c hil d beari n g p ote ntial ...................................... 2 7 4. 3 T R E A T M E N T C O M P LI A N C E ................................ ........................................ 2 7 5. A S S E S S M E N T S ................................ ................................ .................................. 2 8 5. 1 A S S E S S M E N T O F E F FI C A C Y ................................ ........................................ 2 8 5. 1. 1 E n d p oi nts of effic ac y........................................................................................... 2 8 5. 1. 1. 1 Pri mar y e n d p oi nt ................................ ................................ ................................... 2 8 5. 1. 1. 2 Sec o n dar y e n d p oi nts ................................ ............................................................. 2 8 5. 1. 2 Assess me nt of effic ac y ................................ ......................................................... 2 9 5. 1. 2. 1 6 Mi n ute wal k test ................................ ................................ ................................. 2 9 5. 1. 2. 2 C ha n ge i n q ualit y of life ................................ ........................................................ 2 9 5. 1. 2. 3 Assess me nt of l u n g f u ncti o n ................................ ................................................. 2 9 5. 1. 2. 4 Dail y acti vit y m o nit ori n g ................................ ...................................................... 3 0 5. 1. 2. 6 P R Oacti ve t o ol...................................................................................................... 3 1 5. 2 A S S E S S M E N T O F S A F E T Y ................................ ............................................. 3 1 5. 2. 1 P h ysic al e x a mi n ati o n ................................ .......................................................... 3 1 5. 2. 2 Vit al si g ns ................................ ................................ ............................................. 3 1 5. 2. 3 S afet y l a b or at or y p ar a meters ................................ ............................................ 3 2 5. 2. 4 Electr oc ar di o gr a m ................................ .............................................................. 3 3 5. 2. 5 Ot her s afet y p ar a meters..................................................................................... 3 3 5. 2. 6 Assess me nt of a d verse e ve nts ................................ ............................................. 3 3 5. 2. 6. 1 Defi niti o ns of A Es ................................ ................................ ................................ 3 3 5. 2. 6. 2 A d verse e ve nt a n d seri o us a d verse e ve nt c ollecti o n a n d re p orti n g ...................... 3 5 5. 2. 6. 3 Re p orti n g t o healt h a ut h orities ................................ .............................................. 3 7 5. 3 D R U G C O N C E N T R A TI O N M E A S U R E M E N T S A N D P H A R M A C O KI N E TI C S ................................ ................................................... 3 7 5. 3. 1 Assess me nt of p h ar m ac o ki netics ................................ ....................................... 3 7 5. 3. 2 Met h o ds of s a m ple c ollecti o n ................................ ............................................. 3 7 5. 3. 3 A n al ytic al deter mi n ati o ns ................................ .................................................. 3 7 5. 3. 4 P h ar m ac o ki netic –p h ar m ac o d y n a mic rel ati o ns hi p ........................................ 3 7 5. 4 A S S E S S M E N T O F BI O M A R K E R( S) .............................................................. 3 7 5. 5 O T H E R A S S E S S M E N T S ................................ ................................................... 3 8 5. 6 A P P R O P RI A T E N E S S O F M E A S U R E M E N T S .............................................. 3 8 6. I N V E S TI G A TI O N A L P L A N ................................ ............................................. 3 9 6. 1 VI SI T S C H E D U L E ................................ ............................................................. 3 9"
9,page_9,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6. 2 D E T AI L S O F T RI A L P R O C E D U R E S A T S E L E C T E D VI SI T S ................. 4 0 6. 2. 1 Scree ni n g a n d r u n -i n peri o d(s) ................................ .......................................... 4 0 6. 2. 2 Tre at me nt peri o d(s) ................................ ............................................................ 4 1 6. 2. 3 F oll o w u p peri o d a n d tri al c o m pleti o n .............................................................. 4 2 7. S T A TI S TI C A L M E T H O D S A N D D E T E R MI N A TI O N O F S A M P L E SI Z E ................................ ................................ .................................... 4 4 7. 1 S T A TI S TI C A L D E SI G N - M O D E L ................................ ................................. 4 4 7. 2 N U L L A N D A L T E R N A TI V E H Y P O T H E S E S ............................................... 4 4 7. 3 P L A N N E D A N A L Y S E S ................................ ..................................................... 4 4 7. 3. 1 Pri m ar y e n d p oi nt a n al yses ................................ ................................................. 4 5 7. 3. 2 Sec o n d ar y e n d p oi nt a n al yses ................................ ............................................. 4 5 7. 3. 4 S afet y a n al yses ................................ ................................ ..................................... 4 7 7. 3. 5 P h ar m ac o ki netic a n d P h ar m ac o d y n a mic a n al yses.......................................... 4 7 7. 4 I N T E RI M A N A L Y S E S...................................................................................... 4 7 7. 5 H A N D LI N G O F MI S SI N G D A T A ................................ ................................... 4 8 7. 6 R A N D O MI S A TI O N ................................ ........................................................... 4 8 7. 7 D E T E R MI N A TI O N O F S A M P L E SI Z E ......................................................... 4 8 8. I N F O R M E D C O N S E N T, T R I A L R E C O R D S, D A T A P R O T E C TI O N, P U B LI C A TI O N P O LI C Y, A N D A D MI NI S T R A TI V E S T R U C T U R E ........ 4 9 8. 1 T RI A L A P P R O V A L, P A TI E N T I N F O R M A TI O N, I N F O R M E D C O N S E N T ................................ ................................ ........................................... 4 9 8. 2 D A T A Q U A LI T Y A S S U R A N C E ................................ ...................................... 5 0 8. 3 R E C O R D S ................................ ................................ ........................................... 5 0 8. 3. 1 S o urce d oc u me nts ................................ ............................................................... 5 0 8. 3. 2 Direct access t o s o urce d at a a n d d oc u me nts..................................................... 5 1 8. 3. 3 St or a ge peri o d of rec or ds................................................................................... 5 2 8. 4 E X P E DI T E D R E P O R TI N G O F A D V E R S E E V E N T S .................................. 5 2 8. 5 S T A T E M E N T O F C O N FI D E N TI A LI T Y A N D P A TI E N T P RI V A C Y ........ 5 2 8. 5. 1 C ollecti o n, st or a ge a n d f ut ure use of bi ol o gic al s a m ples a n d c orres p o n di n g d at a ................................ ............................................................. 5 2 8. 6 T RI A L MI L E S T O N E S ................................ ....................................................... 5 3 8. 7 A D MI NI S T R A TI V E S T R U C T U R E O F T H E T RI A L................................... 5 3 9. R E F E R E N C E S ................................ ................................ .................................... 5 5 9. 1 P U B LI S H E D R E F E R E N C E S ................................ ............................................ 5 5 9. 2 U N P U B LI S H E D R E F E R E N C E S ................................ ...................................... 5 6 1 0. A P P E N DI C E S ................................ ................................ ..................................... 5 7 1 0. 1 E X E R CI S E T E S TI N G I N C L U DI N G 6 MI N U T E W A L K T E S T A N D W O R K C Y C L E E R G O M E T R Y ................................ ....................................... 5 7 1 0. 1. 1 Ge ner al c o nsi de r ati o ns f or 6 M W T a n d e xercise testi n g ................................. 5 7 1 0. 1. 2 Si x -mi n ute w al k test ................................ ............................................................ 5 9"
10,page_10,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 2 M O DI FI E D B O R G S C A L E ( M B S -S) ............................................................... 6 7 1 0. 3 S T. G E O R G E’ S R E S PI R A T O R Y Q U E S TI O N N AI R E ( S G R Q) ................... 6 8 1 0. 4 E L E C T R O NI C DI A R Y WI T H D AI L Y P R O A C TI V E T O O L ...................... 7 7 1 0. 4. 1 T he P R O acti ve T o ol ................................ ............................................................ 7 7 1 0. 4. 2 Electr o nic Di ar y –P R O acti ve Q uesti o n n aire................................................... 7 9 1 0. 5 K BI L D ................................ ................................ .................................................. 8 1 1 0. 6 U C S D M E DI C A L C E N T E R P U L M O N A R Y R E H A BI LI T A TI O N P R O G R A M S H O R T N E S S -O F -B R E A T H Q U E S TI O N N AI R E ( U C S D - S O B Q) ................................ ................................ .................................................. 8 4 1 0. 7 L U N G F U N C TI O N C RI T E R I A ................................ ........................................ 8 9 1 1. D E S C RI P TI O N O F G L O B A L A M E N D M E N T( S) ......................................... 9 0 1 1. 1 G L O B A L A M E N D M E N T 1 ................................ .............................................. 9 0 1 1. 2 G L O B A L A M E N D M E N T 2 ................................ .............................................. 9 8
11,page_11,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 A B B R E VI A TI O N S A D R(s) A d verse Dr u g Reacti o n(s) A E A d verse E ve nt A E SI A d verse E ve nt of S pecial I nterest A L A T Lati n A merica n T h oracic Ass ociati o n A L T Ala ni ne A mi n otra nsferase A N C O V A A nal y sis of C o varia nce A S T As partate A mi n otra nsferase A T P A de n osi ne Tri p h os p hate A T S A merica n T h oracic S ociet y b.i. d. / BI D bis i n die (t wice dail y d osi n g) ß H C G Beta H u ma n C h ori o nic G o na d otr o p hi n C A C o m pete nt A ut h orit y C O P D C hr o nic O bstr ucti ve P ul m o nar y Disease C R A Cli nical Researc h Ass ociate C R F Case Re p ort F or m, pa per or electr o nic (s o meti mes referre d t o as “e C R F”) C T C A E C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts C T L Cli nical Trial L ea der C T M Cli nical Trial Ma na ger C W R C E C o nsta nt W or k Rate C y cle Er g o metr y DI LI Dr u g I n d uce d Li ver I nj ur y D Lc o Car b o n M o n o xi de Diff usi o n Ca pacit y D O M S Dela y e d O nset M uscle S ore ness D-P P A C Dail y Assess me nt of P h ysical Acti vit y d/t Vel ocit y ( dista nce/ti me) E C G Electr ocar di o gra m E D C /e D C Electr o nic Data Ca pt ure e Diar y Electr o nic Diar y / Electr o nic I nterface E E L V E n d -E x pirat or y L u n g V ol u me E O T E n d of Treat me nt E R S E ur o pea n Res pirat or y S ociet y E u dra C T E ur o pea n Cli nical Trial s Data base f Breat hi n g Fre q ue nc y F C Fl o w C hart F D A F o o d a n d Dr u g A d mi nistrati o n F G F/ R Fi br o blast Gr o wt h Fact or/ Rece pt or F L T 3 F ms -li ke T y r osi ne Ki nase - 3 F V C F orce d Vital Ca pacit y G C P G o o d Cli nical Practice H g b He m o gl o bi n H R Heart Rate H R Q o L Healt h Relate d Q ualit y of L ife H R C T Hi g h Res ol uti o n C o m p ute d T o m o gra p h y I C I ns pirat or y Ca pacit y"
12,page_12,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 I C H I nter nati o nal C o u ncil o n Har m o nizati o n I E C I n de pe n de nt Et hics C o m mittee I L D I nterstitial L u n g Disease I P F I d io pat hic P ul m o nar y Fi br osis I R B I nstit uti o nal Re vie w B oar d I R T I nteracti ve Res p o nse Tec h n ol o g y I S F I n vesti gat or Site File J R S Ja pa nese Res pirat or y S ociet y K BI L D Ki n g’s Brief I L D Q uesti o n naire L D H Lactic Aci d De h y dr o ge nase L P D D Last Patie nt Dr u g Disc o nti n uati o n M A H Mar keti n g A ut h orizati o n H ol der Me d D R A Me dical Dicti o nar y f or Dr u g Re g ulat or y Acti vities N A C N- Acet y l C ys ti ne n R T Ks N o n -rece pt or T y r osi ne Ki nases O P U O perati n g U nit P D G F/ R Platelet Deri ve d Gr o wt h Fact or/ Rece pt or P R P ul m o nar y Re ha bilitati o n Q L F Q ua ntitati ve L u n g Fi br osis Sc ore Q o L Q ualit y of Life R E M L Restricte d Ma xi m u m L i keli h o o d 2 R S Ra n d o mize d Set R T Ks Rece pt or T yr osi ne Ki nases S A D R(s) Seri o us A d verse Dr u g Reacti o n(s) S A E Seri o us A d verse E ve nt Sa O 2 O x y ge n Sat urati o n S D Sta n dar d De viati o n S O P(s) Sta n dar d O perati n g Pr oce d ure(s) S P 0 2 Bl o o d O x y ge n Sat urati o n or peri p heral ca pillar y o x y ge n sat urati o n Te E x pirati o n Ti me Ti I ns pirati o n Ti me T L C T otal L u n g Ca pacit y T S A P Trial Statistical A nal y sis Pla n U C S D S O B Q U ni versit y of Calif or nia Sa n Die g o S h ort ness of Breat h Q uesti o n naire U L N U p per Li mit of N or mal U S U nite d States V E Mi n ute Ve ntilati o n V E G F/ R Vasc ular E n d ot helial Gr o wt h Fact or/ Rece pt or V C O 2 Car b o n Di o xi de Pr o d ucti o n V M U Vect or Ma g nit u de U nits per Mi n ute V O 2 O x y ge n C o ns u m pti o n VT Ti dal V ol u me Wca p Ma xi mal W or k Ca pacit y W H O W orl d Healt h Or ga nizati o n W O C B P W o m a n of c hil d beari n g p ote ntial 6 M W D Si x Mi n ute Wal k Dista nce
13,page_13,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6 M W T Si x Mi n ute Wal k Test
14,page_14,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1. I N T R O D U C TI O N 1. 1 M E DI C A L B A C K G R O U N D I di o pat hic P ul m o nar y Fi br osis (I P F) is a c hr o nic disease of u n k n o w n aeti ol o g y t hat is c haracterize d b y pr o gressi ve fi br otic destr ucti o n of t he l u n g, res ulti n g i n disa bli n g d ys p nea a n d p o or gas e xc ha n ge. T he a vera ge life e x pecta nc y i n I P F patie nts is 3 -5 y ears ( U 0 7 - 1 2 4 8- 0 7 ). Ni nte da ni b ( O F E V) is a s mall m olec ule a nti -fi br otic ki nase i n hi bit or ( P D G F/ R [ platelet deri ve d gr o wt h fact or/rece pt or], F G F/ R [fi br o blast gr o wt h fact o r/rece pt or], V E G F/ R [ vasc ular e n d ot helial gr o wt h fact or/rece pt or]) t hat has bee n de vel o pe d f or t he trea t me nt of I P F. T he oretical a n d p har mac ol o gical m o dels s u g gest t hat i n hi biti o n of t hese ki nase rece pt ors ma y i nterfere wit h t he fi br otic si g nali n g casca de. O F E V was a p pr o ve d as a treat me nt f or I P F i n 2 0 1 4. 1. 2 D R U G P R O FI L E Ni nte da ni b is a s mall m olec ule t hat i n hi bits m ulti ple rece pt or t yr osi ne ki nases ( R T Ks) a n d n o n- rece pt or t yr osi ne ki nases ( n R T Ks). Ni nte da ni b i n hi bits t he f oll o wi n g R T Ks: platelet - deri ve d gr o wt h fact or rece pt or ( P D G F R) a n d fi br o blast gr o wt h fact or rece pt or ( F G F R) 1 -3, vasc ular e n d ot helial gr o w t h fact or rece pt or ( V E G F R) 1 -3, a n d F ms -li ke t y r osi ne ki nase - 3 ( F L T 3). A m o n g t he m, F G F R, P D G F R, a n d V E G F R ha ve bee n i m plicate d i n I P F pat h o ge nesis. Ni nte da ni b bi n ds c o m petiti vel y t o t he a de n osi ne tri p h os p hate ( A T P) bi n di n g p oc ket of t hese rece pt ors a n d bl oc ks t he i ntracell ular si g nali n g w hic h is cr ucial f or t he pr oliferati o n, mi grati o n, a n d tra nsf or mati o n of fi br o blasts re prese nti n g esse ntial mec ha nis ms of t he I P F pat h ol o g y . I n a d diti o n, ni nte da ni b i n hi bits t he f oll o wi n g n R T Ks: L c k, L y n a n d Src ki nases. T he c o ntri b uti o n of F L T 3 a n d n R T K i n hi biti o n t o I P F efficac y is u n k n o w n. F or a m ore detaile d descri pti o n of t he ni nte da ni b pr ofile please refer t o t he c urre nt a p pr o ve d la beli n g ( R 1 8 - 1 2 8 9 ). 1. 3 R A TI O N A L E F O R P E R F O R MI N G T H E T RI A L P ul m o n ar y re ha bilitati o n ( P R) has bee n defi ne d as a n “e vi de nce- base d, m ulti disci pli nar y , a n d c o m pre he nsi ve i nter ve nti o n f or patie nts wit h c hr o nic res pirat or y disease w h o are s y m pt o matic a n d ofte n ha ve decrease d dail y life acti vities.” ( A T S/ E R S State me nt o n P ul m o nar y Re ha bilitati o n). ( R 1 3 - 1 5 7 8 ) Data s u p p orti n g its use c o me lar gel y fr o m t he st u d y of C O P D (c hr o nic o bstr ucti ve p ul m o nar y disease) , i n w hic h P R has bee n s h o w n t o i ncrease e xercise e n d ura nce, decrease d ys p nea, i m pr o ve healt h r elate d q ualit y of life, a n d re d uce healt h -care c ost. Data e xa mi ni n g t he r ole of P R i n i nterstitial l u n g disease (I L D) has bee n less v ol u mi n o us a n d nee ds t o be a d dresse d. St u dies t hat s u p p ort t he use of P R i n I L D ha ve all bee n t o o s h ort a n d t o o s mall t o dr a w a n y c o ncl usi o ns. St u dies t hat ha ve bee n c o m plete d use si milar pr ot oc ols t o t he C O P D P R e x perie nce, wit h t otal P R ti me of 1 0 –1 2 wee ks. M ost ha ve i ncl u de d b ot h a n e xercise a n d e d ucati o nal c o m p o ne nt. T he rece nt P H Y S A C T O st u d y utilize d a n d a d diti o nal c o m p o ne nt of be ha vi o ural m o dificati o n a n d trai ni n g as part of Je a n"
15,page_15,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 B o ur bea u’s “ L i vi n g W ell wit h C O P D” pr o gra m (P 1 6 - 0 4 4 4 2 ). T h us far t here are n o re p orte d I L D pr o gra ms t hat ha ve i ncl u de d t his c o m p o ne nt. St u dies t hat ha ve bee n d o ne wit h P R f or I L D, ha ve s h o w n s h ort ter m i m pact b ut n o e n d uri n g effect i n 6 M W D, Q o L a n d s y m pt o ms ( R 1 8 -1 7 0 4 ). O ne li kel y ca use of t his o utc o me is t hat t he P R has a be nefit , b ut o nce st o p pe d t he patie nt is left wit h a n u n derl yi n g pr o gressi ve de bilitati n g disease t hat ca n n ot be a de q uatel y a d dresse d. T he c o nti n ui n g disease pr o gressi o n ma y accelerate t he l oss of t he i nitial P R be nefit. Wit h treat me nt a vaila ble t hat sl o ws t he u n derl y i n g disease pr o gressi o n, it is reas o na ble t o e val uate w het her t he ni nte da ni b i m pact o n pr o gressi o n m a y e n ha nce a n d e xte n d P R be nefits a n d its e n d ura nce o ver ti me. Alt h o u g h ni nte da ni b t hera p y re d uces t he a n n ual rate of F V C decli ne b y 5 0 %, n o c o nsiste nt mea ni n gf ul Healt h Relate d Q ualit y of Life ( H R Q o L ) effect was n ote d. T heref ore t he o p p ort u nit y t o i m pr o ve H R Q o L i n patie nts wit h I P F re mai ns a n i m p orta nt u n met me dical ga p. T h us, t he h y p ot hesis is t hat c o m bi ni n g ni nte da ni b a n d P R will re d uce t he rate of F V C decli ne a n d i m pr o ve or mai ntai n patie nt f u ncti o nal perf or ma nce a n d H R Q o L 1. 4 B E N E FI T - RI S K A S S E S S M E N T T his is n ot a p har mac ol o gic i nter ve nti o nal trial. All patie nts will be treate d wit h ni nte da ni b 1 5 0 m g BI D (t wice dail y) f or u p t o t hirt y m o nt hs . Patie nts will ha ve bee n all o we d t o ha ve d osa ge a dj ust me nt f or ma na ge me nt of a d verse e ve nts b ut wit h res ulta nt c o nti n ua nce of ni nte da ni b t hera p y. T he y will n ot be all o we d t o ha ve c o nc urre nt pirfe ni d o ne or N -acet yl c y stei ne ( N A C) t hera p y b ut if treate d wit h eit her dr u g pre vi o usl y t he y will n ee d t o c o m plete a was h o ut. Alt h o u g h rare, a p ote ntial f or gastr oi ntesti nal perf orati o n a n d dr u g -i n d uce d li ver i nj ur y ( DI LI) is u n der c o nsta nt s ur veilla nce b y s p o ns ors a n d re g ulat ors. T heref ore, t his trial re q uires ti mel y detecti o n, e val uati o n, a n d f oll o w - u p of la b orat or y alterati o ns i n selecte d li ver la b orat or y para meters t o e ns ure patie nt s´ safet y, see als o secti o n 5. 2. 6 , a d verse e ve nts of s pecial i nterest . P ul m o nar y re ha bilitati o n ( P R) is a sta n dar d t hera pe utic c o m p o ne nt t o t he treat me nt of patie nts wit h c hr o nic l u n g disease. All patie nts are assesse d f or t heir a p pr o priate ness f or P R pri or t o i nitiati o n a n d d uri n g t he c o urse of P R. At a n y p oi nt i n ti me t hat it is deter mi ne d t hat t he patie nt is n o l o n ger a p pr o priate f or P R, t he pr o gra m is disc o nti n ue d."
16,page_16,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 2. T RI A L O B J E C TI V E S A N D E N D P OI N T S 2. 1 M AI N O B J E C TI V E S, P RI M A R Y A N D S E C O N D A R Y E N D P OI N T S 2. 1. 1 M ai n o bjecti ves T he f oc us of t his st u d y is t o assess t he be nefit of P R i n I P F patie nts recei vi n g sta ble ni nte da ni b t hera p y ( f or u p t o 3 0 m os.) a n d t o deter mi ne w het her t he P R be nefit is mai ntai ne d f oll o wi n g cessati o n of P R. I n a d diti o n, t he “ be y o n d t he pill” or patie nt f oc use d i m pact will be e val uate d b y meas uri n g t he effects of P R o n patie nt acti vit y le vels a n d H R Q o L . T he e n d uri n g effect of t hese o utc o mes is i m p orta nt t o t he well -bei n g of t he patie nt. C o nce pt uall y ni nte da ni b re d ucti o ns i n F V C decli ne m a y all o w f or a n e n d uri n g effect f oll o wi n g P R . T he mai n o bjecti ves of t his st u d y are: Deter mi ne t he differe nce i n c ha n ge fr o m baseli ne i n 6 M W D w he n p u l m o nar y re ha bilitati o n ( P R) is a d de d t o sta ble u n derl yi n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) Deter mi ne t he differe nce i n c ha n ge i n Q o L w he n p ul m o nar y r e ha bilitati o n ( P R) is a d de d t o sta ble u n derl yi n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) Deter mi ne if t here is a n e n d uri n g effect i n 6 M W D, Q o L a n d l u n g f u ncti o n fr o m p ul m o nar y r e ha bilitati o n ( P R) w he n p ul m o nar y r e ha bilitati o n ( P R) is a d de d t o sta ble u n derl yi n g ni nte da ni b t hera p y i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F) 2. 1. 2 Pri m ar y en d p oi nt(s) oC ha n ge fr o m baseli ne i n 6 M W D at 1 2 wee ks 2. 1. 3 Sec o n d ar y e n d p oi nt(s) oC ha n ge fr o m baseli ne i n Q o L ( S G R Q, K BI L D, U C S D S O B Q) at 1 2 a n d 2 4 wee ks oC ha n ge fr o m baseli ne i n 6 M W D at 2 4 wee ks oC ha n ge fr o m baseli ne i n l u n g f u ncti o n ( F V C) at 1 2 wee ks a n d 2 4 wee ks usi n g eac h of A bs ol ute c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d Relati ve c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decrease b y > 5 %, i ncrease b y > 5 %, a n d c ha n ge wit hi n ≤ 5 A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decr ease b y > 1 0, i ncrease b y > 1 0, a n d c ha n ge wit hi n ≤ 1 0 oC ha n ge fr o m baseli ne i n dail y acceler o meter acti vit y at 1 2 a n d 2 4 wee ks"
17,page_17,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
18,page_18,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 3. D E S C RI P TI O N O F D E SI G N A N D T RI A L P O P U L A TI O N 3. 1 O V E R A L L T RI A L D E SI G N A N D P L A N T his is a P hase I V, m ulti -ce ntre, pr os pecti ve, ra n d o mise d, o pe n la bel cli nical trial t o i n vesti gate t he effect of p ul m o nar y re ha bilitati o n i n patie nts wit h I P F c urre ntl y treate d wit h ni nte da ni b at a d ose of 1 5 0 m g bi d f or u p t o 3 0 m o nt hs . A t otal of a p pr o xi matel y 2 9 0 patie nts wit h c o nfir me d I P F dia g n osis, alrea d y usi n g ni nte da ni b will be ra n d o mise d, 1 4 5 i n acti ve ar m a n d 1 4 5 i n t he c o ntr ol gr o u p. After a scree ni n g visit, if t he patie nt c o m plies wit h all i ncl usi o n a n d e xcl usi o n criteria a n d pr o vi des i nf or me d c o nse nt, ra n d o misati o n will be perf or me d b y p h o ne or I nter net, usi n g a n I nteracti ve p h o ne/ w e b Res p o nse S y ste m ( I R T). Patie nts will t he n e nter t he treat me nt p hase f or 2 4 wee ks . T he treat me nt p hase c o nsists of 1 2 wee ks of p ul m o nar y re ha bilitati o n f or t h ose patie nts ra n d o mize d t o t hat ar m, t o ta ke place d uri n g t he first 1 2 wee ks of t he treat me nt p h ase. 3. 2 DI S C U S SI O N O F T RI A L D E SI G N, I N C L U DI N G T H E C H OI C E O F C O N T R O L G R O U P( S) T he use of p ul m o nar y re ha bilitati o n i n I P F has bee n e x pl ore d i n s mall st u dies t hat ha ve s h o w n a p os iti ve o utc o me b ut wit h o ut c o ncl usi ve e vi de nce of a n e n d uri n g effect. It is belie ve d t hat t his is i n part d ue t o t he u n derl yi n g pr o gressi ve disease n ot bei n g a d dresse d t hr o u g h acti ve treat me nt. C o nsi derati o n s h o ul d t heref ore be gi ve n t o t he be nefit of u n derl y i n g a ntifi br otic t hera p y li miti n g t he rate of l u n g f u ncti o n decli ne a n d all o wi n g t he effect of p ul m o nar y re ha bilitati o n t o be m ore e n d uri n g. T he c o h ort i n t his st u d y is patie nts t hat are treate d wit h ni nte da ni b f or u p t o 3 0 m o nt hs. T his p ote ntiall y a d dresses t he c o ncer n t hat patie nts fi nis h p ul m o nar y re ha bilitati o n a n d t he n ret ur n to a less acti ve state beca use t he y are still left wit h a n u n derl yi n g c hr o nic pr o gressi ve disease. Gi ve n t he fi n di n gs i n t hree pi v otal st u dies t hat ni nte da ni b sl o ws t he rate of decli ne i n l u n g f u ncti o n ( c 0 2 0 9 8 7 7 5 - 0 2, c 0 2 1 5 5 5 7 4 - 0 2 ), t his a p pr oac h wit h t his sta ble c o h ort ma y all o w f or a m ore e n d uri n g o utc o me fr o m P R. 3. 3 S E L E C TI O N O F T RI A L P O P U L A TI O N T his trial will ra n d o mize 2 9 0 patie nts ( 1 4 5 per treat me nt gr o u p at a p pr o xi matel y 5 4 sites acr oss t he U nite d States ( U S). Scree ni n g of patie nts f or t his trial is c o m petiti ve, i.e. scree ni n g f or t he trial will st o p at all sites at t he sa me ti me o nce a s ufficie nt n u m ber of patie nts has bee n scree ne d. I n vesti gat ors"
19,page_19,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 will be n otifie d a b o ut scree ni n g c o m pleti o n a n d will t he n n ot be all o we d t o scree n a d diti o nal patie nts f or t his trial. A l o g of all patie nt s e nr olle d i nt o t he trial (i.e. w h o ha ve si g ne d i nf or me d c o nse nt) will be mai ntai ne d i n t he i n vesti gat o r site file (I S F ) at t he i n vesti gati o nal site. Rescree ni n g of patie nts w h o are pre vi o usl y scree n faile d f or t he trial is all o we d wit hi n 1 - 2 wee ks f or patie nts t hat fail d ue t o F V C, s pir o metr y m a y be re peate d o nce. Rescree ni n g f or a d mi nistrati ve or ot her r e as o ns m ust be disc usse d wit h t he cli nical m o nit or 3. 3. 1 M ai n di a g n osis f or tri al e ntr y T o q ualif y f or t he trial, patie nts m ust ha ve a dia g n osis of I d i o pat hic P ul m o nar y Fi br osis (I P F) acc or di n g t o A merica n T h oracic S ociet y ( A T S), E ur o pea n Res pirat or y S ociet y ( E R S ), Ja pa nese Res pirat or y S ociet y (J R S), a n d Lati n A merica n T h oracic Ass ociati o n ( A L A T) criteria p u blis he d i n 2 0 1 1 , c o nsiste nt wit h I N P U L SI S criteria. Patie nts m ust als o ha ve bee n treate d wit h ni nte da ni b 1 5 0 m g BI D at a sta ble d ose f or u p t o 3 0 m o nt hs . Please refer t o secti o n 8. 3. 1 ( S o urce D oc u me nts) f or t he d oc u me ntati o n re q uire me nts pertai ni n g t o t he i n -a n d e xcl usi o n criteria. 3. 3. 2 I ncl usi o n criteri a 1. Patie nts bei n g treate d wit h a sta ble d ose of ni nte da ni b 1 5 0 m g BI D f or u p t o 3 0 m o nt hs. Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m ust be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. 2. A ge ≥ 4 0 years at scree ni n g 3. W o me n of c hil d beari n g p ote ntial ( W O C B P) 1m ust be rea d y a n d a ble t o use hi g hl y effecti ve met h o ds of birt h c o ntr ol per I C H M 3 ( R 2) (R 1 7 - 1 3 9 9 )t hat res ult i n a l o w fail ure rate of less t ha n 1 % per ye ar w he n use d c o nsiste ntl y a n d c orrectl y . A list of c o ntrace pti o n met h o ds meeti n g t hese criteria is pr o vi de d i n t he patie nt c o nse nt f or m 4. Si g ne d a n d date d writte n i nf or me d c o nse nt i n acc or da nce wit h I C H- G C P (I nter nati o nal C o u ncil o n Har m o nizati o n a n d G o o d Cli nical Practice ) a n d l ocal le gislati o n pri or t o a d missi o n t o t he trial 5. C o nfir me d dia g n osis of I P F acc or di n g t o 2 0 1 1 A T S/ E R S/J R S/ A L A T g ui deli nes b y l u n g bi o ps y or H R C T ( base d u p o n I N P U L SI S criteria (c 0 2 0 9 8 7 7 5 - 0 2 ,c 0 2 1 5 5 5 7 4 - 0 2 ), (if bi o ps y o nl y or H R C T d o ne > 2 4 m o nt hs pri or t o scree ni n g, a ne w H R C T t o be d o ne after c o nse nt a n d pri or t o or u p t o 7 da y s after Visit 2 f or q ua ntitati ve l u n g fi br osis sc ore ( Q L F) f or disease c haracterizati o n) 1A w o ma n is c o nsi dere d of c hil d beari n g p ote ntial ( W O C B P) , i.e. fertile, f oll o wi n g me narc he a n d u ntil bec o mi n g p ost - me n o pa usal u nless per ma ne ntl y sterile. Per ma ne nt sterilisati o n met h o ds i ncl u de h ysterect o m y, bilateral sal pi n gect o m y a n d bilateral o o p h orect o m y. A p ost me n o pa usal stat e is defi ne d as n o me nses f or 1 2 m o nt hs wit h o ut a n alter nati ve me dical ca use."
20,page_20,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6. F orce d Vita l Ca pacit y ( F V C) ≥ 4 5 %of pre dicte d b y t he N H A N E S e q uati o n (R 0 4 - 1 0 0 1 ) or e q ui vale nt (after disc ussi o n wit h Cli nical M o nit or), hist orical wit hi n past 3 0 da y s ca n be u se d. Car b o n m o n o xi de Diff usi o n Ca pacit y ( D L C O ) (c orrecte d f or he m o gl o bi n [ H g b]) 3 0- 7 9 % of pre dicte d 7. F E V 1/ F V C greater t ha n/e q ual t o . 7 8. P h y sicall y ca pa ble of perf or mi n g b ot h a 6 mi n ute wal k test a n d , m ust s uccessf ull y c o m p lete t he practice tests f or t he 6 mi n ute wal k test, per t he i nstr ucti o ns 3. 3. 3 E xcl usi o n criteri a 1. Maj or s ur ger y ( maj or acc or di n g t o t he i n vesti gat or’s assess me nt) perf or me d wit hi n 1 2 wee ks pri or t o ra n d o mizati o n or pla n ne d wit hi n 6 m o nt hs after scree ni n g, e. g. hi p re place me nt w hic h c o ul d i nte rfere wit h t he a bilit y t o partici pate i n p ul m o nar y re ha bilitati o n. 2. A n y d oc u me nte d acti ve or s us pecte d mali g na nc y or hist or y of mali g na nc y wit hi n 3years pri or t o scree ni n g, e xce pt a p pr o priatel y treate d basal cell carci n o ma of t he s ki n or i n sit u carci n o ma of uteri ne cer vi x 3. Patie nts w h o m ust or wis h t o c o nti n ue t he i nta ke of restricte d me dicati o ns (see Secti o n 4. 2. 2. 1 ) or a n y dr u g c o nsi dere d li kel y t o i nterfere wit h t he safe c o n d uct of t he trial 4. Pre vi o us e nr ol me nt i n t his trial (e xce pt f or rescree ni n g as descri be d i n Secti o n 3. 3 ) 5. C urre ntl y e nr olle d i n a n ot her i nter ve nti o nal i n vesti gati o nal de vice or dr u g trial, or less t ha n 3 0 da y s si nce e n di n g a n ot her i n vesti gati o nal de vice or dr u g trial(s), or recei vi n g ot her i n vesti gati o nal treat me nt(s) 6. C hr o nic alc o h ol or dr u g a b use or a n y c o n diti o n t hat, i n t he i n vesti gat or’s o pi ni o n, m a kes t he m a n u nrelia ble trial patie nt or u nli kel y t o c o m plete t he trial 7. W o me n w h o are pre g na nt, n ursi n g, or w h o pla n t o bec o me pre g na nt i n t he trial 8. Pre vi o us partici pati o n i n p ul m o nar y re ha bilitati o n pr o gra m wit hi n 4 5 da y s pri or t o si g ni n g c o nse nt 3. 3. 4 Wit h dr a w al of p atie nt s fr o m t her a p y or assess me nts Patie nts ma y p ote ntiall y be wit h dra w n fr o m trial treat me nt or fr o m t he trial as a w h ole (“ wit h dra wal of c o nse nt”) wit h ver y differe nt i m plicati o ns, please see secti o ns 3. 3. 4. 1 a n d 3. 3. 4. 2 bel o w. Ever y eff ort s h o ul d be ma de t o kee p t he ra n d o mis e d patie nts i n t he trial :if p ossi ble o n tre at me nt, or at least t o c ollect i m p orta nt trial data. Meas ures t o c o ntr ol t he wit h dra wal rate i ncl u de c aref ul patie nt selecti o n, a p pr o priate e x pla nati o n of t he trial re q uire me nts a n d pr oce d ures pri or t o ra n d o mizati o n, as well as t he e x pla nati o n of t he c o nse q ue nces of wit h dra wal."
21,page_21,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he decisi o n t o wit h dra w fr o m trial treat me nt or fr o m t he w h ole trial as well as t he reas o n m ust be d oc u me nte d i n t he patie nt files a n d C R F (case rec or d f or m) . I n t he e ve nt a patie nt or part ner of a patie nt has bec o me pre g na nt pri or t o wit h dra wal fr o m t he trial, t he pr oce d ures i n Secti o n 5. 2. 6. 1 s h o ul d be f oll o we d. If a patie nt bec o mes pre g na nt d uri n g t he trial, t he prescri bi n g p h ys icia n s h o ul d be n otifie d a n d c o nti n uati o n of ni nte da ni b treat me nt a d dresse d b y t he prescri bi n g p h ys icia n. C o nti n ue d partici pati o n i n t he trial s h o ul d be disc usse d wit h t he cli nical m o nit or. 3. 3. 4. 1 Wit h dra wal fr o m trial treat me nt A n i n di vi d ual patie nt is t o be wit h dra w n fr o m trial treat me nt if: T he patie nt wa nts t o wit h dra w fr o m trial treat me nt, wit h o ut t he nee d t o j ustif y t he decisi o n. T he patie nt nee ds t o ta ke c o nc o mita nt treat me nt st hat i nterfere wit h t he re q uire d O F E V treat me nt. T he patie nt ca n n o l o n ger be treate d wit h trial pr oce d ures f or ot her me dical reas o ns (s uc h as s ur ger y , a d verse e ve nts, ot her diseases, or pre g na nc y ). T he patie nt has re peate dl y s h o w n t o be n o n -c o m plia nt wit h i m p orta nt trial pr oce d ures a n d, i n t he o pi ni o n of b ot h, t he i n vesti gat or a n d s p o ns or re prese ntati ve, is n ot willi n g or a ble t o c o m pl y wit h t he trial re q uire me nts i n t he f ut ure. Gi ve n t he patie nt ’s a gree me nt, t he patie nt will u n der g o t he pr oce d ures f or ea rl y treat me nt disc o nti n uati o n a n d f oll o w u p as o utli ne d i n t he Fl o w C hart (F C )a n d secti o n 6. 2. 3 . F or all patie nt s t he reas o n f or wit h dra wal fr o m trial treat me nt (e. g. a d verse e ve nts) m ust be rec or de d i n t he C R F . T hese data will be i ncl u de d i n t he trial data base a n d re p orte d. 3. 3. 4. 2 Wit h dra wal of c o nse nt f or trial partici pati o n Patie nt sma y wit h dra w t heir c o nse nt f or trial partici pati o n at a n y ti me wit h o ut t he nee d t o j ustif y t he decisi o n. T his will h o we ver mea n t hat n o f urt her i nf or mati o n ma y be c ollecte d f or t he p ur p ose of t he trial a n d ne gati ve i m plicati o ns f or t he scie ntific val ue ma y be t he c o nse q ue nce. F urt her m ore it ma y mea n t hat f urt her patie nt f oll o w u p o n saf et y ca n n ot o cc ur. If a patie nt wa nts t o wit h dra w c o nse nt, t he i n vesti gat or s h o ul d e x plai n t he differe nce bet wee n treat me nt wit h dra wal a n d w it h dra wal of c o nse nt f or trial partici pati o n a n d e x plai n t he o pti o ns f or c o nti n ue d f oll o w u p after wit h dra wal fr o m trial treat me nt, please s ee secti o n 3. 3. 4. 1 a b o ve . 3. 3. 4. 3 Disc o nti n uati o n of t he trial b y t he s p o ns or B oe hri n ger I n gel hei m reser ves t he ri g ht t o disc o nti n ue t he trial o verall or at a partic ular trial site at a n y ti me f or t he f oll o wi n g reas o ns:"
22,page_22,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1. Fail ure t o meet e x pecte d e nr ol me nt g oals o verall or at a partic ular trial site 2. E mer ge nce of a n y efficac y /safet y i nf or mati o n i n vali dati n g t he earlier p ositi ve be nefit - ris k- assess me nt t hat c o ul d si g nifica ntl y affect t he c o nti n uati o n of t he trial 3. Vi olati o n of G C P, t he trial pr ot oc ol , or t he c o ntract i m pairi n g t he a p pr o priate c o n d uct of t he trial T he i n vesti gat or / t he trial site will be rei m b urse d f or reas o na ble e x pe nses i nc urre d i n case of trial ter mi nati o n (e xce pt i n case of t he t hir d reas o n)."
23,page_23,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 4. T R E A T M E N T S 4. 1 I N V E S TI G A TI O N A L T R E A T M E N T S 4. 1. 1 I de ntit y of t he in vesti g ati o n al me dici n al pr o d ucts N o st u d y me dicati o n is i ncl u de d i n t his trial, t his trial is a c o m paris o n of p ul m o nar y re ha bilitati o n vers us sta n dar d care i n patie nts wit h I P F alrea d y ta ki n g a sta ble d ose of ni nte da ni b. T he acti ve treat me nt ar m will c o nsist of a sta n dar d p ul m o nar y re ha bilitati o n re gi me n t w o or t hree ti mes wee kl y f or 1 2 wee ks. Patie nts assi g ne d t o P R will be referre d t o a facilit y c o n ve nie nt f or t he patie nt. T he p ul m o nar y re ha bilitati o n s h o ul d f oll o w t he facilit y’s sta n dar d re gi me n as l o n g as t he re gi me n meets basic sta n dar ds (t o be pr o vi de d i n t he I S F) . N o st u d y s pecific data c ollecti o n is re q uire d b y t he P R facilit y , h o we ver sta n dar d treat me nt re p orts m ust be a vaila ble t o t he i n vesti gat or t o d oc u me nt t h e atte n da nce a n d pr o gress of P R. 4. 1. 2 Selecti o n of d oses i n t he tri al Patie nts are re q uire d t o be usi n g t he F D A ( F o o d a n d Dr u g A d mi nistrati o n) a p pr o ve d d ose of ni nte da ni b 1 5 0 m g BI D f or u p t o 3 0 m o nt hs t o q ualif y f or t he trial a n d t o c o nti n ue o n ni nte da ni b f or t he d urati o n of t he trial. Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m us t be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. Te m p orar y dose a dj ust me nt f or t he ma na ge me nt of a d verse e ve nts is all o we d d uri n g t he c o n d uct of t he st u d y . 4. 1. 3 Met h o d of assi g ni n g p atie nt s t o tre at me nt gr o u ps D uri n g visit 2eli gi ble patie nt s will be ra n d o m ise d t o eit her c o nti n ue o n ni nte da ni b treat me nt al o ne or c o nti n ue o n ni nte da ni b wit h a p ul m o nar y re ha bilitati o n pr o gra m a d de d i n a 1: 1 rati o acc or di n g t o a ra n d o mizati o n pla n. T he assi g n me nt will occ ur via I nteracti ve Res p o nse Tec h n ol o g y (I R T). 4. 1. 4 Dr u g assi g n me nt a n d a d mi nistr ati o n of d oses f or e ac h p atie nt S u bjects are re q uire d t o be treate d o n a sta ble ( u p t o 3 0 m o nt hs) d ose of ni n te da ni b 1 5 0 m g BI D , a d mi nistere d per prescri bi n g i nstr ucti o ns ( R 1 8 - 1 2 8 9 ), t o e nter t he trial a n d t o c o nti n ue o n t his d ose t hr o u g h o ut t he trial . Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m ust be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. Patie nts t hat ha ve ha d a n i nterr u pti o n i n ni nte da ni b treat me nt or a te m p orar y d ose re d uct i o n ca n be e ntere d i nt o t he trial w he n t he y ha ve ret ur ne d t o a d ose of 1 5 0 m g BI D a n d t heir c o n diti o n is deter mi ne d t o be sta ble b y t he i n vesti gat or a n d te m p orar y d ose re d ucti o ns t o treat a d verse e ve nts is per mitte d d uri n g t he trial ."
24,page_24,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 4. 1. 5 Bli n di n g a n d pr oce d ures f or u n bli n di n g 4. 1. 5. 1 Bli n di n g Q ualifie d s u bjects will be ra n d o mize d at Visit 2 t o eit her c o nti n ue wit h t heir us ual treat me nt or t o a d d a p ul m o nar y re ha bilitati o n pr o gra m t o t heir us ual treat me nt. I n t his o pe n -la bel trial , treat me nt all ocati o n will n ot be c o ncea le d t hr o u g h o ut t he trial . T he C R F will c o ntai n i nf or mati o n o n ra n d o m ise d treat me nt. As patie nts are ra n d o mize d t o eit her n o p ul m o nar y re ha bilitati o n or p ul m o nar y re ha bilitati o n, it is n ot p ossi ble t o bli n d t he treat me nts i n t his trial. 4. 1. 5. 2 U n bli n di n g a n d brea k i n g t he c o de N ot a p plica ble , t his trial is n ot bli n de d . 4. 1. 6 P ac k a gi n g, l a belli n g, a n d re- s u p pl y N o ta p plica ble, n o st u d y me dicati o n is pr o vi de d i n t his trial. 4. 2 O T H E R T R E A T M E N T S , E M E R G E N C Y P R O C E D U R E S , R E S T RI C TI O N S 4. 2. 1 Ot her tre at me nts a n d e mer ge nc y pr oce d ures 4. 2. 1. 1Ma na ge me nt of a d verse e ve nts relate d t o ni nte da ni b A d verse e ve nts relate d t o ni nte da ni b s h o ul d be ma na ge d acc or di n g t o t he c urre nt pac ka ge i nsert ( R 1 8 - 1 2 8 9 )i n c o nj u ncti o n wit h t he prescri bi n g p h y sicia n. 4. 2. 1. 2 Ma na ge me nt of ot her a d verse e ve nts A d verse e ve nts relate d t o t he st u d y pr oce d ures s uc h as p ul m o nar y re ha bilitati o n, 6 M W T as well as u nrelate d a d verse e ve nts, will be ma na ge d as cli nicall y i n dicate d. If a patie nt e x perie nces a n a d verse e ve nt w hic h i m pacts t heir a bilit y t o c o nti n ue wit h p ul m o nar y re ha bilitati o n (if assi g ne d) or a bilit y t o c o nti n ue wit h t he e xercise testi n g, t he cli nical m o nit or s h o ul d be c o ns ulte d re gar di n g c o nti n ue d partici pati o n i n t h e trial pri or t o disc o nti n uati o n. 4. 2. 2 Restricti o ns 4. 2. 2. 1 Restricti o ns o n co nc o mita nt treat me nt T he f oll o wi n g dr u gs m ust n ot be ta ke n wit hi n 8 wee ks of visit 1: Pirfe ni d o ne A n y ot her e x peri me ntal I P F t hera p y ."
25,page_25,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he f oll o wi n g t hera pies are n ot all o we d d uri n g t he e ntire treat me nt peri o d ( Visit 2 - 7) . I n case a n y of t he f oll o wi n g is me dicall y i n dicate d d uri n g t he c o urse of t he trial a 4 wee k was h -o ut of ni nte da ni b s h o ul d be o bser ve d bef ore t heir use : Fi bri n ol y sis, f ull -d ose t hera pe utic a ntic oa g ulati o n (e. g. vita mi n K a nta g o nists, da bi gatra n, he pari n, hir u di n etc), or hi g h d ose a nti platelet t hera p y . T he f oll o wi n g dr u gs are n ot all o we d d uri n g t he st u d y treat me nt e xce pt i n case of ac ute e xacer bati o n of I P F or i n case of deteri orati o n at t he discreti o n of t he i n vesti gat o r (see secti o n 4. 2. 2. 2 ): Azat hi o pri ne, c y cl o p h os p ha mi de a n d c y cl os p ori ne A must n ot be ta ke n wit hi n 8 wee ks of visit 1. N- Acet y l C ys tei ne ( N A C). M ust n ot be ta ke n wit hi n 2 wee ks of visit 1. Pre d nis o ne at > 1 5 m g / da y ( or > 3 0 m g e ver y 2 da y s or e q ui vale nt d ose of ot her oral c ortic oster oi d) must n ot be ta ke n wit hi n 2 wee ks of visit 1. 4. 2. 2. 2 C o nc o mita nt treat me nts all o we d F oll o wi n g me dicati o n is all o we d if sta bilize d f or at least 8 wee ks pri or t o visit 1: Pre d nis o ne if stea d y d ose ≤ 1 5 m g / da y ( or ≤ 3 0 m g e ver y 2 da y s) or e q ui vale nt. I n case of ac ute e xacer bati o ns: all s u g geste d me dicati o ns (e. g. pre d nis o ne at hi g h d ose, azat hi o pri ne, c y cl o p h os p ha mi de, c y cl os p ori ne A or N A C) ca n be freel y i nitiate d or i ncrease d at I n vesti gat or’s dis creti o n exce pt pirfe ni d o ne. I n case of deteri orati o n of I P F: Pre d nis o ne at hi g h d ose, azat hi o pri ne, c y cl o p h os p ha mi de, c y cl os p ori ne A or N A C ca n be freel y i nitiate d or i ncrease d at I n vesti gat or’s discreti o n exce pt pirfe ni d o ne. A ≥ 1 0 % decrease i n t he a bs o l ute val ue of F V C % pre dicte d or a ≥ 1 5 % decrease i n D L C O % pre dicte d is c o nsi dere d deteri orati o n ( pr o gressi o n of disease). E xa m ple: a c ha n ge fr o m 5 0 % pre dicte d F V C t o 4 0 % pre dicte d F V C re prese nts deteri orati o n. Pr o p h y lactic a ntic oa g ulati o n: Pr o p h y lactic l o w d ose he pari n or he pari n fl us h as nee de d f or mai nte na nce of a n i n d welli n g i ntra ve n o us de vice (e. g. e n o xa pari n 4 0 0 0 I. U. s.c. per da y ), as well as pr o p h y lactic use of a nti platelet t hera p y (e. g. acet yl salic y lic aci d u p t o 3 2 5 m g/ d, or cl o pi d o grel at 7 5 m g / d, or e q ui vale nt d oses of ot her a nti platelet t hera p y) s h o ul d be all o we d. 4. 2. 2. 3 Restricti o ns o n diet a n d life st y le T here are n o restricti o ns o n diet a n d life st y le ot her t ha n t h ose re q uire d f or t he e xercise testi n g a n d s pir o metr y ( A p pe n di x 1 0. 1 a n d Secti o n 5. 1. 2. 3 )."
26,page_26,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 4. 2. 2. 4 Restricti o ns re gar di n g w o me n of c hil d beari n g p ote ntial W o me n of c hil d beari n g p ote ntial m ust use t he c o ntrace pti o n met h o ds descri be d i n Secti o n 3. 3. 2 a n d f oll o w t he restricti o ns descri be d i n t he patie nt i nf or mati o n f or ni nte da ni b (R 1 8 - 1 2 8 9 ). 4. 3 T R E A T M E N T C O M P LI A N C E Co u nsel patie nts o n t he i m p orta nce of ta ki n g bac k gr o u n d me dic ati o n as directe d at eac h visit, as well as rei nf orci n g atte n da nce at p ul m o nar y re ha bilitati o n f or t h ose patie nts assi g ne d t o t hat treat me nt ar m ."
27,page_27,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 5. A S S E S S M E N T S 5. 1 A S S E S S M E N T O F E F FI C A C Y 5. 1. 1 E n d p oi nts of effic ac y 5. 1. 1. 1 Pri mar y e n d p oi nt oC ha n ge fr o m baseli ne i n 6 M W D at 1 2 wee ks 5. 1. 1. 2 Sec o n dar y e n d p oi nts oC ha n ge fr o m baseli ne i n Q o L ( S G R Q, K BI L D, U C S D S O B Q ) at 1 2 a n d 2 4 wee ks oC ha n ge fr o m baseli ne i n 6 M W D at 2 4 wee ks oC ha n ge fr o m baseli ne i n l u n g f u ncti o n ( F V C) at 1 2 wee ks a n d 2 4 wee ks usi n g eac h of Abs ol ute c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d Relati ve c ha n ge fr o m baseli ne of F V C a n d F V C % pre dicte d A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decrease b y > 5 %, i ncrease b y > 5 %, a n d c ha n ge wit hi n ≤ 5 A bs ol ute cate g orical c ha n ge of F V C % pre dicte d u p t o 1 2 a n d 2 4 wee ks: decre ase b y > 1 0, i ncrease b y > 1 0, a n d c ha n ge wit hi n ≤ 1 0 oC ha n ge fr o m baseli ne i n dail y acceler o meter acti vit y fr o m baseli ne at 1 2 a n d 2 4 wee ks"
28,page_28,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 2 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 5. 1. 2 Assess me nt of effic ac y 5. 1. 2. 1 6 Mi n ute wal k test T he dista nce meas ure d i n t he 6 Mi n ute Wal k Test at 1 2 a n d 2 4 wee ks will be assess e d acc or di n g t o t he pr oce d ures descri be d i n A p pe n di x 1 0. 1 . F o ur 6 M W Ts will be perf or me d d uri n g t he trial ( o ne practice a n d t hree tests) . At Visit 1 a practice 6 M W T, als o referre d t o as t he Titrati o n Wal k Test, will be c o n d ucte d t o ac q uai nt t he patie nt wit h t he pr oce d ure a n d t o deter mi ne t he le vel of o x y ge n nee de d f or s u bse q ue nt testi n g. As per i ncl usi o n c riteri o n # 8, patie nts m ust be p h y sicall y a ble t o perf or m a 6 M W T , as per t he i nstr ucti o ns . Patie nts w h o ca n n ot c o m plete t he Titrati o n Wal k Test will be c o nsi dere d a Scree n Fail ure. T hree 6 M W Ts will be c o n d ucte d d uri n g t he ra n d o mize d treat me nt p hase at Vi sits 2 ( baseli ne), 5 a n d 7 ( E n d of Treat me nt). D uri n g t he 6 M W T, t he B or g Scale will be a d mi nistere d. Detaile d i nstr ucti o ns f or t he c o n d uct of t he 6 M W T a n d B or g Scale are pr o vi de d i n t he I S F a n d A p pe n di x 1 0. 1 a n d 1 0. 2 a n d i n t he distri b ute d i nstr ucti o nal vi de o. I t is i m p orta nt t he i nstr ucti o ns are f oll o we d e xactl y. T he test will be perf or me d at a p pr o xi matel y t he sa me ti me eac h da y fr o m ti me of Visit 2 testi n g. Patie nts w h o ca n n ot c o m plete t he 6 M W T after ra n d o mizati o n will r e mai n i n t he trial . 5. 1. 2. 2 C ha n ge i n q ualit y of life C ha n ge fr o m baseli ne i n Q o L will be meas ure d usi n gt he S G R Q , K BI L D , a n d U C S D -S O B Q q uesti o n naires at 1 2 a n d 2 4 wee ks. T he q uesti o n naires are descri be d i n A p pe n di x 1 0. 3 , 1 0. 5 a n d 1 0. 6 . T he q uesti o n naires s h o ul d be c o m plete d first d uri n g t he st u d y visit, pri or t o p ul m o nar y f u ncti o n testi n g a n d ot her pr oce d ures. T he q uesti o n naires will be c o m plete d at Visits 1, 2, 5 a n d 7 . 5. 1. 2. 3 Assess me nt of l u n g f u ncti o n L u n g f u ncti o n will be assesse d at all visits usi n g sta n dar d s pir o metr y , usi n g e q ui p me nt pr o vi de d at t he st u d y site a n d t he N H A N E S e q uati o n ( or e q ui vale nt after disc ussi o n wit h Cli nical M o nit or ). S pir o metr y meas ure me nts m ust be perf or me d acc or di n g t o A T S/ E R S 2 0 0 5 g ui deli ne ( P 0 5 -1 2 7 8 2 ), i ncl u di n g dail y cali brati o n of t he s pir o meter, a n d re g ular cali brati o n of t he cali brati o n p u m p. S pir o metr y will be c o n d ucte d w hile t he patie nt is i n a seate d p ositi o n. T he test will be d o ne i n tri plicate (t hree c ur ves t o be pr o vi de d), a n d t he best res ult selecte d acc or di n g t o t he g ui deli nes. T he best of t hree eff orts will be defi ne d as t he hi g hest F V C, o btai ne d o n a n y of t he t hree bl o ws meeti n g t he A T S/ E R S criteria wit h prefera bl y a ma xi m u m of fi ve ma n oe u vres. Eff orts s h o ul d be ma de, t o sc he d ule t he s pir o metric meas ure me nts at a p pr o xi matel y t he sa me ti me of t he da y , wit h refere nce t o baseli ne meas ure me nt ( Visit 2). O n da y s of cli nic visits, patie nts m ust refrai n fr o m str e n u o us acti vit y at least 1 2 h o urs pri or t o p ul m o nar y f u ncti o n testi n g. S m o ki n g s h o ul d be disc o ura ge d t hr o u g h o ut t he visit da y s (cli nic visit) a n d will n ot be per mitte d i n t he 3 0 -mi n ute peri o d pri or t o s pir o metr y . Patie nts s h o ul d als o a v oi d c ol d te m perat ures, e n vir o n me ntal s m o ke, d ust, or areas wit h str o n g o d o urs (e. g. perf u mes). If"
29,page_29,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 treate d wit h br o nc h o dilat ors, was h - o ut of 2 4 h o urs f or l o n g acti n g a n d 8 h o urs f or s h ort acti n g br o nc h o dilat ors s h o ul d be o bser ve d bef ore s pir o metr y . C ha n ges fr o m baseli ne i n F V C fr o m baseli ne t o 1 2 a n d 2 4 wee ks of treat me nt will be re p orte d as: A bs ol ute a n d relati ve c ha n ge fr o m baseli ne of F V C a n d F V C % pre d icte d A bs ol ute cate g orical c ha n ge of F V C % u p t o 1 2 a n d 2 4 wee ks : decrease b y > 5, i ncrease b y >5 a n d c ha n ge wit hi n ≤ 5 A bs ol ute cate g orical c ha n ge of F V C % u p t o 1 2 a n d 2 4 wee ks : decrease b y >1 0, i ncrease b y > 1 0, a n d c ha n ge wit hi n ≤ 1 0 Resti n g S p O 2s h o ul d be d o ne pri or t o F V C at t he sc he d ule d visits, a n d D Lc o s h o ul d be d o ne after t he F V C at t he desi g nate d visits. F urt her i n f or mati o n o n p ul m o nar y f u ncti o n testi n g ca n be f o u n d i n A p pe n di x 1 0. 7 . 5. 1. 2. 4 Dail y acti vit y m o nit ori n g Dail y acti vit y m o nit ori n g will be c o n d ucte d usi n g t he D y na p ort de vice bet wee n Visits 0 a n d 1, 1 a n d 2 a n d f or 7 da y s pri or t o Visits 5 a n d 7 ( E n d of Treat me nt - E O T). T he de vice will be dis pe nse d t o t he patie nt via eit her pic ki n g u p at t he office or se nt via c o m mercial s hi p pi n g t o t he patie nt i n a d va nce of t he sc he d ule d start date. T he patie nt will wear t he de vice f or 7 c o nsec uti ve da y s, 2 4 h o urs a da y , bet wee n or pri or t o t he sc he d ule d visits a n d bri n g t he de vice wit h t he m t o t he visit. T he i nf or mati o n will be d o w nl oa de d b y t he i n vesti gat or at t he sc he d ule d visit. F urt her i nf or mati o n a n d i nstr ucti o ns f or t he acti vit y m o nit ori n g will be pr o vi de d i n t he I S F."
30,page_30,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 5. 1. 2. 6 P R Oacti ve t o ol I n t his trial, t he P R Oacti ve t o ol ( D -P P A C) t o get her wit h t he acti vit y m o nit or will be use d t o c ollect t he P R Oacti ve ite m sc ores. T he D- P P A C c o nsists of 9 ite ms i n t otal: 7 ite ms fille d o ut o n a n electr o nic i nterface (e Diar y )a n d 2ite ms t o be o btai ne d fr o m t he acti vit y m o nit or (see A p pe n di x 1 0. 4 ) T he ite ms o n t he e Diar y will be c o m plete d b y t he patie nt at h o me e ver y da y f or 7 da y s bef ore Visits 1, 2, 5, a n d 7 ( E O T) . Patie nts will recei ve a leaflet wit h detaile d i nstr ucti o ns o n h o w t o use it, as well as bei n g gi ve n a de m o nstrati o n at t he st u d y site. Data fr o m t he e Diar y f or eac h peri o d will be u pl oa de d t o t he ve n d or’s data base, a n d s u bse q ue ntl y tra nsferre d t o t he trial data base. T he e Diar y a n d t he acti vit y m o nit or data will be u pl oa de d t o t he trial data base f or use i n calc ulati n g t he d o mai n sc ores a n d P R Oacti ve t otal a n d d o mai n sc ores . 5. 2 A S S E S S M E N T O F S A F E T Y 5. 2. 1 P h ysic al e x a mi n ati o n A c o m plete p h ys ical e xa mi nati o n will be perf or me d at t he ti me p oi nts s pecifie d i n t he fl o wc hart . It i ncl u des at a mi ni m u m ge neral a p peara nce, nec k, l u n gs, car di o vasc ular s ys te m, a b d o me n, e xtre mities, a n d s ki n. Meas ure me nt of h ei g ht a n d b o d y wei g ht will be perf or me d at Visit 1 . T he res ults m ust be i ncl u de d i n t he s o urce d oc u me nts a vaila ble at t he site. A n y cli nicall y si g nifica nt a b n or malities at Visit 1 will be rec or de d as baseli ne c o n diti o ns i n t he e C R F. A n y cli nicall y si g nific a nt c ha n ges at s u bse q ue nt visits will be assesse d a n d re p orte d as a d verse e ve nts if t he y meet t he defi niti o ns i n Secti o n 5. 2. 6 . 5. 2. 2 Vit al si g ns Vital si g ns will be e val uate d at t he ti me p oi nts s pecifie d i n t he fl o wc hart, pri or t o bl o o d sa m pli n g if a p plica ble."
31,page_31,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T his i ncl u des s y st olic a n d diast olic bl o o d press ure a n d p ulse rate (electr o nicall y or b y pal pati o n c o u nt f or 1 mi n ute ) i n a seate d p ositi o n after 5 mi n utes of rest. 5. 2. 3 S afet y l a b or at or y p ar a meters La b orat or y tests Safet y la b orat o r y testi n g will be c o n d ucte d ( n o n- fasti n g) o n all patie nts at t he scree ni n g visit ( Visit 1), a n d all st u d y visits ( Visits 2 -9). T he la b orat or y tests at Visit 1 will be c o nsi dere d as t he baseli ne meas ure me nts. L a b orat or y s peci me ns will be c ollecte d i n t he m or ni n g pri or t o t he e xercise testi n g. Patie nts s h o ul d be i nstr ucte d n ot t o d o a n y u nacc ust o me d p h y sical e xercise 3 6 h o urs pri or t o la b orat or y testi n g. Hae mat ol o g y , bl o o d c he mistr y , uri nal ys is a n d ß -H C G (ser u m h u ma n c h ori o nic g o na d otr o pi n) will be a nal ys e d b y t he l ocal la b orat or y of eac h partici pati n g site. La b orat or y data will be c ollecte d b ut n ot ca pt ure d i n t he e C R F wit h t he e xce pti o n of he m o gl o bi n. He m o gl o bi n res u lts will be rec or de d i n t he e C R F at visits 1, 2, 5 a n d 7 t o all o w calc ulati o n of t he c orre cte d D Lc o. It is res p o nsi bilit y of t he i n vesti gat or t o e val uate c ha n ges i n la b orat or y val ues a n d re p orti n g of a n y la b orat or y relate d a d verse e ve nt s h o ul d be f oll o we d acc or di n g t o t he defi niti o ns o utli ne d i n Secti o n 5. 2. 6 . Hae mat ol o g y Hae m o gl o bi n, hae mat ocrit, re d bl o o d cell c o u nt, w hite bl o o d cell c o u nt i ncl u di n g differe ntial ( ne utr o p hils, l y m p h oc y tes, m o n oc y tes, e osi n o p hils, bas o p hils), t otal e osi n o p hil c o u nt a n d platelet c o u nt. Bl o o d c he mistr y Al kali ne p h os p hatase, L D H, Ga m ma -G T, A L T ( Ala ni ne A mi n otra nsferase) , A S T ( As partate A mi n otra nsferase) , gl uc ose, calci u m, i n or ga nic p h os p h or us, uric aci d, urea nitr o ge n, creati ni ne, t otal pr otei n, p otassi u m, s o di u m, c hl ori de, t otal bilir u bi n, creati ne p h os p h o ki nase. Uri nal y sis S pecific gra vit y, p H, gl uc ose, pr otei n, occ ult bl o o d. Pre g na nc y Testi n g A ser u m h u ma n c h ori o nic g o na d otr o pi n ( H C G) test will be perf or me d o n all fe males of c hil d - beari n g p ote ntial at Visit 1. Uri ne pre g na nc y tests are t o be perf or me d at Visits 2 - 7 , as a n alter nati ve, a ser u m pre g na nc y test ca n be perf or me d at Visits 2 -7 if re q uire d b y site or et hics b oar d . I n case t he criteria f or he patic i nj ur y are met , a n u m ber of a d diti o nal meas ures will be perf or me d ( p lease see Secti o n 5. 2. 6. 1 a n d t he DI LI C hec klist pr o vi de d i n t he I S F or"
32,page_32,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 electr o nic data ca pt ure ( e D C )s y ste m. T he a m o u nt of bl o o d ta ke n fr o m t he patie nt c o ncer ne d will be i ncrease d d ue t o t his a d diti o nal sa m pli n g. 5. 2. 4 Electr oc ar di o gr a m T he 1 2 -lea d E C Gs will be rec or de d as sc he d ule d i n t he fl o wc hart . T he i n vesti gat or or a desi g nee will e val uate w het her t he E C G is n or mal or a b n or mal a n d w het her it is cli nicall y rele va nt, if a b n or mal. E C Gs ma y be re peate d f or q u alit y reas o ns a n d t he re peate d rec or di n g use d f or a nal y sis. A d diti o nal E C Gs ma y be rec or de d f or safet y reas o ns. Date d a n d si g ne d pri nt o uts of E C G wit h fi n di n gs s h o ul d be d oc u me nte d i n patie nt’s me dical rec or d. Cli nicall y rele va nt a b n or mal fi n di n gs will be re p orte d eit her as baseli ne c o n diti o n (if i de ntifie d at t he scree ni n g visit) or ot her wise as a d verse e ve n ts as descri be d i n Secti o n 5. 2. 6 a n d will be f oll o we d u p a n d/ or treate d as me dicall y a p pr o priate. 5. 2. 5 Ot her s afet y p ar a meters Safet y para meters t o be assesse d d uri n g t he w or k c y cle er g o metr y a n d 6 mi n ute wal k test are descri be d i n A p pe n di x 1 0. 1 . 5. 2. 6 Assess me nt of a d verse e ve nts 5. 2. 6. 1 Defi niti o ns of A Es A d verse e ve nt A n a d verse e ve nt ( A E) is defi ne d as a n y u nt o war d me dical occ urre nce i n a patie nt or cli nical i n vesti gati o n s u bject a d mi nistere d a me dici nal pr o d uct a n d w hic h d oes n ot necessaril y ha ve t o ha ve a ca usal relati o ns hi p wit h t his treat me nt. A n A E ca n t heref ore be a n y u nfa v o ura ble a n d u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease te m p orall y ass ociate d wit h t he use of a me dici nal pr o d uct, w het her or n ot c o nsi dere d relate d t o t he me dici nal pr o d uct. A d verse re acti o n A n a d verse reacti o n ( A D R) is defi ne d as a res p o nse t o a me dici nal pr o d uct w hic h is n o xi o us a n d u ni nte n de d. Res p o nse i n t his c o nte xt mea ns t hat a ca usal relati o ns hi p bet wee n a me dici nal pr o d uct a n d a n a d verse e ve nt is at least a reas o na ble p ossi bilit y . A d verse reacti o ns ma y arise fr o m use of t he p r o d uct wit hi n or o utsi de t he ter ms of t he mar keti n g a ut h orisati o n or fr o m occ u pati o nal e x p os ure. C o n diti o ns of use o utsi de t he mar keti n g a ut h orizati o n i ncl u de off -la bel use, o ver d ose, mis use, a b use a n d me dicati o n err ors."
33,page_33,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Seri o us a d verse e ve nt Aseri o us a dverse e ve nt is defi ne d as a n y A E w hic h -res ults i n deat h, -is life -t hreate ni n g, -re q uires i n -patie nt h os pitalizati o n, or -pr ol o n gati o n of e xisti n g h os pitalisati o n, -res ults i n persiste nt or si g nifica nt disa bilit y or i nca pacit y , or -is a c o n ge nital a n o mal y/ birt h defect Life -t hreate ni n g i n t his c o nte xt refers t o a reacti o n i n w hic h t he patie nt was at ris k of deat h at t he ti me of t he reacti o n; it d oes n ot refer t o a reacti o n t hat h y p ot heticall y mi g ht ha ve ca use d deat h if m ore se vere. Me dical a n d scie ntific j u d ge me nt s h o ul d be e xercise d i n deci di n g w het her ot her sit uati o ns s h o ul d be c o nsi dere d seri o us reacti o ns, s uc h as i m p orta nt me dical e ve nts t hat mi g ht n ot be i m me diatel y life t hreate ni n g or res ult i n deat h or h os pitalisati o n b ut mi g ht je o par dise t he patie nt or mi g ht re q uire i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d a b o ve. E xa m ples of s uc h e ve nts are i nte nsi ve treat me nt i n a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d y scrasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pitalisati o n or de vel o p me nt of de pe n de nc y or a b use .A n y s us pecte d tra ns missi o n via a me dici nal pr o d uct of a n i nfecti o us a ge nt is als o c o nsi dere d a seri o us a d verse reacti o n. A d verse e ve nts of s peci al i nterest ( A E SIs) T he ter m A E SI relates t o a n y s pecific A E t hat has bee n i de ntifie d at t he pr oject le vel as bei n g of partic ular c o ncer n f or pr os pecti ve safet y m o nit ori n g a n d safet y assess me nt wit hi n t his trial, e. g. t he p ote ntial f or A Es base d o n k n o wle d ge fr o m ot her c o m p o u n ds i n t he sa me class. T he f oll o wi n g are c o nsi dere d as A E SIs: Gastr oi ntesti nal perf orati o n He patic i nj ur y A he patic i nj ur y is defi ne d b y t he f oll o wi n g alterati o ns of he patic la b orat or y para meters: a n ele vati o n of A S T a n d/ or A L T >3 f ol d u p per li mit of n or mal ( U L N )c o m bi ne d wit h a n ele vati o n of t otal bilir u bi n > 2 f ol d U L N meas ure d i n t he sa me bl o o d dra w sa m ple, a n d/ or a mi n otra nsferase ( A L T, a n d/ or A S T) ele vati o ns ≥ 1 0 f ol d U L N T hese la b fi n di n gs c o nstit ute a he patic i nj ur y alert a n d t he patie nt s s h o wi n g t hese la b a b n or malities nee d t o be f oll o we d u p acc or di n g t o t he “ DI LI c hec klist” pr o vi de d i n t he I S F or e C R F . I n case of cli nical s y m pt o ms of he patic i nj ur y (icter us, u ne x plai ne d e nce p hal o pat h y , u ne x plai ne d c oa g ul o pat h y , ri g ht u p per q ua dra nt a b d o mi nal pai n, etc.) wit h o ut la b res ults ( A L T, A S T, t otal bilir u bi n) a vaila ble, t he i n vesti gat or s h o ul d ma ke s ure t hese para meters are"
34,page_34,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 a nal ys e d, if necessar y i n a n u nsc he d ule d bl o o d test. S h o ul d t he res ults meet t he criteria of he patic i nj ur y alert, t he pr oce d ures descri be d i n t h e DI LI c hec klist ( pr o vi de d i n I S F or e D C) s h o ul d be f oll o we d. 5. 2. 6. 2 A d verse e ve nt a n d seri o us a d verse e ve nt c ollecti o n a n d re p orti n g T he i n vesti gat or s hall mai ntai n a n d kee p detaile d rec or ds of all A Es i n t heir patie nt files. C ollect i o n of A Es T he st u d y desi g n is of n o n -i nter ve nti o nal nat ure re gar di n g st u d y me dicati o n a n d t he st u d y is c o n d ucte d wit hi n t he c o n diti o ns of t he a p pr o ve d mar keti n g a ut h orisati o n. S ufficie nt data fr o m c o ntr olle d i nter ve nti o nal trials are a vaila ble t o s u p p ort t he e vi de nc e o n t he safet y a n d efficac y of t he st u die d BI dr u g. F or t his reas o n t he f oll o wi n g A E c ollecti o n a n d re p orti n g re q uire me nts ha ve bee n defi ne d. T he f oll o wi n g m ust be c ollecte d b y t he i n vesti gat or fr o m si g ni n g t he i nf or me d c o nse nt o n war ds u ntil t he e n d of t h e st u d y : -all Seri o us A d verse E ve nts ( S A Es) (re gar dless of ca usalit y ), -all N o n -seri o us A D Rs -a n d A E SIs All S A Es, all n o n -seri o us A D Rs, a n d A E SIs i ncl u di n g t h ose persisti n g after st u d y c o m pleti o n m ust be f oll o we d u p u ntil t he y are res ol ve d, ha ve bee n s uff icie ntl y c haracterize d, or n o f urt her i nf or mati o n ca n be o btai ne d. T he i n vesti gat or caref ull y assesses w het her a n A E c o nstit utes a n A D R usi n g t he i nf or mati o n bel o w. Ca usal relati o ns hi p of a d verse e ve nt T he defi niti o n of a n a d verse reacti o n i m plies at least a reas o na ble p ossi bilit y of a ca usal relati o ns hi p bet wee n a s us pecte d me dici nal pr o d uct a n d a n a d verse e ve nt. A n a d verse reacti o n, i n c o ntrast t o a n a d verse e ve nt, is c haracterise d b y t he fact t hat a c a usal relati o ns hi p bet wee n a me dici nal pr o d uct a n d a n occ urre nce is s us pecte d. Me dical j u d g me nt s h o ul d be use d t o deter mi ne t he relati o ns hi p, c o nsi deri n g all rele va nt fact ors, i ncl u di n g patter n of reacti o n, te m p oral relati o ns hi p, de -c halle n ge or re -c halle n ge, c o nf o u n di n g fact ors s uc h as c o nc o mita nt me dicati o n, c o nc o mita nt diseases a n d rele va nt hist or y . Ar g u me nts t hat ma y s u g gest a re as o n a ble c a us al rel ati o ns hi p c o ul d be: •T he e ve nt is c o nsiste nt wit h t he k n o w n p h ar m ac ol o g y of t he dr u g •T he e ve nt is k n o w n t o be ca use d b y or attri b ute d t o t he dr u g cl ass . •A pl a usi ble ti me t o o nset of t he e ve nt relati ve t o t he ti me of dr u g e x p os ure."
35,page_35,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 •E vi de nce t hat t he e ve nt is re pr o d uci ble w he n t he dr u g is re- i ntr o d uce d •N o me dic all y s o u n d alter n ati ve eti ol o gi es t hat c o ul d e x plai n t he e ve nt (e. g. pree xisti n g or c o nc o mita nt diseases, or c o -me dicati o ns). •T he e ve nt is t y picall y dr u g -rel ate d a n d i nfre q ue nt i n t he ge ner al p o p ul ati o n n ot e x p ose d t o dr u gs (e. g. Ste ve ns -J o h ns o n s y n dr o me). •A n i n dicati o n of d ose -res p o nse (i.e. greater effect size if t he d ose is i ncrease d, s maller effect size if d ose is di mi nis he d). Ar g u me nts t hat ma y s u g gest t hat t here is n o re as o n a ble p ossi bilit y of a c a us al rel ati o ns hi p c o ul d be: •N o pla usi ble ti me t o o nset of t he e ve nt relati ve t o t he ti me of dr u g e x p os ure is e vi de nt (e. g. pre -treat me nt cases, dia g n osis of ca ncer or c hr o nic disease wit hi n da ys/ wee ks of dr u g a d mi nistrati o n; a n aller gic reacti o n wee ks after disc o nti n uati o n of t he dr u g c o ncer ne d) •C o nti n uati o n of t he e ve nt des pite t he wit h d ra wal of t he me dicati o n, ta ki n g i nt o acc o u nt t he p har mac ol o gical pr o perties of t he c o m p o u n d (e. g. after 5 half- li ves). Of n ote, t his criteri o n ma y n ot be a p plica ble t o e ve nts w h ose ti me c o urse is pr ol o n ge d des pite re m o vi n g t he ori gi nal tri g ger. •A d diti o nal ar g u me nts a m o n gst t h ose state d bef ore, li ke alter nati ve e x pla nati o n (e. g. sit uati o ns w here ot her dr u gs or u n derl yi n g diseases a p pear t o pr o vi de a m ore li kel y e x pla nati o n f or t he o bser ve d e ve nt t ha n t he dr u g c o ncer ne d). •Disa p peara nce of t he e ve nt e ve n t h o u g h t he st u d y dr u g treat me nt c o nti n ues or re mai ns u nc ha n ge d. I nte nsit y of a d verse e ve nt T he i nte nsit y of t he A E s h o ul d be j u d ge d base d o n t he f oll o wi n g: Mil d: A ware ness of si g n(s) or s y m pt o m(s) w hic h is/are easil y t olerate d M o derate: E n o u g h disc o mf ort t o ca use i nterfere nce wit h us ual acti vit y Se vere: I n ca pacitati n g or ca usi n g i na bilit y t o w or k or t o perf or m us ual acti vities Pre g na nc y : I n rare cases, pre g na nc y mi g ht occ ur i n a st u d y . O nce a s u bject has bee n e nr olle d i nt o t he st u d y , after ha vi n g ta ke n ni nte d a ni b, t he i n vesti gat or m ust re p ort a n y dr u g e x p os ure d uri n g pre g na nc y , w hic h occ urre d i n a fe male s u bject or i n a part ner t o a male s u bject t o t he S p o ns or b y mea ns of Part A of t he Pre g na nc y M o nit ori n g F or m. T he o utc o me of t he pre g na nc y ass ociate d wit h t he dr u g e x p os ure d uri n g pre g na nc y m ust be f oll o we d u p a n d re p orte d b y mea ns of Part B of t he Pre g na nc y M o nit ori n g F or m. I n t he a bse nce of a re p orta ble A E, o nl y t he Pre g na nc y M o nit ori n g F or m m ust be c o m plete d, ot her wise t he NI S A E f or m is t o be c o m plete d a n d f or war de d as well wit hi n t he res pecti ve ti meli nes."
36,page_36,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 E x pe dite d Re p orti n g of A Es a n d Dr u g E x p os ure D uri n g Pre g na nc y T he f oll o wi n g m ust be r e p orte d b y t he i n vesti gat or o n t he NI S A E f or m fr o m si g ni n g t he i nf or me d c o nse nt o n war ds u ntil t he e n d of t he st u d y: T y pe of Re p ort Ti meli ne All Seri o us A d verse E ve nts (re g ar dless of c a us alit y i m me diatel y wit hi n 2 4 h o urs All n o n -seri o us A D Rs ass ociate d wit h ni nte da ni b 7 cale n dar da y s All pre g n a nc y m o nit ori n g f or ms 7 cale n dar da y s T he sa me ti meli nes a p pl y if f oll o w - u p i nf or mati o n bec o mes a vaila ble f or t he res pecti ve e ve nts. I n s pecific occasi o ns t he I n vesti gat or c o ul d i nf or m t he S p o ns or u p fr o nt via tele p h o ne. T his d oes n ot re place t he re q uire me nt t o c o m plete a n d s u b mit t he NI S A E f or m. I n f or mati o n re q uire d F or eac h re p orta ble a d verse e ve nt, t he i n vesti gat or s h o ul d pr o vi de t he i nf or mati o n re q ueste d o n t he NI SA E f or m. 5. 2. 6. 3 Re p orti n g t o healt h a ut h orities A d verse e ve nt re p orti n g t o re g ulat or y a ge ncies will be d o ne b y t he M A H acc or di n g t o l ocal a n d i nter nati o nal re g ulat or y re q uire me nts. 5. 3 D R U G C O N C E N T R A TI O N M E A S U R E M E N T S A N D P H A R M A C O KI N E TI C S 5. 3. 1 Assess me nt of ph ar m ac o ki netics N ot a p plica ble, t here are n o p har mac o ki netic assess me nts pla n ne d f or t his trial. 5. 3. 2 Met h o ds of s a m ple c ollecti o n N ot a p plica ble, t here are n o p har mac o ki netic assess me nts pla n ne d f or t his trial 5. 3. 3 A n al ytic al deter mi n ati o ns N ot a p plica ble, t here are n o p har mac o ki netic assess me nts pla n ne d f or t his trial. 5. 3. 4 P h ar m ac o ki netic – p h ar m ac o d y n a mic rel ati o ns hi p N ot a p plica ble, t here are n o p har mac o ki netic assess me nts pla n ne d f or t his trial. 5. 4 A S S E S S M E N T O F BI O M A R K E R ( S) N ot a p plica ble, t here are n o bi o mar ker assess me nts pla n ne d i n t his trial."
37,page_37,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 5. 5 O T H E R A S S E S S M E N T S N o ot her assess me nts are pla n ne d f or t his trial. 5. 6 A P P R O P RI A T E N E S S O F M E A S U R E M E N T S All meas ure me nts c o n d ucte d f or pri mar y a n d sec o n dar y e n d p oi nts are usi n g sta n dar d met h o ds.
38,page_38,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 3 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6. I N V E S TI G A TI O N A L P L A N 6. 1 VI SI T S C H E D U L E T his trial c o nsists of t w o parts, a scree n i n g a n d a n i nter ve nti o nal peri o d. T he scree ni n g peri o d c o nsists of t he ti me bet wee n si g ni n g c o nse nt a n d ra n d o mizati o n, a n d will last a mi ni m u m of 7 da y s. T he i nter ve nti o nal peri o d c o nsists of t he ti me fr o m ra n d o mizati o n t hr o u g h t he wee k 2 4 assess me nt visit. T here are t w o scree ni n g visit s( Visit 1 ,w hic h m ust be prece de d b y a se parate i nf or me d c o nse nt Visit 0) a n d 6visits ( Visits 2 t o 7) pla n ne d wit hi n t he 2 4 wee k i nter ve nti o nal peri o d . T here is n o f oll o w u p peri o d i n t his trial. After gi vi n g his/ her i nf or me d c o nse nt, t he patie nt will be scree ne d f or i ncl usi o n (se e Secti o n 3. 3. 2 a n d e xcl usi o n criteria (see Secti o n 3. 3. 3 ) f or t he trial at Visit s 0, 1 a n d Visit 2 (refer t o Fl o wc hart ). T he patie nt will be dis pe nse d a n acti vit y m o nit or a n d Pr o Acti ve t o ol (e Diar y) at t he c o nse nt visit, a n d will wear t he acti vit y m o nit or a n d use t he e Diar y f or 7 da y s pri or t o Visit 1 f or trai ni n g p ur p oses. Visit 2 ca n be perf or me d o nce t he res ults fr o m l ocal la b orat or y of Visit 1 are o btai ne d a n d t he patie nt has w or n t he acti vit y m o nit or a n d c o m plete d t he e Diar y f or 7 da y s. If f or a n y reas o n t he scree ni n g p hase f or a n i n di vi d ual patie nt lasts f or m ore t ha n 6 wee ks, t he n t he la b orat or y e xa mi n ati o n f or Visit 1 has t o be re peate d bef ore ra n d o mizati o n. T he patie nt will be ra n d o mize d at Visit 2 if all i ncl usi o n a n d n o ne of t he e xcl usi o n criteria are f ulfille d. Ce ntral H C R T is n ot re q uire d pri or t o ra n d o mizati o n, b ut if hist orical H R C T is n ot a vail a ble t o be se nt f or ce ntral calc ulati o n of Q L F, a sca n s h o ul d be o btai ne d after scree ni n g/c o nse nt at t he latest 7 da y s after Visit 2. O n treat me nt visits will be perf or me d at 3, 6, 1 2, 1 8 a n d 2 4 wee ks. Pr oce d ures f or t hese visits are o utli ne d i n t he fl o w c hart a n d detaile d i nstr ucti o ns are a vaila ble i n Secti o n 5 , select a p pe n dices a n d t he I S F ,as a p plica ble. Visit 7 is t he e n d of treat me nt visit, t here is n o f oll o w u p peri o d. Visit 7 pr oce d ures s h o ul d be f oll o we d f or earl y ter mi nati o n visits if p ossi ble. If a patie nt misses a visit, t he visit s h o ul d be resc he d ule d as s o o n as p ossi ble. If u na ble t o resc he d ule, t he cli nical m o nit or s h o ul d be c o ntacte d."
39,page_39,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 6. 2 D E T AI L S O F T RI A L P R O C E D U R E S A T S E L E C T E D VI SI T S 6. 2. 1 Scree ni n g a n d r u n -i n peri o d(s) Scree ni n g Peri o d Visit 0 -I nf or me d c o nse nt ( at le ast 7 d a ys bef ore Visit 1) I n f or me d c o nse nt will be o btai ne d pri or t o patie nt partici pati o n i n t he trial, w hic h i ncl u des a n y me dicati o n was h - o ut pr oce d ures or restricti o ns as well as H R C T tra nsfer t o ce ntral re vie w. U p o n o btai ni n g i nf or me d c o nse nt, t he patie nt will be i nstr ucte d o n t he me dicati o n was h o ut a n d ot her restricti o ns nee de d , a n d dis pe nse d a n e Diar y ( or e Diar y a p plicati o n f or o w n de vice) a n d acti vit y m o nit or if t he y meet t he i ncl usi o n a n d e xcl usi o n cr iteria at t his ti me. A preli mi nar y c hec k of i n -/e xcl usi o n criteria is rec o m me n de d at ti me of i nf or me d c o nse nt t o a v oi d u n necessar y pr oce d ures i n n o n - eli gi ble patie nts. C o nfir mati o n t hat t he patie nt is bei n g treate d wit h ni nte da ni b f or u p t o 3 0 m o nt hs will be c o nfir me d via me dical rec or ds, o bser vati o n of t he patie nt prescri pti o n me dicati o n, or me dical rec or ds will be re q ueste d t o c o nfir m. Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m ust be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. A n H R C T n ot ol der t ha n 2 4 m o nt hs will be se nt f or ce ntral calc ulati o n of Q L F , t o assess H R C T patter n f or patie nt c haracterizati o n. Pr o vi de d t he patie nt meets all ot her eli gi bilit y criteria, t he H R C T ca n be perf or me d f or t he p ur p oses of partici pati o n i n t he trial if t he patie nt d oes n ot ha ve a H R C T wit hi n 2 4 m o nt hs, at t he ti me of t he sc he d ule d Visit 2. Site pers o n nel will perf or m a scree ni n g call i n I R T t o e ns ure acc urat e trac ki n g of trial partici pati o n. Visit 1 De m o gra p hics Me dical hist or y i ncl u di n g pre -e xisti n g c o n diti o ns Me dicati o n rec or ds nee de d f or c o nfir mati o n t hat t he patie nt has bee n treate d wit h ni nte da ni b f or u p t o 3 0 m o nt hs will be re vie we d at t his visit if n ot a vaila ble at c o nse nt visit .Patie nts w h o ha ve rece ntl y starte d ni nte da ni b 1 5 0 m g BI D a n d ha ve starte d b y t he da y of ra n d o mizati o n m ust be o n ni nte da ni b 1 5 0 m g BI D a mi ni m u m of 1 0 da y s b y t he first da y of p ul m o nar y re ha bilitati o n. A n y a d verse e ve nts (si nce c o nse nt, if a p plica ble) S G R Q, K BI L D a n d U C S D S O B Q will be c o m plete d b y t he patie nt, pri or t o a n y pr oce d ures C ollect a n d d o w nl oa d/ re vie w P R Oacti ve T o ol fr o m e Diar y a n d acti vit y m o nit or data P h y sical e xa mi nati o n i ncl u di n g vital si g ns"
40,page_40,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 A resti n g 1 2 -lea d electr ocar di o gra m usi n g site’s o w n e q ui p me nt will be perf or me d a n d e val uate d b y t he I n vesti gat or ( if p ossi ble pri or t o bl o o d dra w) Resti n g S P 0 2 F V C meas ure me nt swill be c o n d ucte d usi n g t he site’s o w n e q ui p me nt, per t he i nstr ucti o ns i n Secti o n 5. 1. 2. 3 D L c o meas ure me nt will be c o n d ucte d. F V C meas ure me nt has t o be d o ne first, f oll o we d b y patie nt’s rest a n d s u bse q ue nt D L c o meas ure me nt Bl o o d a n d uri ne sa m ples (safet y la b a n d ser u m pre g na nc y if w o ma n of c hil d beari n g p ote ntial ) will b e c ollecte d a n d s u b mitte d t o t he l ocal la b orat or y (f or details refer t o Secti o n 5. 2. 3 ). Pri or t o bl o o d dra w a pre -assess me nt of all i ncl usi o n a n d e xcl usi o n criteria is hi g hl y rec o m me n de d Practice 6 mi n ute wal k test I n cre me ntal a n d practice wor k rate c y cle er g o metr y test perf or me d at t he cli nic at e n d of Visit 1 Se n d H R C T t o ce ntral calc ulati o n of Q L F if a vaila ble, or sc he d ule patie nt f or H R C T if n ot a vaila ble F or patie nts q ualifie d t o e nter t he scree ni n g peri o d, patie nts will be dis pe nse d a n e Diar y ( or e Diar y a p plicati o n f or o w n de vice) a n d acti vit y m o nit or a n d i nstr ucte d o n t he use of b ot h de vices, wit h s pecific i nstr ucti o ns gi ve n t o use b ot h de vices f or 7 da ys pri or t o Visit 2 Visit 2 will be sc he d ule d If patie nt fails scree ni n g, I R T call t o disc o nti n ue patie nt 6. 2. 2 Tre at me nt peri o d(s) Treat me nt p hase will be a 2 4 wee k peri o d, be gi n ni n g at visit 2. Visits are pla n ne d after 3, 6, 1 2, 1 8 a n d 2 4 wee ks after ra n d o mi zati o n. If a d diti o nal ti me is nee de d after ra n d o mizati o n t o sc he d ule t he p ul m o nar y re ha bilitati o n f or a patie nt ra n d o mize d t o t hat gr o u p, t he ti me bet wee n visits 2 a n d 3 ma y be e xte n de d u p t o 6wee ks. T he visit sc he d ule will res u me o n t he da y of t he first p ul m o nar y re ha bilitati o n visit, a n d all s u bse q ue nt visit swill be sc he d ule d acc or di n gl y t o kee p t he ti me bet wee n visits per pr ot oc ol a n d a t otal 2 4 wee k treat me nt peri o d . D uri n g all t he visits it is i m p orta nt t hat patie nts’ q uesti o n naires are c o m plete d bef ore a n y ot her pr oce d ure. T he or der of t he ot her pr oce d ures t o be f oll o we d is gi ve n bel o w as a n i n dicati o n b ut ca n be a da pte d f or practical reas o ns."
41,page_41,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Visit 2 S G R Q, K BI L D a n d U C S D S O B Q A d verse e ve nts a n d c o nc o mita nt t hera p y assess me nt si nce last visit D o w nl oa d /re vie w P R Oacti ve T o ol a n d acti vit y m o nit or res ults P h y sical e xa mi nati o n i ncl u di n g vital si g ns Resti n g S p O 2 Bl o o d sa m ples f or la b orat or y tests Uri nar y pre g na nc y test P ul m o nar y f u ncti o n test i ncl u di n g F V C D L C O Assess me nt of i n/e xcl usi o n criteria Ra n d o misati o n via I R T 6 mi n ute wal k test  Sc he d ule patie nt f or p ul m o nar y re ha bilitati o n if ra n d o mize d t o t hat treat me nt gr o u p Sc he d ule Visit 3 Se n d H R C T f or calc ulati o n of Q L F if n ot pre vi o usl y a vaila ble . Visits 3, 4, 5 a n d 6: A d verse e ve nts a n d c o nc o mita nt t hera p y assess me nt si nce last visit C ollect a n d d o w nl oa d/re vie w P R O Acti ve T o ol fr o m e Diar y a n d acti vit y m o nit or data at Visit 5 Re vie w p ul m o nar y re ha bilitati o n atte n da nce wit h patie nt a n d rec or d i nf or mati o n fr o m p ul m o nar y re ha bilitati o n re p orts i nt o e C R F f or patie nts i n t he P R treat me nt gr o u p at Visits 3, 4 a n d 5 P h y sical e xa mi nati o n i ncl u di n g vital si g ns Bl o o d sa m ples f or la b orat or y tests Uri nar y pre g na nc y test S G R Q, K BI L D a n d U C S D S O B Q at Visit 5 P ul m o nar y f u ncti o n test i ncl u di n g F V C at Visit 5 D L C O at Visit 5 S P 0 2 at Visit 5 Si x mi n ute wal k test at Visit 5  I nstr uct patie nt o n acti vit y m o nit ori n g a n d e Diar y ( or e Diar y a p plicati o n f or o w n de vice) a n d re mi n d patie nt t he y nee d t o pic k u p or will recei ve de vice i n t he mail t o all o w 7 da y s of use pri or t o ne xt visit at Visits 4 a n d 6 Sc he d ule ne xt visit. 6. 2. 3 F oll o w u p p eri o d a n d tri al co m pleti o n Visit 7/ E n d of Treat me nt ( E O T) or w he n t he patie nt is disc o nti n ue d A d verse e ve nts a n d c o nc o mita nt t hera p y assess me nt si nce last visit"
42,page_42,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Re vie w p ul m o nar y re ha bilitati o n atte n da nce wit h patie nt a n d rec or d i nf or mati o n fr o m p ul m o nar y re ha bilitati o n re p orts i nt o e C R F f or patie nts i n t he P R treat me nt gr o u p (f or patie nts disc o nti n ue d d uri n g first 1 2 wee ks) P h y sical e xa mi nati o n i ncl u di n g vital si g ns S G R Q, K BI L D a n d U C S D S O B Q C ollect a n d d o w nl oa d/re vie w P R O Acti ve T o ol fr o m e Diar y a n d acti vit y m o nit or data Resti n g S p O 2 Resti n g 1 2 -lea d electr ocar di o gra m Bl o o d sa m ples f or la b orat or y tests Uri nar y pre g na nc y test ( d o ne l ocall y) P ul m o nar y f u ncti o n test i ncl u di n g F V C D L C O Si x mi n ute wal k test  E n d Of Treat me nt pa ge t o be c o m plete d"
43,page_43,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 7. S T A TI S TI C A L M E T H O D S A N D D E T E R MI N A TI O N O F S A M P L E SI Z E 7. 1 S T A TI S TI C A L D E SI G N - M O D E L T his is a m ulti -ce ntre, pr os pecti ve, ra n d o mise d, o pe n la bel cli nical trial t o i n vesti gate t he effect of p ul m o nar y re ha bilitati o n i n patie nts wit h I P F c urre ntl y treate d wit h ni nte da ni b at a d ose of 1 5 0 m g bi d f or u p t o 3 0 m o nt hs . T he pri mar y e n d p oi nt is t he c ha n ge fr o m baseli ne i n 6 M W D at 1 2 wee ks. 6 M W D will be a nal ys e d o n t he ori gi nal scale usi n g t he A nal ys is of C o varia nce ( A N C O V A) m o del i ncl u di n g i nter ve nti o n as a fi xe d cate g orical c o variate a n d baseli ne 6 M W D as a c o nti n u o us c o variate. M ore detail is pr o vi de d i n Secti o n 7. 3. 1 . T he sec o n dar y a n d f urt her e n d p oi nts are liste d i n Secti o n 5. 1. 1 . T he 1 2 -wee k e n d p oi nts will be a nal ys e d usi n g si milar A N C O V A met h o d ol o g y as t he pri mar y e n d p oi nt. T he 2 4 - wee k en d p oi nts will be a nal y ze d usi n g a mi xe d m o del wit h re peate d meas ures. M ore detail is pr o vi de d i n Secti o n 7. 3. 2 . 7. 2 N U L L A N D A L T E R N A TI V E H Y P O T H E S E S T he o bjecti ve of t his st u d y is t o de m o nstrate t he differe nce of Ni nte da ni b a n d p ul m o nar y re ha bili tati o n c o m bi nati o n i nter ve nti o n c o m pare d t o Ni nte da ni b -o nl y i n t he treat me nt of patie nts wit h I P F. T his will be teste d usi n g t he set of h y p ot heses i n dicate d bel o w. T he n ull h y p ot hesis is H 0: N o differe nce i n mea n f or c ha n ge i n 6 M W D at 1 2 wee ks bet wee n Ni nte da ni b a n d p ul m o nar y re ha bilitati o n c o m bi nati o n i nter ve nti o n a n d Ni nte da ni b -o nl y i nter ve nti o n . T he alter nati ve h y p ot hesis is Ha: T he mea n f or c ha n ge i n 6 M W D at 1 2 wee ks is differe nt f or patie nts ta ki n g Ni nte da ni b a n d p ul m o nar y re ha bili tati o n c o m bi nati o n i nter ve nti o n t ha n i n Ni nte da ni b - o nl y i nter ve nti o n . H 0 will be teste d at t he 5 % le vel (t w o -si de d test). 7. 3 P L A N N E D A N A L Y S E S All i n di vi d ual data will be liste d. Sta n dar d statistical para meters ( n u m ber of n o n -missi n g val ues, mea n, ge o metric mea n, sta n dar d de viati o n ( S D), me dia n, q uartiles, mi ni m u m a n d ma xi m u m) or fre q ue nc y ta bles will be calc ulate d w here a p pr o priate. I n ge neral, t hese para meters or fre q ue ncies will be calc ulate d se paratel y f or eac h i nter ve nti o n , b ut j oi ntl y f or all st u d y ce nt res."
44,page_44,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he statistical a nal ys is will be base d o n t he f oll o wi n g p o p ulati o ns: Ra n d o mize d Set ( R S): T he Ra n d o mise d set ( R S) c o nsists of t h ose patie nts w h o were ra n d o mize d t o a ni nter ve nti o n . The efficac y will be c o n d ucte d o n t he Ra n d o mize d Set . F or efficac y a nal ys is, all meas ure me nt sperf or me d wit hi n visits 2 -7 will be use d. Alt h o u g h t here is n o per pr ot oc ol data set i n t he st u d y , reas o ns f or i m p orta nt pr ot oc ol vi olati o ns will be s pecifie d i n t he Trial Statistical A nal y sis Pla n ( T S A P). Patie nts wit h p ote ntial i m p orta nt pr ot oc ol vi olati o ns (t h ose t hat relate t o patie nt safet y or efficac y) will be i de ntifie d at Bli n de d Re vie w Pla n ni n g Meeti n gs a n d liste d i n t he cli nical trial . 7. 3. 1 Pri m ar y e n d p oi nt a n al yses T he pri mar y a nal ys is is a restricte d ma xi m u m li keli h o o d ( R E M L ) base d a nal y sis of c o varia nce ( A N C O V A) c o m pari n g t he c ha n ge fr o m baseli ne of 6 M W D after 1 2 wee ks of treat me nt wit h a dj ust me nt f or t he c o variates of i nter ve nti o n as a fi xe d cate g orical c o variate a n d baseli ne 6 M W D val ue as a c o nti n u o us c o variate. T he statistical m o del will be as f oll o ws:      =      +    +          =res p o nse varia ble f or t he s u bject  recei vi n g i nter ve nti o n     = fi xe d effect re gressi o n c oefficie nt of baseli ne effect   =t he baseli ne meas ure me nt of s u bject  ,   = 1, 2, … w here t he baseli ne meas ure me nt is c ollecte d o n Da y 1 of t he i nter ve nti o nal peri o d   = t he fi xe d effect of i nter ve nti o n j, j= 1, 2   =t he ra n d o m err or ass ociate d wit h t he    s u bject, i de nticall y i n de pe n de nt n or mall y distri b ute d wit h mea n 0 a n d u n k n o w n varia nce   . T he Ke n war d -R o ger a p pr o xi mati o n will be use d t o esti mate de n o mi nat or de grees of free d o m a n d a dj ust sta n dar d err ors. Si g nifica nce tests will be base d o n least -s q u ares mea ns usi n g a t w o- si de d α = 0. 0 5 (t w o -si de d 9 5 % c o nfi de nce i nter vals). T he pri mar y i nter ve nti o n c o m paris o n will be t he least -s q uares mea ns c o ntrast bet wee n i nter ve nti o ns .Pri mar y e n d p oi nt a nal ys es will be d o ne o n c o m plete cases. Secti o n 7. 3. 2 disc uss es pla n ne d se nsiti vit y a nal ys is t o assess t he i m pact of patie nts missi n g p ost- ra n d o misati o n data. 7. 3. 2 Sec o n d ar y e n d p oi nt a n al yses T he sec o n dar y e n dp oi nts i ncl u de t h ose liste d i n Secti o n 5. 1. 1. 2 . All ot her sec o n dar y e n d p oi nts will b e a nal y se d o n t he ori gi nal scales."
45,page_45,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he 1 2 - wee k sec o n dar y e n d p oi nts will be a nal y se d e q ui vale ntl y as t he pri mar y e n d p oi nt usi n g t he A N C O V A m o del i ncl u di n g i nter ve nti o n as a fi xe d cate g orical c o variate a n d baseli ne val ue as a c o nti n u o us c o variate. T he 2 4 -wee k sec o n dar y e n d p oi nts will be a nal y se d wit h a restricte d ma xi m u m li keli h o o d ( R E M L ) base d a p pr oac h usi n g a mi xe d m o del wit h re peate d meas ure me nts ( M M R M) c o m pari n g t he c ha n ge fr o m baseli ne after 2 4 wee ks of i nter ve nti o n . T he a nal y sis will i ncl u de t he fi xe d, cate g orical effects of i nter ve nti o n a n d t he fi xe d c o nti n u o us effects of baseli ne at eac h visit. Visit will be treate d as t he re peate d meas ure wit h a n u nstr uct ure d c o varia nce str uct ure use d t o m o del t he wit hi n -patie nt meas ure me nts. T he statistical m o del will be as f oll o ws:        =      +       +            ~    (  ,  )        =res p o nse varia ble f or t he s u bject  at visit  recei vi n g i nter ve nti o n  ,   =coefficie nt of baseli ne effect at visit  ,   =t he baseli ne meas ure me nt of s u bject  ,   = 1, 2, …      =t he effect of i nter ve nti o n kat visit j; j = 1, 2 (, 3) a n d k= 1, 2      =t he ra n d o m err or ass ociate d wit h t he    visit of t he      s u bject, Err ors are i n de pe n de nt bet wee n s u bjects,   = a n u nstr uct ure d c o varia nce matri x. T he Ke n war d -R o ger a p pr o xi mati o n will be use d t o esti mate de n o mi nat or de grees of free d o m a n d a dj ust sta n dar d err ors. Si g nifica nce tests will be base d o n least -s q uares mea ns usi n g a t w o- si de d α = 0. 0 5 (t w o -si de d 9 5 % c o nfi de n ce i nter vals). T he pri mar y i nter ve nti o n c o m paris o n will be t he least -s q uares mea ns c o ntrast bet wee n treat me nts. A se nsiti vit y a nal ys is of t he pri mar y a nal ys is will be perf or me d usi n g m ulti ple i m p utati o n t o ha n dle missi n g data. All varia bles i ncl u de d i n t he a nal ys is m o del will be i ncl u de d i n t he i m p utati o n m o del. I n a d diti o n, after e x pl ori n g t he missi n g data mec ha n is m a n d o bser ve d meas ure me nts o n t he bli n de d data, a d diti o nal varia bles ma y be i ncl u de d i n t he i m p utati o n m o del, base d o n t heir ass ociati o ns wit h t he o bser ve d e n d p oi nt val ue a n d/ or t he missi n g ness mec ha nis m. T h ose varia bles will be i de ntifie d i n t he T S A P. F or eac h i m p ute d c o m plete dataset, t he pri mar y a nal y sis m o del will be use d f or t he a nal ys is. T he res ults will be p o ole d f oll o wi n g t he sta n dar d m ulti ple i m p utati o n pr oce d ure."
46,page_46,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 7. 3. 4 S afet y a n al yses A nal y sis of a d verse e ve nts will be restricte d t o ni nte da ni b -relate d seri o us a d verse e ve nts, ni nte da ni b - n o n-relate d seri o us a d verse e ve nts a n d e ve nts of s pecial i nte rest. A d verse e ve nts will be c o de d usi n g t he Me dical Dicti o nar y f or Dr u g Re g ulat or y Acti vities ( Me d D R A). Sta n dar d BI s u m mar y ta bles a n d listi n gs will be pr o d uce d. A d verse e ve nts wit h a n o nset bet wee n start of p ul m o nar y re ha bilitati o n treat me nt a n d e n d of t rial will be assi g ne d t o t he o n-treat me nt peri o d f or e val uati o n. All ra n d o mize d patie nts will be i ncl u de d i n t he safet y a nal ysis. I n ge neral, safet y a nal ys es will be descri pti ve i n nat ure a n d will be base d o n BI sta n dar ds. N o h y p ot hesis testi n g is pla n ne d . Fre q ue nc y , se verit y, a n d ca usal relati o ns hi p of a d verse e ve nts will be ta b ulate d b y s ys te m or ga n class a n d preferre d ter m after c o di n g acc or di n g t o t he c urre nt versi o n of t he Me dical Dicti o nar y f or Dr u g Re g ulat or y Acti vities at t he data base l oc k. Vital si g ns, p h ys ical e xa mi nati o ns, or ot her safet y-rele va nt data o bser ve d at scree ni n g, baseli ne, d uri n g t he c o urse of t he trial a n d at t he e n d - of- trial e val uati o n will be assesse d wit h re gar d t o p ossi ble c ha n ges c o m pare d t o fi n di n gs bef ore start of p ul m o nar y re ha bilitati o n. A nal y sis of la b orat or y data a n d electr ocar di o gra m is n ot pla n ne d. 7. 3. 5 P h ar m ac o ki netic a n d P h ar m ac o d y n a mic a n al yses T here is n o p har mac o ki netic a nal ys es pla n ne d f or t his trial. 7. 4 I N T E RI M A N A L Y S E S N o i nteri m a nal ys is is pla n ne d. A re g ular re vie w of safet y data will als o be c o n d ucte d t o m o nit or t he safet y of patie nts i n t he trial."
47,page_47,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 7. 5 H A N D LI N G O F MI S SI N G D A T A I n efficac y a nal ys es of c o nti n u o us e n d p oi nts missi n g data will n ot be i m p ute d. M ulti ple i m p utati o n will be use d as a se nsiti v it y a nal ys is t o ha n dle missi n g data. Detaile d descri pti o n of m ulti ple i m p utati o n will be i ncl u de d i n t he T S A P. 7. 6 R A N D O MI S A TI O N Patie nts will be ra n d o mize d i n bl oc ks t o p ul m o nar y re ha bilitati o n gr o u ps wit h a n e q ual pr o ba bilit y of assi g n me nt t o eac h treat me nt gr o u p (see Secti o ns 4. 1. 2, 4. 1. 3 a n d 4. 1. 4 f or details). BI will arra n ge f or t he ra n d o mi sati o n. T he ra n d o mis ati o n list will be ge nerate d usi n g a n I nteracti ve Res p o nse Tec h n ol o g y (I R T) , w hic h i n v ol ves a pse u d o -ra n d o m n u m ber ge nerat or s o t hat t he res ulti n g treat me nt will be b ot h re pr o d uci ble a n d n o n -pre dicta ble. Access t o t he c o des will be c o ntr olle d a n d d oc u me nte d. T he bl oc k size will be d oc u me nte d i n t he cli nical trial re p ort. 7. 7 D E T E R MI N A TI O N O F S A M P L E SI Z E I n t he 1 1 9 9. 1 8 7 6 -m o nt h data, a n u na dj uste d mea n f or a bs ol ute c ha n ge fr o m baseli ne i n 6 M W T dista nce of 4. 9 meters (s d = 7 6. 5) was o bser ve d f or ni nte da ni b. T o c o nser vati vel y esti mate t he sa m ple size, a sta n dar d de viati o n of 8 5. 0 is use d i n esti mati o n. I n t he 2 0 1 4 C oc hra ne Data base of S yste matic Re vie ws [ R 1 8 -1 7 0 4 ], a mea n f or a bs ol ute c ha n ge fr o m baseli ne i n 6 M W T dista nce of 4 4. 3 meters was o bser ve d f or p ul m o nar y re ha bilitati o n f or i nterstitial l u n g dis ease. T he mi ni mal cli nicall y i m p orta nt differe nce f or t he 6 M W D f or I P F patie nts wit h c o m bi ne d treat me nt of ni nte da ni b a n d p ul m o nar y re ha bilitati o n vers us I P F patie nts treate d wit h ni nte da ni b o nl y is 3 0 meters [R 1 8 - 1 7 6 7 ]. I n li g ht of t he a vaila ble e vi de nce, at least 2 5 4 patie nts w o ul d be re q uire d t o pr o vi de 8 0 % p o wer t o detect a differe nce i n mea ns of 3 0 meters bet wee n ni nte da ni b a n d p ul m o nar y re ha bilitati o n c o m bi nati o n treat me nt vers us ni nte da ni b b y itself wit h a t w o- si de d t y pe- I err or of 0. 0 5. Ass u mi n g 1 0 % dr o p o ut, at least 1 4 1 patie nts per ar m, or 2 8 2 patie nts will be re q uire d. Calc ulati o ns were perf or me d usi n g n Q uer y A d vis or ® 6. 1 statistical pac ka ge b y Statistical S ol uti o ns L t d. u n der t he fi xe d ter m test of mea ns wit h t w o g r o u ps o pti o n f or st u de nt t -test wit h e q ual varia nce. Differe nce i n Mea ns C o m m o n Sta n dar d De viati o n P o wer ( %) T otal N of ra n d o mize d patie nts 3 0. 0 7 7. 0 8 0 2 1 0 3 0. 0 8 5. 0 8 0 2 5 4"
48,page_48,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 4 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 8. I N F O R M E D C O N S E N T, T RI A L R E C O R D S, D A T A P R O T E C TI O N, P U B LI C A T I O N P O LI C Y, A N D A D MI NI S T R A TI V E S T R U C T U R E T he trial will be carrie d o ut i n c o m plia nce wit h t he pr ot oc ol, t he et hical pri nci ples lai d d o w n i n t he Declarati o n of Helsi n ki, i n acc or da nce wit h t he I C H Har m o nize d Tri partite G ui deli ne f or G o o d Cli nical Practice ( G C P), rele va nt BI Sta n dar d O perati n g Pr oce d ures ( S O Ps), Sta n dar d me dical care ( pr o p h y lactic, dia g n ostic a n d t hera pe utic pr oce d ures) re mai ns t he res p o nsi bilit y of t he treati n g p h y sicia n of t he patie nt . T he i n vesti gat or will i nf or m t he s p o ns or i m me diatel y of a n y ur ge nt safet y meas ures ta ke n t o pr otect t he trial patie nts a gai nst a n y i m me diate hazar d, as well as of a n y s eri o us breac hes of t he pr ot oc ol or of I C H G C P. T he B oe hri n ger I n gel hei m tra ns pare nc y a n d p u blicati o n p olic y ca n be f o u n d o n t he f oll o wi n g we b pa ge : trials. b oe hri n ger -i n gel hei m.c o m . T he ri g hts of t he i n vesti gat or a n d of t he s p o ns or wit h re gar d t o p u blicati o n of t he res ults of t his trial are descri be d i n t he i n vesti gat or c o ntract. As a r ule, n o trial res ults s h o ul d be p u blis he d pri or t o fi nalizati o n of t he Cli nical Trial Re p ort. 8. 1 T RI A L A P P R O V A L, PA TI E N T I N F O R M A TI O N, I N F O R M E D C O N S E N T T his trial will be i nitiate d o nl y after all re q uire d le gal d oc u me ntati o n has bee n re vie we d a n d a p pr o ve d b y t he res pecti ve I nstit uti o nal Re vie w B oar d (I R B) / I n de pe n de nt Et hics C o m mittee (I E C) a n d c o m pete nt a ut h orit y ( C A ) acc or di n g t o nati o nal a n d i nter nati o nal re g ulati o ns. T he sa me a p plies f or t he i m ple me ntati o n of c ha n ges i ntr o d uce d b y a me n d me nts. Pri or t o patie nt partici pati o n i n t he trial , writte n i nf or me d c o nse nt m ust be o btai ne d fr o m eac h patie nt ( or t he patie nt ’s le gall y acce pte d re prese ntati ve) acc or di n g t o I C H / G C P a n d t o t he re g ulat or y a n d le gal re q uire me nts of t he partici pati n g c o u ntr y . Eac h si g nat ure m ust be pers o nall y date d b y eac h si g nat or y a n d t he i nf or me d c o nse nt a n d a n y a d diti o nal patie nt - i nf or mati o n f or m retai ne d b y t he i n vesti gat or as part of t he trial rec or ds. A si g ne d c o p y of t he i nf or me d c o nse nt a n d a n y a d diti o nal patie nt i nf or mati o n m ust be gi ve n t o eac h patie nt or t he patie nt ’s le gall y acce pte d re prese ntati ve.” T he i n vesti gat or m ust gi ve a f ull e x pla nati o n t o trial patie nt s base d o n t he patie nt i nf or mati o n f or m. A la n g ua ge u n dersta n da ble t o t he patie nt s h o ul d be c h ose n, tec h nical ter ms a n d e x pressi o ns a v oi de d, if p ossi ble."
49,page_49,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he patie nt m ust be gi ve n s ufficie nt ti me t o c o nsi der partici pati o n i n t h e trial . T he i n vesti gat or o btai ns writte n c o nse nt of t he patie nt ’s o w n free will wit h t he i nf or me d c o nse nt f or m after c o nfir mi n g t hat t he patie nt u n dersta n ds t he c o nte nts. Re -c o nse nti n g ma y bec o me necessar y w he n ne w rele va nt i nf or mati o n bec o mes a vaila ble a n d s h o ul d be c o n d ucte d acc or di n g t o t he s p o ns or’s i nstr ucti o ns. T he c o nse nt a n d re - c o nse nti n g pr ocess s h o ul d be pr o perl y d oc u me nte d i n t he s o urce d oc u me ntati o n. 8. 2 D A T A Q U A LI T Y A S S U R A N C E A q ualit y ass ura nce a u dit/i ns pecti o n of t his trial ma y be c o n d ucte d b y t he s p o ns or, s p o ns or’s desi g nees, or b y I R B / I E C or b y re g ulat or y a ut h orities. T he q ualit y ass ura nce a u dit or will ha ve access t o all me dical rec or ds, t he i n vesti gat or ’s trial -relate d files a n d c orres p o n de nce, a n d t he i nf or me d c o nse nt d oc u me ntati o n of t his cli nical trial . 8. 3 R E C O R D S C R F sf or i n di vi d ual patie nt s will be pr o vi de d b y t he s p o ns or. 8. 3. 1 S o urce d oc u me nts I n acc or da nce wit h re g ulat or y re q uire me nts t he i n vesti gat or s h o ul d pre pare a n d mai ntai n a de q uate a n d acc urate s o urce d oc u me nts a n d trial rec or ds t hat i ncl u de all o bser vati o ns a n d ot her data perti ne nt t o t he i n vesti gati o n o n eac h trial patie nt . S o urce data as well as re p orte d data s h o ul d f oll o w g o o d d oc u me ntati o n practices a n d be attri b uta ble, le gi ble, c o nte m p ora ne o us, ori gi nal a n d acc urate . C ha n ges t o t he data s h o ul d be tracea ble (a u dit trail). Data re p orte d o n t he C R F m ust be c o nsiste nt wit h t he s o urce data or t he discre pa ncies m ust be e x plai ne d. T he c urre nt me dical hist or y of t he patie nt m a y n ot be s ufficie nt t o c o nfir m eli gi bilit y f or t h e trial a n d t he i n vesti gat or ma y nee d t o re q uest pre vi o us me dical hist ories a n d e vi de nce of a n y dia g n ostic tests. I n t his case t he i n vesti gat or m ust ma ke t hree d oc u me nte d atte m pts t o retrie ve pre vi o us me dical rec or ds. If t his fails a ver bal hist or y fr o m t h e patie nt , d oc u me nte d i n t heir me dical rec or ds, w o ul d be acce pta ble. D uri n g t he site visit t he s p o ns or’s C R A or a u dit or m ust be gra nte d access t o t he ori gi nal patie nt file ( please see secti o n 8. 3. 2 ). T he i n vesti gat or m ust e ns ur e t ha t all patie nt i de ntifiers (e. g. patie nt ’s na me, i nitials, a d dress, p h o ne n u m ber, s ocial sec urit y n u m ber ) ha ve pr o perl y bee n re m o ve d or re dacte d fr o m a n y c o p y of t he patie nt s’ s o urce d oc u me nts bef ore se n di n g t he m t o t he s p o ns or . If t he patie nt is n ot c o m plia nt wit h t he pr ot oc ol , a n y c orrecti ve acti o n e. g. re -trai ni n g m ust be d oc u me nte d i n t he patie nt file"
50,page_50,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 F or t he C R F, data m ust be deri ve d fr o m s o urce d oc u me nts, f or e xa m ple: Patie nt i de ntificati o n : ge n der, year of birt h (i n acc or da nce wit h l ocal la ws a n d re g ulati o ns ) Patie nt partici pati o n i n t he trial (s u bsta nce, trial n u m ber, patie nt n u m ber, date patie nt was i nf or me d) Dates of patie nt ’s visits, i ncl u di n g dis pe nsi n g of trial me dicati o n Me dical hist or y (i ncl u di n g trial i n dicati o n a n d c o nc o mita nt diseases, if a p plica ble) Me dicati o n hist or y A d verse e ve nts a n d o utc o me e ve nts ( o nset date ( ma n dat or y ), a n d e n d date (if a vaila ble)) Seri o us a d verse e ve nts ( o nset date ( ma n dat or y ), a n d e n d date (if a vaila ble)) C o nc o mita nt t hera p y (start date, c ha n ges) Ori gi nals or c o pies of la b orat or y res ults a n d ot her i ma gi n g or testi n g res ults, wit h pr o per d oc u me nte d me dical e val uati o n (i n vali date d electr o nic f or mat, if a vaila ble) C o m pleti o n of patie nt’s p artici pati o n i n t he trial ” (e n d date; i n case of pre mat ure disc o nti n uati o n d oc u me nt t he reas o n f or it). Pri or t o all ocati o n of a patie nt t o a treat me nt i nt o a cli nical trial , t here m ust be d oc u me nte d e vi de nce i n t he s o urce data (e. g. me dical rec or ds) t hat t he trial partici pa nt meets all i ncl usi o n criteria a n d d oes n ot meet a n y e xcl usi o n criteria. T he a bse nce of rec or ds (eit her me dical rec or ds, ver bal d oc u me nte d fee d bac k of t he patie nt or testi n g c o n d ucte d s pecific f or a pr ot oc ol) t o s u p p ort i ncl usi o n/e xcl usi o n criteria d oes n ot ma ke t he patie nt eli gi ble f or t he cli nical trial . 8. 3. 2 Direct access t o s o urce d at a a n d d oc u me nts T he s p o ns or will m o nit or t he c o n d uct of t he trial b y re g ular o n -site m o nit ori n g visits a n d i n - h o use data q ualit y re vie w. T he fre q ue nc y of site m o nit ori n g will be deter mi ne d b y asses si n g all c haracteristics of t he trial , i ncl u di n g its nat ure, o bjecti ve, met h o d ol o g y a n d t he de gree of a n y de viati o ns of t he i nter ve nti o n fr o m n or mal cli nical practice. T he i n vesti gat or /i nstit uti o n will all o w site trial -relate d m o nit ori n g, a u dits, I R B /I E C re vie w a n d re g ulat or y i ns pecti o ns. Direct access m ust be pr o vi de d t o t he C R F a n d all s o urce d oc u me nts/ data, i ncl u di n g pr o gress n otes, c o pies of la b orat or y a n d me dical test res ults, w hic h m ust be a vaila ble at all ti mes f or re vie w b y t he C R A , a u dit or a n d r e g ulat or y i ns pect or (e. g. F D A). T h e y m a y re vie w all C R Fs a n d i nf or me d c o nse nts. T he acc urac y of t he data will be verifie d b y direct c o m paris o n wit h t he s o urce d oc u me n ts descri be d i n secti o n 8. 3. 1 .T he s p o ns or will als o m o nit or c o m plia nce wit h t he pr ot oc ol a n d G C P. A n a da pti ve a p pr oac h t o cli nical trial m o nit ori n g will be utilise d. T his is i nitiate d b y a n assess me nt of t he ris k ass ociate d wit h t he trial c o m bi ne d wit h i de ntificati o n of critical dat a a n d pr ocesses. A n I nte grate d Q ualit y a n d Ris k Ma na ge me nt Pla n d oc u me nts t he strate gies i n v ol ve d wit h t he i m ple me ntati o n of o nsite, offsite a n d ce ntral m o nit ori n g ac ti vities i n or der t o direct f oc us t o t he areas of greatest ris k w hic h ha ve t he m ost p ote ntial i m pact t o patie nt safet y a n d data q ualit y. Trial o versi g ht is ac hie ve d b y re g ular re vie w of a re p ort of ris k w hic h t he n i nfl ue nces a n y m o nit ori n g a da ptati o ns."
51,page_51,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 T he i n vesti gat or /i nstit uti o n will all o w o n -site trial -relate d m o nit ori n g, a u dits, I R B/ I E C re vie w a n d re g ulat or y i ns pecti o ns. Direct a ccess s h o ul d be gra nte d t o all s o urce d oc u me nts (pa per a n d e -rec or ds) i ncl u di n g pr o gress n otes, c o pies o f la b orat or y a n d me dical test res ults T he C R A a n d a u dit or ma y re vie w all C R Fs a n d i nf or me d c o nse nts. T he ac c urac y of t he data will be verifie d b y direct c o m paris o n wit h t he s o urce d oc u me nts descri be d i n secti o n 8. 3. 1 .T he s p o ns or will als o m o nit or c o m plia nce wit h t he pr ot oc ol a n d I C H G C P. 8. 3. 3 St or a ge peri o d of rec or ds Trial site(s): T he trial site(s) m ust retai n t he s o urce a n d esse ntial d oc u me nts (i ncl u di n g I S F) acc or di n g t o c o ntract or t he l ocal re q uire me nts vali d at t he ti me of t he e n d of t he trial ( w hate ver is l o n ger). S p o ns or : T he s p o ns or m ust retai n t he esse ntial d oc u me nts acc or di n g t o t he s p o ns or’s S O Ps. 8. 4 E X P E DI T E D R E P O R TI N G O F A D V E R S E E V E N T S BI is res p o nsi ble t o f ulfil t heir le gal a n d re g ulat or y re p orti n g o bli gati o n i n acc or da nce wit h re g ulat or y re q uire me nts. 8. 5 S T A T E M E N T O F C O N FI D E N TI A LI T Y A N D P A TI E N T P RI V A C Y I n di vi d ual patie nt data o btai ne d as a res ult of t his trial is c o nsi dere d c o nfi de ntial a n d discl os ure t o t hir d parties is pr o hi bite d wit h t he e xce pti o ns n ote d bel o w. Patie nt pri vac y will be e ns ure d b y usi n g patie nt i de ntificati o n c o de n u m bers. Data pr otecti o n a n d data sec urit y meas ures are i m ple me nte d f or t he c ollecti o n, st ora ge a n d pr ocessi n g of patie nt data i n acc or da nce wit h t he pri nci ples 6 a n d 1 2 of t he W H O G C P ha n d b o o k. Treat me nt data ma y be gi ve n t o t he patie nt ’s pers o nal p h y sicia n or t o ot her a p pr o priate me dical pers o n nel res p o nsi ble f or t he patie nt ’s welfare. Data ge nerate d as a res ult of t he trial nee d t o be a vaila ble f or i ns pecti o n o n re q uest b y t he partici pati n g p h ys icia ns, t he s p o ns or’s re prese ntati ves, b yt he I R B / I E C a n d t he re g ulat or y a ut h orities. 8. 5. 1 C ollecti o n, st or a ge a n d f ut ure use of bi ol o gic al s a m ples a n d c orres p o n di n g d at a Meas ures are i n place t o c o m pl y wit h t he a p plica ble r ules f or t he c ollecti o n, st ora ge a n d f ut ure use of bi ol o gical sa m ples fr o m cli nical trial partici pa nts a n d t he c orres p o n di n g data, i n partic ular A Q ualit y Ma na ge me nt S y ste m has bee n i m ple me nte d t o e ns ure t he a d here nce wit h t he Pri nci ples of G o o d Cli nical Practice as o utli ne d i n ' N ote F or G ui da nce O n G o o d Cli nical Practice' ( C P M P/I C H/ 1 3 5/ 9 5) T he BI -i nter nal facilities st ori n g a n d a nal ys i n g bi ol o gical sa m ples a n d data fr o m cli nical trial partici pa nts as well as t he la b orat ories' acti vities f or cli nical trial s s p o ns ore d b y B oe hri n ger I n gel hei m are re g ularl y a u dite d. T he a nal y tical gr o u ps a n d"
52,page_52,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 t he ba n ki n g facilit yare t heref ore assesse d t o be q ualifie d f or t he st ora ge a n d use of bi ol o gical sa m ples a n d data c ol lecte d i n cli nical trial s. Sa m ples a n d data are use d o nl y if a n a p pr o priate i nf or me d c o nse nt is a vaila ble. 8. 6 T RI A L MI L E S T O N E S T he st art of t he tri al is defi ne d as t he date w he n t he first patie nt i n t he w h ole trial si g ns i nf or me d c o nse nt . T he e n d of t he tri al is defi ne d as t he date of t he last visit of t he last patie nt i n t he w h ole trial (“ Last Patie nt O ut” ). E arl y ter mi n ati o n of t he tri al is defi ne d as t he pre mat ure ter mi nati o n of t he trial d ue t o a n y rea s o n bef ore t he e n d of t he trial as s pecifie d i n t his pr ot oc ol. Te m p or ar y h alt of t he tri al is defi ne d as a n y u n pla n ne d i nterr u pti o n of t he trial b y t he s p o ns or wit h t he i nte nti o n t o res u me it. S us pe nsi o n of t he tri al is defi ne d as a n i nterr u pti o n of t he trial base d o n a Healt h A ut h orit y re q uest. 8. 7 AD MI NI S T R A TI V E S T R U C T U R E O F T H E T RI A L T he trial is s p o ns ore d b y B oe hri n ger I n gel hei m ( BI). Rele va nt d oc u me ntati o n o n t he partici pati n g ( Pri nci pal) I n vesti gat ors (e. g. t heir c urric ula vitae ) will be file d i n t he (I n vesti gat or Site File) I S F. T he i n vesti gat ors will ha ve access t o t he BI cli nical trial p ortal ( Cli ner gize) t o facilitate d oc u me nt e xc ha n ge a n d mai ntai n electr o nic I S F. BI has a p p oi nte d a Cli nical Trial Lea der , res p o nsi ble f or c o or di nati n g all re q uire d acti vities, i n or der t o -ma n a ge t he trial i n acc or da nce wit h a p plica ble re g ulati o ns a n d i nter nal S O Ps, -direct t he cli nical trial tea m i n t he pre parati o n, c o n d uct, a n d re p orti n g of t he trial, -e ns ure a p pr o priate trai ni n g a n d i nf or mati o n of Cli nical Trial Ma na ger s ( C T M ), Cli nical Resear c h Ass ociates ( C R As), a n d i n vesti gat ors of partici pati n g c o u ntries. T he or ga nisati o n of t he trial i n t he partici pati n g c o u ntries will be perf or me d b y t he res pecti ve l ocal or re gi o nal BI- or ga nisati o n ( O perati n g U nit, O P U) i n acc or da nce wit h a p plica ble re g ulati o ns a n d BI S O Ps ,or b y a C o ntract Researc h Or ga nisati o n ( C R O) wit h w hic h t he res p o nsi bilities a n d tas ks will ha ve bee n a gree d a n d a writte n c o ntract file d bef ore i nitiati o n of t he cli nical trial . Data Ma na ge me nt a n d Statistical E val uati o n will be d o ne b y BI acc or di n g t o BI S O Ps. Tas ks a n d f u ncti o ns assi g ne d i n or der t o or ga nise, ma na ge, a n d e val uate t he trial are defi ne d acc or di n g t o BI S O Ps. A list of res p o nsi ble pers o ns a n d rele va nt l ocal i nf or mati o n ca n be f o u n d i n t he I S F."
53,page_53,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 An I R T ve n d or a n d ot her ce ntral ve n d ors (acti vit y m o nit or, e Diar y ) will be use d i n t his trial . Details will be pr o vi de d i n t he I R T Ma n ual a n d ve n d or s pecific ma n uals ,a vaila ble i n t he I S F."
54,page_54,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 9. R E F E R E N C E S 9. 1 P U B LI S H E D R E F E R E N C E S P 0 5 - 1 2 7 8 2 Miller M R, Ha n ki ns o n J, Br usasc o V, B ur g os F, Casa b uri R, C oates A, et. al ,Sta n dar disati o n of s pir o metr y . E ur Res pir J 2 6 ( 2), 3 1 9- 3 3 8 ( 2 0 0 5) P 1 6 -0 4 4 4 2 Tr o osters T, B o ur bea u J, Maltais F, Lei d y N, Erze n D, S o usa D de, et. al . E n ha nci n g e xercise t olera nce a n d p h ys ical acti vit y i n C O P D wit h c o m bi ne d p har mac ol o gical a n d n o n -p har mac ol o gical i nter ve nti o ns: P H Y S A C T O ra n d o mize d, place b o -c o ntr olle d st u d y desi g n. B MJ O pe n 6, e 0 1 0 1 0 6 ( 2 0 1 6) P 1 8 - 0 4 5 9 7 Casa b uri, Ric har d. "" Fact ors deter mi ni n g c o nsta nt w or k rate e xercis e t olera nce i n C O P D a n d t heir r ole i n dictati n g t he mi ni mal cli nicall y i m p orta nt differe nce i n res p o nse t o i nter ve nti o ns."" C O P D: J o ur nal of C hr o nic O bstr ucti ve P ul m o nar y Disease 2. 1 ( 2 0 0 5): 1 3 1 - 1 3 6 R 9 8 - 1 4 8 8 O’ D o n nell D E, Wee b b K A. E xerti o nal breat hless ness i n patie nts wit h c hr o nic airfl o w li mitati o n. T he r ole of l u n g h y peri nflati o n. A m Re v Res pir Dis 1 4 8, 1 3 5 1- 1 3 5 7 ( 1 9 9 3) R 0 4 - 1 0 0 1 Ha n ki ns o n J L , O de ncra ntz J R, Fe da n K B S pir o metric refere nce val ues fr o m a sa m ple of t he ge neral U. S. p o p ulati o n. A m J Res pir Crit Care Me d 1 5 9, 1 7 9- 1 8 7 ( 1 9 9 9) R 0 6 -2 0 0 2 Maci nt y re N, Cra p o R O, Vie gi G, J o h ns o n D C, Gri nte n C T M va n der, Br usasc o V, et. al Sta n dar disati o n of t he si n gle- breat h deter mi nati o n of car b o n m o n o xi de u pta ke i n t he l u n g. E ur Res pir J 2 6 ( 4), 7 2 0- 7 3 5 ( 2 0 0 5) R 1 1 - 4 4 7 1 Bra w ner C A, E hr ma n J K, Al dre d H, Sc hairer J R, Kete y ia n SJ. Q ualit y ass ura nce a n d car di o p ul m o nar y e xercise testi n g i n cli nical trials. J Car d Fail 1 4 ( 4), 2 8 3 -2 8 9 ( 2 0 0 8). R 1 3 - 1 5 7 8 Nici L , Z u Wallac k R, W o uters E, D o n ner C F . O n p ul m o nar y re ha bilitati o n an d t he fli g ht of t he b u m ble bee: t he A T S/ E R S state me nt o n p ul m o nar y re ha bilitati o n . E ur Res pir J 2 8 ( 3), 4 6 1 -4 6 2 ( 2 0 0 6) R 1 4 -0 9 7 5 Haree n dra n A, Lei d y N K, M o nz B U, Wi n nette R, Bec ker K, Ma hler D A. Pr o p osi n g a sta n dar dize d met h o df or e val uati n g patie nt re p ort of t he i nte nsit y of d y s p nea d uri n g e xercise testi n g i n C O P D. I nt J C hr o nic O bstr uct P ul m Dis 7, 3 4 5 -3 5 5 ( 2 0 1 2) R 1 6 - 5 3 5 3 Gi mi n o -Sa nt os E, Raste Y, De me y er H, L o u varis Z, J o n g C de, Ra bi n o vic h R A, et. al , P R Oacti ve C o ns orti u m. T he P R Oacti ve i nstr u me nts t o me as ure p h y sical acti vit y i n patie nts wit h c hr o nic o bstr ucti ve p ul m o nar y disease. E ur Res pir J 4 6, 9 8 8 -1 0 0 0 ( 2 0 1 5)."
55,page_55,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 R 1 7 - 1 3 9 9 G ui da nce f or i n d ustr y: M 3( R 2) n o ncli nical safet y st u dies f or t he c o n d uct of h u ma n cli nical trials a n d mar keti n g a ut h orizati o n f or p har mace uticals (Ja n uar y 2 0 1 0, I C H, re visi o n 1). htt ps:// w w w.f da. g o v/ d o w nl oa ds/ g ui da nces/ uc m 0 7 3 2 4 6. p df (access date 1 8 A pril 2 0 1 7); U. S. De part me nt of Healt h a n d H u ma Ser vices, F o o d a n d Dr u g A d mi nistrati o n, Ce nter f or Dr u g E val uati o n a n d Researc h ( C D E R), Ce nter f or Bi ol o gics E val uati o n a n d Researc h ( C B E R) ( 2 0 1 0) R 1 8- 1 2 8 9 Ofe v ( ni nte da ni b) ca ps ules, f or oral use ( B oe hri n ger I n gel he i m P har mace uticals) ( U. S. prescri bi n g i nf or mati o n, re vise d: 1/ 2 0 1 8 ). R 1 8 - 1 7 0 4 D o w ma n L, Hill CJ, H olla n d P ul m o nar y re ha bilitati o n f or i nterstitial l u n g disease (re vie w). C oc hra ne Data base S ys t Re v ( 1 0), C D 0 0 6 3 2 2 ( 2 0 1 4). R 1 8 - 1 7 6 7 Nat ha n S, Al bera C, d u B ois R, Bra df or d W, C osta bel U, Ki n g T, et. Al, 6- mi n ute wal k test ( 6 M W T) i n patie nts wit h i di o pat hic p ul m o nar y fi br osis (I P F): C o nfir mati o n of t he mi ni mal cli nicall y i m p orta nt differe nce ( M CI D).' E ur o pea n Res pirat or y J o ur nal 4 0. S u p pl 5 6 ( 2 0 1 2): P 3 6 5 6. 9. 2 U N P U B L I S H E D R E F E R E N C E S c 0 2 1 5 5 5 7 4- 0 2 A 5 2 wee ks, d o u ble bli n d, ra n d o mize d, place b o -c o ntr olle d trial e val uati n g t he effect of oral Bi B F 1 1 2 0, 1 5 0 m g t wice dail y , o n a n a n n ual F orce d Vital Ca pacit y decli ne, i n patie nts wit h I d o pat hic P ul m o nar y Fi br osis (I P F) 0 8 A pr 2 0 1 4. c 0 2 0 9 8 7 7 5 - 0 2 A 5 2 wee ks, d o u ble bli n d, ra n d o mize d, place b o - c o ntr olle d trial e val uati n g t he effect of oral Bi B F 1 1 2 0, 1 5 0 m g t wice dail y , o n a n a n n ual F orce d Vital Ca pacit y decli ne, i n patie nts wit h I d o pat hic P ul m o nar y Fi br osis (I P F) 0 8 A pr 2 0 1 4. U 0 7 - 1 2 4 8- 0 7 I n vesti gat or's br oc h ure: BI B F 1 1 2 0, I n dicati o n: I di o pat hic P ul m o nar y Fi br osis. 1 1 9 9. P 3. Versi o n 7. 0 9 Dec 2 0 1 1 ."
56,page_56,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. A P P E N DI C E S 1 0. 1 E X E R CI S E T E S TI N G I N C L U DI N G 6 MI N U T E W A L K T E S T A N D W O R K C Y C L E E R G O M E T R Y T o s u p ple me nt t he i nf or mati o n o n t he Si x Mi n ute Wal k Test descri be d i n t his secti o n , i nstr ucti o ns a n d a n i nstr ucti o nal vi de o has bee n de vel o pe d. M ore detaile d i nf or mati o n o n t he pr oce d ure, o n staffi n g, site a n d e q ui p me nt re q uire me nts, patie nt pre parati o n, I C meas ure me nts, a n d calc ulati o ns etc. ca n be f o u n d i n t he i nstr ucti o ns , w hic h is file d i n t he I S F. 1 0. 1. 1 Ge ner al c o nsi der ati o ns f or 6 M W T a n d e xercise testi n g E xercise perf or m a nce v ari a bility A n u m ber of p h ys i ol o gical a n d ps yc h ol o gical fact ors are k n o w n t o affect e xercise perf or ma nce. Lac k of atte nti o n t o c o ntr olli n g t hese e xtra ne o us fact ors ma y res ult i n a n u nacce pta ble de gree of varia bilit y i n e xercise perf or ma nce. As s uc h, certai n re q uire me nts ha ve bee n p ut i n place t o re d uce e xercise perf or ma nce varia bilit y : P h y si ol o gical: Pre -e xercise diet: S u bjects are t o be e nc o ura ge d t o eat brea kfast bef ore c o mi n g t o t he cli nic. H o we ver, s u bjects s h o ul d n ot eat wit hi n 2 h o urs of e xercise tests. H y drati o n state: S u bjects are t o be e nc o ura ge d t o mai ntai n a n a de q uate h y drati o n state d uri n g t he m or ni n g of t he e xercise tests (i.e., dri n k l ots of water). E n vir o n me ntal c o n diti o ns (te m perat ure, h u mi dit y ): Te m perat ure a n d h u mi dit y wit hi n t he la b orat or y s h o ul d be at c o mf orta ble le vels, a n d s h o ul d be rec or de d eac h tes ti n g da y . Pre vi o us e xercise: Fati g ue: S u bjects s h o ul d be e nc o ura ge d t o sta y well -reste d a n d t o refrai n fr o m a n y stre n u o us, fati g ui n g or e x ha usti n g acti vities (e. g., wal ki n g u p hills, wal ki n g u p ma n y fli g hts of stairs, r u n ni n g, c y cli n g, s h o velli n g s n o w, s tre n u o us h o use h ol d c h ores) o n t he m or ni n g of e xercise tests. Dela y e d o nset m usc ular s ore ness ( D O M S): Ver y stre n u o us, hea v y t y pe of acti vities, es peciall y acti vities t o w hic h t he s u bject is u nacc ust o me d, ca n lea d t o m uscle s ore ness 2 4 -4 8 h o urs after t he ac ti vit y. S u bjects s h o ul d be e nc o ura ge d t o refrai n fr o m a n y t y pe of hea v y lifti n g, e x ha usti ve di g gi n g i n t he gar de n etc., f or 2 -3 da y s pri or t o eac h cli nic visit, es peciall y if t he s u bject has n ot perf or me d t hese acti vities rece ntl y . Ps y c h ol o gical : E xter n al m oti vati o nal c ues: m oti vati o nal c ues pr o vi de d t o t he s u bject ca n ha ve pr of o u n d effects o n e xercise perf or ma nce. It is i m perati ve t hat e xter nal m oti vati o nal c ues are c o ntr olle d acr oss s u bjects a n d acr oss sites."
57,page_57,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Ti me of e xercise: N o vis ual c ues re gar di n g t he ti me of e xercise s h o ul d be pr o vi de d t o t he s u bject. T he s u bject’s watc h s h o ul d be re m o ve d pri or t o e xercise, a n d all ot her ti me kee pi n g de vices (e. g., trial staff watc hes, wall cl oc ks, st o p watc h etc.) s h o ul d be ke pt a wa y fr o m t he s u bject’s vie w. Fa mili arit y wit h s urr o u n di n gs: Trial staff s h o ul d all o w as m uc h ti me as necessar y f or t he s u bject t o bec o me c o mf orta ble wit h t he la b orat or y s urr o u n di n gs. Distracti o ns: D uri n g t he e xercise tests, access t o t he la b orat or y s h o ul d be restricte d t o trial staff as m u c h as p ossi ble. T he n oise le vel i n t he la b orat or y s h o ul d be ke pt t o a mi ni m u m, e xce pt f or t h ose s o u n ds s pecificall y relate d t o t he c o n d uct of t he test. T his will e ns ure t hat t he s u bject is a ble t o c o nce ntrate o n t he tas k at ha n d, a n d will als o e ns ure t hat t he s u bject is atte nti ve t o t he ver bal e nc o ura ge me nt pr o vi de d b y t he desi g nate d me m ber of t he trial tea m. C o mf ort wit h e q ui p me nt: S u bjects s h o ul d be a p pr o priatel y dresse d f or e xercise (e. g., s h orts or trac k pa nts, g y m s h oes, T -s hirt or s weat s hirt), a n d t rial staff s h o ul d e ns ure t hat t he s u bject is c o mf orta ble wit h t he e q ui p me nt pri or t o starti n g t he e xercise. Fa miliarit y wit h test: Bef ore starti n g e xercise, a me m ber of t he trial tea m s h o ul d ma ke s ure t hat t he s u bject is c o m pletel y fa miliar wit h t he t y pe of e xercise t hat is t o be perf or me d , a practice test is e x pecte d pri or t o t he baseli ne test at Visit 2 t o all o w patie nts t o bec o me fa miliar wit h t he testi n g pr oce d ures. Perf or ma nce i nce nti ves: N o e xter nal i nce nti ves f or perf or ma nce (i.e., re war ds f or perf or ma nce) s h o ul d be gi ve n t o t he s u bject, pri or t o or at a n y ti me d uri n g t he e xercise. Pers o n nel q ualificati o ns : E xercise c halle n ges s h o ul d be c o n d ucte d b y a de q uatel y trai ne d pers o n nel wit h a basic k n o wle d ge of e xercise p h y si ol o g y . Tec h nicia ns fa miliar w it h n or mal a n d a b n or mal res p o nses d uri n g e xercise a n d trai ne d i n C P R s h o ul d be prese nt t hr o u g h o ut t he tests. Safet y iss ues : Car diac ( bra d ya rr h yt h mias, ve ntric ular tac h yc ar dia, m y ocar dial i nfarcti o n, heart fail ure, h y p ote nsi o n, a n d s h oc k) a n d n o n -car diac ( m usc ul os keletal tra u ma, se vere fati g ue, dizzi ness, fai nti n g, b o d y ac hes) c o m plicati o ns of e xercise c halle n ges ha ve bee n re p orte d. C o nse q ue ntl y d uri n g t he test, st u d y pers o n nel s h o ul d be alert t o a n y a b n or mal e ve nt. I n dicati o ns t o st o p t he test m ust be cl earl y esta blis he d a n d k n o w n b y t he pers o n nel i n v ol ve d i n testi n g."
58,page_58,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 5 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 S y m pt o ms s uc h as: -ac ute c hest pai n, -s u d de n pall or, -l oss of c o - or di nati o n, -me ntal c o nf usi o n, -e xtre me d y s p n oea. If t he e xercise test has bee n st o p pe d f or o ne of t hese reas o ns, t he s u bject s h o ul d be m o nit ore d i n t he la b orat or y u ntil si g ns / s y m pt o ms / E C G m o dificati o ns ha ve c o m pletel y cleare d. F ull C P R e q ui p me nt s h o ul d be a vaila ble i n t he la b orat or y . F urt her partici p ati o n i n a n y e xercise testi n g a n d c o nti n uati o n of t he patie nt i n t he st u d y s h o ul d be disc usse d wit h t he cli nical m o nit or. 1 0. 1. 2 Si x -mi n ute wal k test A f ull descri pti o n of t he si x mi n ute wal k test will be pr o vi de d i n b ot h t he i nstr ucti o n sa n d i nstr ucti o nal vi de o. Testi n g s h o ul d be perf or me d i n a l ocati o n w here a ra pi d, a p pr o priate res p o nse i n t he e ve nt of a n e mer ge nc y is p ossi ble a n d e mer ge nc y i nstr ucti o ns i n t he ma n ual s h o ul d be f oll o we d . D uri n g t he 6 -M W T patie nts will be m o nit ore d f or b ot h H R a n d S p O 2usi n g p uls e o xi meter. If S p O 2 decreases t o bel o w 8 0% at a n y ti me after t he patie nts be gi ns wal ki n g , first e ns ure t he o xi meter is c o n necte d a n d w or ki n g pr o perl y a n d e ns ure t hat a c o nfi de nt p ulse si g nal is ge nerate d. If S p O 2is still bel o w 8 0 %, st o p t he st u d y a n d all o w t he s u bject t o sit a n d rest, t he st u d y is c o m plete. T he dist a nce wal ke d will be meas ure d i n feet (f) a n d will be rec or de d. If t he test is st o p pe d pre mat urel y, t he dista nce ( f), t he d urati o n ( mi n), a n d t he reas o n f or st o p pi n g will be rec or de d . Patie nts will be as ke d t o rate t he i nte nsit y of d y s p nea (s h ort ness of breat h) a n d fati g ue usi n g t he M o difie d B or g Scale (see Secti o n 1 0. 2 ) as descri be d i n t he i nstr ucti o ns . Assess me nts will be rec or de d i n a w or ks heet d uri n g t he testi n g, a n d tra nsferre d t o t he e D C s y ste m."
59,page_59,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
60,page_60,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
61,page_61,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9 - 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
62,page_62,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
63,page_63,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
64,page_64,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
65,page_65,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
66,page_66,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 2 M O DI FI E D B O R G S C A L E ( M B S -S) R 1 4 - 0 9 7 5 P A TI E N T I N S T R U C TI O N S The B or g Scale is use d t o hel p us u n dersta n d t he i nte nsit y or se verit y of y o ur breat hless ness a n d t he i nte nsit y or se verit y of y o ur fati g ue . We will as k y o u t o use t his scale t o rate t he i nte nsit y of y o ur breat hless ness a n d y o ur fati g ue bef ore, d uri n g, a n d after y o ur e xercise test. Please re vie w t he scale t o see t he vari o us le vels fr o m w hic h y o u ca n c h o ose. F or breat hless ness ( d ys p nea) : T he t o p of t he scale, “ 0 or n ot hi n g at all,” mea ns n o bre at hless ness at all . T he b ott o m of t he scale, “ 1 0 or ma xi mal,” mea ns t he m ost severe bre at hless ness t h at y o u h ave ever ex perie nce d or c o ul d i m a gi ne ex perie nci n g . F or fati g ue : T he t o p of t he scale, “ 0 or n ot hi n g at all,” mea ns n o f ati g ue at all . T he b ott o m of t he scale, “ 1 0 or ma xi mal,” mea ns t he m ost severe f ati g ue t h at y o u h ave ever ex perie nce d or c o ul d i m a gi ne ex perie nci n g. W he n we as k y o u t o rate t he i nte nsit y of y o ur breat hless ness a n d y o ur fati g ue , please place t he ti p of y o ur fi n ger o n t he n u m ber t hat best descri bes t he i nte nsit y t hat y o u are e x perie nci n g at t hat m o me nt. Y o u ma y als o place a fi n ger bet wee n 2 n u m bers if t hat better descri bes t he i nte nsit y of y o ur breat hless ness or y o ur fati g ue . Please let us k n o w if y o u ha ve a n y q uesti o ns bef ore we be gi n. 0 N ot hi n g at all 0. 5 Very, very sli g ht (j ust n otice a ble) 1 Very sli g ht 2 Sli g ht 3 M o der ate 4 S o m e w h at severe 5 Severe 6 7 Very severe 8 9 Very, very severe ( al m ost m a xi m al) 1 0 M a xi m al"
67,page_67,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 St u dy Specific I nstr ucti o ns f or t he B or g Sc ale Pri or t o t he start of e xercise test, eac h s u bject will be t ol d t hat t he y will be as ke d t o rate t he i nte nsit y of 2 se nsati o ns at rest, d uri n g e xercise, a n d at e n d -e xercise. T he 2 se nsati o ns will be descri be d t o t he s u bject as: -S h ort ness of breat h ( d ys p ne aor breat hless ness ) -Fati g ue Use of t he B or g Scale t o rate t hese se nsati o ns will be e x plai ne d t o t he s u bject. W hile s h o wi n g t he scale t o t he s u bject, t he st u d y c o or di nat or or bli n de d tester will e x plai n t hat t he s u bject s h o ul d relate t he w or di n g o n t he B or g Scale t o t he le vel of t he se nsati o n t hat he / s he is e x perie nci n g, a n d t he n place t he e n d of a fi n ger o n a n u m ber t hat best descri bes t he i nte nsit y of t he se nsati o n - e x plai n t hat placi n g a fi n ger bet wee n 2 n u m bers is all o we d. ( B or g Scale n u m bers will be rec or de d t o t he nearest 0. 5 u nits). T he st u d y c o or di nat or or bli n de d tester will a nc h or t he e n d p oi nts of t he scale f or b ot h se nsati o ns. T he st u d y c o or di nat or or bli n de d tester will e x plai n t hat f or t he se nsati o n of “s h ort ness of breat h ”, “ 0 or n ot hi n g at all” c orres p o n ds t o “ n o s h ort ness of breat h ” a n d “ 1 0 or ma xi mal” c orres p o n ds t o t he “ w orst i ma gi na ble s h ort ness of breat h ”. T he st u d y c o or di nat or or bli n de d tester will t he n e x plai n t hat f or t he se nsati o n of “ fati g ue ”, “ 0 or n ot hi n g at all” a gai n c orres p o n ds t o “ n o fati g ue ” a n d “ 1 0 or ma xi mal” c orres p o n ds t o t he “ w orst i ma gi na ble fati g ue ”. S u bjects are t o be gi ve n n o f urt her i nf or mati o n a b o ut t hese se nsati o ns. If a s u bject re q uests f urt her clarificati o n, he/s he will be t ol d t o use his/ her o w n i n di vi d ual i nter pretati o n as t o t he mea ni n g of t he se ns or y descri pt ors. T his will e ns ure t hat t he se ns or y descri pt ors are prese nte d t o eac h s u bject i n a sta n dar d f or mat. 1 0. 3 S T. G E O R G E’ S R E S PI R A T O R Y Q U E S TI O N N AI R E ( S G R Q) W hat is t he St Ge or ge’s Res pirat or y Q uesti o n naire? T he S G R Q is desi g ne d t o meas ure healt h i m pair me nt i n patie nts wit h ast h ma a n d C O P D. I t is als o vali d f or use i n br o nc hiectasis a n d has bee n use d s uccessf ull y i n patie nts wit h k y p h osc oli osis a n d sarc oi d osis. I t is n ot s uita ble f or c y stic fi br osis. It is i n t w o parts. Part I pr o d uces t he S y m pt o ms sc ore, a n d Part 2 t he Acti vit y a n d I m pacts sc ores. A T otal sc ore is als o pr o d uce d. Part 1 ( Q uesti o ns 1 t o 8) c o vers t he patie nts’ rec ollecti o n of t heir s y m pt o ms o ver a prece di n g peri o d t hat ma y ra n ge 1 m o nt h t o 1 y ear. It is n ot desi g ne d t o be a n acc urate e pi de mi ol o gical t o ol; its p ur p ose is t o assess t he patie nt’s perce pti o n of t heir rece nt res pirat or y pr o ble ms. T he ori gi nal versi o n was vali date d usi n g a 1 2 -m o nt h recall peri o d. M ore rece ntl y a 1 m o nt h recall versi o n (a p pr o priatel y w or de d) has bee n vali date d. T his has sli g htl y wea ker ps yc h o metric pr o perties t ha n t he 1 2 - m o nt h versi o n a n d pr o d uces a mar gi nall y l o wer S y m pt o m sc ore a n d T otal sc ore. A 3 -m o nt h recall peri o d has bee n use d ver y satisfact oril y .I n s u m mar y, t he 3 - m o nt h a n d 1- ye ar versi o ns pr o vi de t he best pr o perties, wit h n o s pecific a d va nta ges t o eit her. T he 1 -m o nt h versi o n s h o ul d o nl y be use d w he n t he ti me fra me of t he st u d y dictates."
68,page_68,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 6 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Part 2 ( Q uesti o ns 9 t o 1 6) a d dresses t he patie nts’ c urre nt s tate (i.e. h o w t he y are t hese da y s). T he Acti vit y sc ore j ust meas ures dist ur ba nces t o patie nt’s dail y p h y sical acti vit y . T he I m pacts sc ore c o vers a wi de ra n ge of dist ur ba nces of ps y c h o -s ocial f u ncti o n. Vali dati o n st u dies s h o we d t hat t his c o m p o ne nt relates i n part t o res pirat or y s y m pt o ms, b ut it als o c orrelates q uite str o n gl y wit h e xercise perf or ma nce ( 6- mi n ute wal ki n g test), breat hless ness i n dail y life ( M R C breat hless ness sc ore) a n d dist ur ba nces of m o o d (a n xiet y a n d de pressi o n). T he I m pacts sc ore is, t here f ore, t he br oa dest c o m p o ne nt of t he q uesti o n naires, c o veri n g t he w h ole ra n ge of dist ur ba nces t hat res pirat or y patie nts e x perie nce i n t heir li ves. H o w s h o ul d it be a d mi nistere d? T he q uesti o n naire s h o ul d be c o m plete d i n a q uiet area free fr o m distracti o n a n d t he patie nt s h o ul d i deall y be sitti n g at a des k or ta ble. E x plai n t o t he patie nt w h y t h e y are c o m pleti n g t he q uesti o n naire, a n d h o w i m p orta nt it is f or us t o u n dersta n d h o w t he y feel a b o ut t heir ill ness a n d t he effect it has o n t heir dail y life. As k t he p atie nt t o c o m plete t he q uesti o n naire as h o nestl y as p ossi ble a n d stress t hat t here are n o ri g ht or wr o n g a ns wers; si m pl y t he a ns wer t hat t he patie nt feels a p plies t o t he m. E x plai n t hat t he y m ust a ns wer e ver y q uesti o n a n d t hat s o me o ne will be cl ose at ha n d t o a ns wer a n y q ueries. T he S G R Q is desi g ne d as a s u per vise d self -a d mi nistere d q uesti o n naire. T his mea ns t hat t he patie nts s h o ul d c o m plete t he q uesti o n naire t he msel ves b ut s o me o ne s h o ul d be a vaila ble t o gi ve a d vice if it is re q uire d. T he patie nt’s res p o nses s h o ul d n ot be i nfl ue nce d b y t he o pi ni o ns of fa mil y , frie n ds or me m bers of staff. T he q uesti o n naire is desi g ne d t o elicit t he patie nt’s o pi ni o n of his/ her healt h, n ot s o me o ne else’s o pi ni o n of it. If t he s p o use or part ner has acc o m pa nie d t he patie nt t he y s h o ul d be as ke d t o wait i n a se parate area. Si milarl y , d o n ot all o w patie nts t o ta ke t he S G R Q h o me t o be c o m plete d si nce y o u ca n n ot be s ure t hat it will be c o m plete d wit h o ut t he hel p of fa mil y or frie n ds. It is ver y i m p orta nt, o nce t he patie nt has fi nis he d, t hat y o u c hec k t he q uesti o n naire t o ma ke s ure a res p o nse has bee n gi ve n t o e ver y q uesti o n a n d ret ur n it t he patie nt f or c o m pleti o n of misse d ite ms, bef ore t he patie nt lea ves. W hat s h o ul d I d o a b o ut q ueries re gar di n g c o m pleti o n of t he q uesti o n naire? If a p atie nt as ks f or hel p wit h a q uesti o n, d o n ot pr o vi de a n a ns wer f or t he m. T he p oi nt of t he q uesti o n naire is t o get a n u n dersta n di n g of h o w t he patie nt vie ws his or her ill ness. I t is a p pr o priate t o clarif y a q uesti o n b ut n ot t o pr o vi de a n a ns wer. Q uesti o ns ma y be rea d al o u d if patie nts ha ve diffic ult y wit h rea di n g, b ut t he res p o nses m ust be t heirs al o ne. If a patie nt gi ves a n a ns wer y o u disa gree wit h it is n ot a p pr o priate t o c halle n ge t heir res p o nse or t o q uer y it. It is t heir vie w of t heir c o n diti o n we are i ntereste d i n –n o matter h o w stra n ge t he res p o nse! T he f oll o wi n g are n otes w hic h ma y hel p y o u e x plai n t o patie nts w hat is re q uire d 1. I n Part 1 of t he q uesti o n naire, e m p hasise t o patie nts t hat y o u are i ntereste d i n h o w m uc h c hes t tr o u ble t he y ha ve ha d o ver t he last y ear. T he e xact peri o d is n ot i m p orta nt. We are l o o ki n g f or a n i m pressi o n or perce pti o n of healt h. 2. Ast h ma a n d C O P D ca n var y da y -t o da y . I n Part 2 , we wa nt t o k n o w a b o ut t he patie nt’s c urre nt state (t hese da y s). 3. A se vere or ver y u n pleasa nt attac k of c hest tr o u ble ( Part 1 , Q uesti o n 5 ) is a n y attac k t hat c o ul d be descri be d t hat wa y i n t he patie nt’s o w n j u d ge me nt. N ot ‘ se vere’ as defi ne d b y me dical staff."
69,page_69,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 4. F or Q uesti o n 7 e m p hasise t hat y o u are i ntereste d i n t he n u m ber of g o o d da y s t hat t he y ha ve ha d. 5. Q uesti o n 1 0 re gar di n g e m pl o y me nt ca n ca use patie nts s o me pr o ble ms. We are i ntereste d i n h o w a patie nt’s c hest tr o u ble affects t heir c urre nt w or ki n g life or h o w it affecte d life w he n t he y were w or ki n g. F or e xa m ple, if a patie nt t o o k earl y retire me nt beca use of t heir c hest c o n diti o n, t he res p o nse w o ul d be 1 0a – ‘ M y c hest tr o u ble ma de me st o p w or k’, if a patie nt’s retire me n t was u nrelate d t o t heir c hest tr o u ble, t heir res p o nse w o ul d be 1 0c ‘ M y c hest tr o u ble d oes n ot affect m y w or k’. 6. Q uesti o ns 1 1 t o 1 6 re q uire a res p o nse t o e ver y q uesti o n. I t ma y be w ort h e m p hasisi n g t his t o t he patie nt. 7. Ma n y patie nts d o n ot e n ga ge i n p h y sical acti vit y . It is i m p orta nt t o deter mi ne w het her t his is beca use t he y d o n ot wis h t o (i n w hic h case t he a ns wer w o ul d be ‘ False’) or ca n n ot e n ga ge i n t hese acti vities beca use of t heir c hest tr o u ble (i n w hic h case t he a ns wer w o ul d be ‘ Tr ue’). 8. Me dica ti o n q uesti o ns refer t o me dicati o ns a n d treat me nts gi ve n f or a patie nt´s c hest disease a n d ma y i nterfere wit h t heir life if, f or e xa m ple, t he y are o n o x y ge n s u p p ort a n d ha ve t o carr y it ar o u n d wit h t he m. 9. It s h o ul d be e m p hasise d t hat res p o nses t o Q uesti o n 1 5 are i n ter ms of breat hi n g diffic ulties a n d n ot a n y ot her pr o ble ms. If patie nts d o n ot e n ga ge i n acti vities descri be d i n certai n ite ms, t he y s h o ul d tic k ‘ False’. Patie nts w h o d o n ot e n ga ge i n t hese acti vities beca use t he y are li mite d b y t heir breat hles s ness, s h o ul d tic k ‘ Tr ue’."
70,page_70,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 E X A M P L E O F Q U E S TI O N N AI R E
71,page_71,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
72,page_72,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
73,page_73,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
74,page_74,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
75,page_75,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
76,page_76,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 4 E L E C T R O NI C DI A R Y WI T H D AI L Y P R O A C TI V E T O O L 1 0. 4. 1 T he P R O acti ve T o ol T he P R Oacti ve i nstr u me nt f or t he dail y assess me nt of p h ysical acti vit y ( D -P P A C) will be use d i n t he st u d y . T he D -P P A C e xists i n a n electr o nic versi o n. T he D -P P A C is a ‘ h y bri d’ i nstr u me nt, c o m bi ni n g a s h ort list of P R O ite ms a n d t w o acti vit y m o nit or varia bles t o assess p h y sical acti vit y e x perie nce , a n d pr o vi des a si m ple, vali d a n d relia ble meas ure of p h ys ical acti vit y e x pe rie nce b y C O P D pati e nts [R 1 6 - 5 3 5 3 ]w hic h ca n als o be use d f or ot her res pirat or y diseases . T he D -P P A C i ncl u des i n t otal 9 ite ms, meas uri n g a p h y sical acti vit y ‘ T otal Sc ore’ wit h 2 d o mai ns (‘a m o u nt’ a n d ‘ diffic ult y ’) ( Fi g ure 1 0. 4. 1: 1 ). T he ‘a m o u nt’ d o mai n is c o vere d b y 2 ite ms (a m o u nt of wal ki n g o utsi de a n d c h ores o utsi de) a n d b y 2 acti vit y m o nit or o ut p uts ( vect or ma g nit u de u nits per mi n ute ( V M U/ mi n) a n d ste ps/ da y ). T he ‘ diffic ult y ’ d o mai n is c o vere d b y 5 ite ms. T he i nstr u me nts re q uire b ot h acti vit y m o nit or data a n d ite m data o n a dail y basis. A de q uate p h y sical acti vit y data are c o nsi dere d f or da y s w here m ore t ha n ei g ht h o urs of weari n g ti me ( d uri n g t he da y , fr o m getti n g u p i n t he m or ni n g , u ntil g oi n g t o be d i n t he e ve ni n g) is a vaila ble. It is p ossi ble t hat da y s wit h acti vit y m o nit ori n g are missi n g or patie nts f or get t o fill i n t he dail y P R O i n t he e ve ni n g. I n or der t o o btai n t he D- P P A C sc ores (t otal, a m o u nt a n d diffic ult y ), dail y meas ure me nts fr o m b ot h acti vit y m o nit or a n d q uesti o n naire are mer ge d, a n d dail y sc ores are calc ulate d . T he D -P P A C i nstr u me nt is sc ore d i n a t hree ste ps pr ocess: •First, d o mai ns are sc ore d b y si m ple a d di n g ite ms, w hic h gi ves a val ue f or ‘a m o u nt’ bet wee n 0 a n d 1 7, wit h hi g her val ues re prese nti n g a hi g h a m o u nt of acti vit y, a n d a ‘ diffic ult y ’ sc ore fr o m 0 t o 2 0 wit h a hi g h val ue re prese nti n g a lesser de gree of diffic ult y . F or t he D - P P A C assess me nt t he val ues are 0- 1 7 f or ‘a m o u nt’ a n d 0 -2 0 f or ‘ diffic ult y ’. ( Fi g ure 1 0. 4. 1: 1 ) T he ste p c o u nts a n d V M U’s nee d t o be c o n verte d i nt o t he a p pr o priate dail y sc ore cate g or y. •I n t he sec o n d ste p, t he ra w sc ores are scale d t o a sc ore ra n gi n g fr o m 0 t o 1 0 0, base d o n res ults of Rasc h a nal yses •Fi nall y t he ‘t otal sc ore’ is o btai ne d calc ulati n g t he a vera ge bet wee n t w o d o mai ns. T his sc ore has t he sa me scale of t w o d o mai ns, fr o m 0 t o 1 0 0. After calc ulati n g t he dail y sc ores, wee kl y a vera ges ca n be calc ul ate d."
77,page_77,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S -4 0 - 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Fi g ure 1 0. 4. 1: 1 D- P P A C ite ms
78,page_78,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 7 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 4. 2 Electr o nic Di ar y – P R O acti ve Q uesti o n n aire I N S T R U C TI O N S T O P A TI E N T S D A Y 1: Patie nts wit h c hr o nic l u n g disease li ke y o u ofte n re p ort t hat t he y ha ve pr o ble ms d uri n g p h y sical acti vit y . B y p h ysical a cti vit y , we mea n all acti vities t hat re q uire m o ve me nt of y o ur b o d y . E xa m ples are h o use h ol d acti vities, wal ki n g, g oi n g t o w or k, or getti n g dresse d. H o we ver, please c o nsi der all acti vities y o u d o, a n d n ot o nl y t hese e xa m ples. We w o ul d li ke t o k n o w h o w y o u e x perie nce d y o ur p h ys ical acti vit y si nce y o u w o ke u p T O D A Y . Please c o m plete t his q uesti o n naire i n t he e ve ni n g bef ore g oi n g t o be d. Please select t he b o x ne xt t o t he res p o nse t hat best a p plies t o y o u T O D A Y. T here are n o wr o n g a ns wers. We ver y m uc h val ue y o ur res p o nse. I N S T R U C TI O N S F O R S U B S E Q U E N T D A Y S: We w o ul d li ke t o k n o w h o w y o u e x perie nce d y o ur p h y sical acti vit y si nce y o u w o ke u p T O D A Y. Please c o m plete t his q uesti o n naire i n t he e ve ni n g bef ore g oi n g t o be d. Please select t he b o x ne xt t o t he res p o nse t hat best a p plies t o y o u T O D A Y. Diffi c ult y s c or e A m o u nt s c or e H o w m u c h w al ki n g di d y o u d o o ut si d e t o d a y ? N o n e at all 0 A littl e bit ( u p t o 1 0 mi n ut e s i n t ot al ) 1 S o m e ( u p t o 3 0 mi n ut e s i n t ot al ) 2 A l ot ( u p t o 1 h o ur i n t ot al ) 3 A gr e at d e al ( m or e t h a n 1 h o ur i n t ot al ) 4 H o w m a n y c h or e s di d y o u d o o ut si d e t h e h o u s e t o d a y ? S o m e e x a m pl e s ar e g ar d e ni n g, t a ki n g t h e r u b bi s h o ut, or d oi n g s m all err a n d s. N o n e at all 0 A f e w 1 S o m e 2 A l ot 3 A l ar g e a m o u nt 4 H o w m u c h diffi c ult y di d y o u h a v e g etti n g dr e s s e d t o d a y ? N o n e at all 4 A littl e bit 3 S o m e 2 A l ot 1 A gr e at d e al 0 H o w oft e n di d y o u a v oi d d oi n g a cti viti e s b e c a u s e of y o ur l u n g pr o bl e m s t o d a y ? N ot at all 4 R ar el y 3 S o m eti m e s 2 Fr e q u e ntl y 1 All t h e ti m e 0 H o w br e at hl e s s w er e y o u i n g e n er al d uri n g y o ur a cti viti e s t o d a y ? N ot at all 4 A littl e bit 3 M o d er at el y 2 V er y 1 E xtr e m el y 0 H o w tir e d w er e y o u i n g e n er al d uri n g y o ur a cti viti e s t o d a y ? N ot at all 4"
79,page_79,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 A littl e bit 3 M o d er at el y 2 V er y 1 E xtr e m el y 0 H o w oft e n di d y o u h a v e t o t a k e br e a k s d uri n g y o ur p h y si c al a cti viti e s t o d a y ? N ot at all 4 R ar el y 3 S o m eti m e s 2 Fr e q u e ntl y 1 All t h e ti m e 0 P R O a cti v e d ail y st e p s s c or e T ot al st e p s p er d a y D y n a p ort ≤ 1 9 0 0 1 9 0 1 -3 7 0 0 3 7 0 1 -5 5 0 0 5 5 0 1 -7 3 0 0 > 7 3 0 0 0 0 1 1 2 2 3 3 4 4 P R O a cti v e d ail y V M U s c or e D ail y m e a n V M U / mi n D y n a p ort ≤ 5 0 5 1 -1 1 0 1 1 1 -1 9 0 1 9 1 -2 7 0 2 7 1 -4 4 0 > 4 4 0 0 0 1 1 2 2 3 3 4 4 5 5 T ot al s c or e s ( s u m a b o v e ) : diffi c ult y a m o u nt Fi g ure 1 0. 4. 2 : 1 Dail y P R Oacti ve ( D- P P A C ) e -P R O I T E M S F O R D AI L Y A S S E S S M E N T –Acti vit y m o nit ori n g Ste ps (t otal dail y val ue) 0 t o 1 9 0 0 ste ps/ da y 1 9 0 1 t o 3 7 0 0 ste ps/ da y 3 7 0 1 t o 5 5 0 0 ste ps/ da y 5 5 0 1 t o 7 3 0 0 ste ps/ da y > 7 3 0 1 ste ps/ da y V M U ( dail y V M U/ mi n) 0 t o 5 0 V M U/ mi n 5 1 t o 1 1 0 V M U/ mi n 1 1 1 t o 1 9 0 V M U/ mi n 1 9 1 t o 2 7 0 V M U/ mi n 2 7 1 t o 4 4 0 V M U/ mi n > 4 4 1 V M U/ mi n
80,page_80,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 5 K BI L D
81,page_81,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
82,page_82,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6
83,page_83,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 6 U C S D M E DI C A L C E N T E R P U L M O N A R Y R E H A BI LI T A TI O N P R O G R A M S H O R T N E S S -O F -B R E A T H Q U E S TI O N N AI R E (U C S D - S O B Q) U C S D M E DI C A L C E N T E R P U L M O N A R Y R E H A BI LI T A TI O N P R O G R A M S H O R T N E S S - O F- B R E A T H Q U E S TI O N N AI R E © 1 9 9 5 T he Re ge nts of t he U ni versit y of Calif or nia Please rate t he breat hless ness y o u e x perie nce w he n y o u d o, or if y o u were t o d o, eac h of t he f oll o wi n g tas ks. D o n ot s ki p a n y ite ms. If y o u’ ve ne ver perf or me d a tas k or n o l o n ger perf or m it, gi ve y o ur best esti mate of t he breat hless ness y o u w o ul d e x perie nce w hile d oi n g t hat acti vit y . Please re vie w t he t w o sa m ple q uesti o ns bel o w bef ore t ur ni n g t he pa ge t o be gi n t he q uesti o n naire. W he n I d o, or if I were t o d o, t he f oll o wi n g t as ks, I w o ul d r ate m y bre at hless ness as: 0N o ne at all 1 2 3 4Se vere 5 Ma xi m al or u na ble t o d o beca use of breat hless ness 1. Br us hi n g teet h .................................................. 0 1 2   4 5 Harr y has felt m o deratel y s h ort of breat h d uri n g t he past wee k w hile br us hi n g his teet h a n d s o circles a t hree f or t his acti vit y ."
84,page_84,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 2. M o wi n g t he la w n ............................................. 0 1 2 3 4   A n ne has ne ver m o we d t he la w n bef ore b ut esti mates t hat s he w o ul d ha ve bee n t o o breat hless t o d o t his acti vit y d uri n g t he past wee k. S he circles a fi ve f or t his acti vit y ."
85,page_85,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 W he n I d o, or if I were t o d o, t he f oll o wi n g t as ks, I w o ul d r ate m y bre at hless ness as: 0N o ne at all 1 2 3 4Se vere 5 Ma xi m al or u na ble t o d o beca use of breat hless ness 1. At rest .............................................................. 0 1 2 3 4 5 2. Wal ki n g o n a le vel at y o ur o w n pace .......................................................... 0 1 2 3 4 5 3. Wal ki n g o n a le vel wit h ot hers y o ur a ge ........................................................... 0 1 2 3 4 5 4. Wal ki n g u p a hill ............................................. 0 1 2 3 4 5 5. Wal ki n g u p stairs ............................................. 0 1 2 3 4 5 6. W hile eati n g ..................................................... 0 1 2 3 4 5 7. Sta n di n g u p fr o m a c hair ................................. 0 1 2 3 4 5 8. Br us hi n g teet h .................................................. 0 1 2 3 4 5 9. S ha vi n g a n d/ or br us hi n g hair ........................... 0 1 2 3 4 5 1 0. S h o weri n g/ bat hi n g........................................... 0 1 2 3 4 5"
86,page_86,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 W he n I d o, or if I were t o d o, t he f oll o wi n g t as ks, I w o ul d r ate m y bre at hless ness as: 0N o ne at all 1 2 3 4Se vere 5 Ma xi m al or u na ble t o d o beca use of breat hless ness 1 1. Dressi n g ........................................................... 0 1 2 3 4 5 1 2. Pic ki n g u p a n d strai g hte ni n g........................... 0 1 2 3 4 5 1 3. D oi n g dis hes .................................................... 0 1 2 3 4 5 1 4. S wee pi n g / vac u u mi n g ..................................... 0 1 2 3 4 5 1 5. Ma ki n g be d ...................................................... 0 1 2 3 4 5 1 6. S h o p pi n g .......................................................... 0 1 2 3 4 5 1 7. D oi n g la u n dr y .................................................. 0 1 2 3 4 5 1 8. Was hi n g car ..................................................... 0 1 2 3 4 5 1 9. M o wi n g la w n ................................................... 0 1 2 3 4 5 2 0. Wateri n g la w n .................................................. 0 1 2 3 4 5 2 1. Se x ual acti vities ............................................... 0 1 2 3 4 5"
87,page_87,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 0N o ne at all 1 2 3 4Se vere 5 Ma xi m al or u na ble t o d o beca use of breat hless ness H o w m uc h d o t hese li mit y o u i n y o ur d ail y life ? 2 2. S h ort ness of breat h .......................................... 0 1 2 3 4 5 2 3. Fear of "" h urti n g m ys elf"" b y o vere xerti n g ..................................................... 0 1 2 3 4 5 2 4. Fear of s h ort ness of breat h ............................... 0 1 2 3 4 5"
88,page_88,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 8 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 0. 7 L U N G F U N C TI O N C RI T E R I A F V C m ust f ulfil t he f oll o wi n g criteria: o4 5 % pre dicte d of n or mal ≤ F V C of pre dicte d n or mal oPre dicte d n or mal val ues will be calc ulate d acc or di n g t o N H A N E S D Lc o m ust f ulfil t he f oll o wi n g criteria: o3 0 % pre dicte d of n or mal ≤ D L C O c orrecte d f or H b < 8 0 % pre dicte d of n or mal F or pre dicte d n or mal val ues, differe nt sites ma y use differe nt pre dicti o n f or m ulas, base d o n t he met h o d use d t o meas ure D Lc o. I n a n y case, t he met h o d use d m ust be i n c o m plia nce wit h t he A T S/ E R S g ui deli ne o n D Lc o meas ure me nts ( R 0 6 - 2 0 0 2 ), a n d t he pre dicti o n f or m ula a p pr o priate f or t hat met h o d. Ra w data ( gas mi xt ure, e q uati o n us e d f or pre dicti o n of n or mal, f urt her a dj ust me nts ma de if s o) m ust be trace d. D L C O c orrecte d f or hae m o gl o bi n ( R 0 6 - 2 0 0 2 ): Males: D Lc o c orrecte d f or H b = D L C O meas ure d x ( 1 0. 2 2 + H b) / 1. 7 H b Fe males: D Lc o c orrecte d f or H b = D L C O meas ure d x ( 9. 3 8 + H b)/ 1. 7 H b w here H b is e x presse d i n g· d L- 1. F or decisi o n o n i ncl usi o n / e xcl usi o n, D Lc o res ults fr o m visit 1will be c orrecte d f or hae m o gl o bi n b y t he site , if hist orical data wit hi n 3 0 da y s is n ot a vaila ble . F or a nal y sis of t he trial data, D Lc o res ults fr o m visits 2, 5 a n d 7 will be c orrecte d f or hae m o gl o bi n b y ce ntral data ma na ge me nt. T his mea ns t hat t he site has t o e nter t he D Lc o res ult wit h o ut hae m o gl o bi n c orrecti o n i n t he e- C R F, at all visits . T he val ue t o be e ntere d i n t he e - C R F is t he mea n of t he acce pta ble ma n oe u vers p erf or me d d uri n g a test. T here s h o ul d be at least t w o acce pta ble tests t hat meet t he re peata bilit y re q uire me nt of eit her bei n g wit hi n 3 m L C O ( S T P D)• mi n -1 • m m H g - 1 ( or 1 m m ol• mi n - 1 • k Pa - 1 ) of eac h ot her or wit hi n 1 0 % of t he hi g hest val ue. If hi g hest val ue wa s e ntere d at baseli ne a n d ca n n ot be c orrecte d retr os pecti vel y , t he sa me meas ure me nt s h o ul d be rec or de d u ntil t he 2 4 wee k e val uati o n ."
89,page_89,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 1. D E S C RI P TI O N O F G L O B A L A M E N D M E N T( S) 1 1. 1 G L O B A L A M E N D M E N T 1 D ate of a m e n d me nt 3 0 A pr 2 0 1 9 E u dr a C T n u m ber E U n u m ber N ot a p plic a ble BI Tri al n u m ber 1 1 9 9- 0 3 2 4 BI I n vesti g ati o n al Pr o d uct(s) ni nte d a ni b Title of pr ot oc ol St u d y of P ul m o n ar y Re h a bilit ati o n I n Ni nte d a ni b Tre ate d P atie nts wit h I P F: I m pr o ve me nts i n Acti vit y, E xercise E n d ur a nce Ti me, a n d Q o L T o be i m ple me nte d o nl y after a p pr o v al of t he I R B / I E C / C o m pete nt A ut h orities X T o be i m ple me nte d i m me di atel y i n or der t o eli mi n ate h az ar d – I R B / I E C / C o m pete nt A ut h orit y t o be n otifie d of c h a n ge wit h re q uest f or a p pr o v al C a n be i m ple me nte d wit h o ut I R B / I E C / C o m pete nt A ut h orit y a p pr o v al as c h a n ges i n v ol ve l o gistic al or a d mi nistr ati ve as pects o nl y Secti o n t o be c h a n ge d Title P a ge Descri pti o n of c h a n ge U p d ate d t he f oll o wi n g: Tri al Cli nic al M o nit or t o Cli nic al Tri al Le a der Cli nic al Tri al Le a der t o C o or di n ati n g i n vesti g at or t o St at us Versi o n a n d D ate of Pr ot oc ol R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ges Secti o n t o be c h a n ge d Cli nic al Tri al Pr ot oc ol S y n o psis Descri pti o n of c h a n ge U p d ate d t he f oll o wi n g: Re visi o n D ate C o or di n ati n g i n vesti g at or t o C h a n ge d i ncl usi o n criteri a fr o m 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ges. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d Fl o wc h art Descri pti o n of c h a n ge"
90,page_90,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 R ati o n ale f or c h a n ge T o pr o vi de m ore cl arific ati o n as t o w he n i ncre me nt al c ycle er g o metr y will be c o n d ucte d a n d t h at t he i ncre me nt al a n d pr actice test c a n b ot h be d o ne at Visit 1 . Secti o n t o be c h a n ge d A b bre vi ati o ns Secti o n Descri pti o n of c h a n ge C orrecte d s pelli n g of w or ds “electr o nic, ass oci ati o n a n d i di o p at hic ”. M o ve d “ C O P D ” t o f oll o w al p h a betic all y. U p d ate d “ C M L Cli nic al M o nit or L oc al a n d T C M Tri al Cli nic al M o nit or t o C T M Cli nic al Tri al M a n a ger a n d C T L Cli nic al Tri al Le a der. R ati o n ale f or c h a n ge T y p o; a d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 3. 1 Descri pti o n of c h a n ge C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 2 Descri pti o n of c h a n ge C orrecte d s pelli n g of w or d “ p ositi ve ”. C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge T y p o; a d mi nistr ati ve c h a n ge. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 2. 1. 1 Descri pti o n of c h a n ge C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities."
91,page_91,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Secti o n t o be c h a n ge d 3. 3. 1 Descri pti o n of c h a n ge C orrecte d s pelli n g of w or d “ ni nte d a ni b ” C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge T y p o; a d mi nistr ati ve c h a n ge. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 3. 2 Descri pti o n of c h a n ge C orrecte d s pelli n g of w or d “ ni nte d a ni b ”. I C 1 -c h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs . I C 8 -a d de d “, per t he i nstr ucti o ns. P ote nti al s u b -st u d y p atie nts t h at re q uire s u p ple me nt al o x y ge n or c a n n ot c o m plete t he i ncre me nt al or pr actice w or k r ate c ycle er g o metr y test will n ot p artici p ate i n t he s u b -st u d y, b ut will q u alif y f or t he m ai n st u d y. ” t o e n d of se nte nce. R ati o n ale f or c h a n ge T y p o; a d mi nistr ati ve c h a n ge. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 3. 3 Descri pti o n of c h a n ge E C 4 -a d de d “(e xce pt f or rescree ni n g as descri be d i n Secti o n 3. 3). ” t o e n d of se nte nce. R ati o n ale f or c h a n ge T o a d d m ore cl arific ati o n re g ar di n g rescree ns. Secti o n t o be c h a n ge d 4. 1. 2 Descri pti o n of c h a n ge C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs . R ati o n ale f or c h a n ge U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 4. 1. 4 Descri pti o n of c h a n ge C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs . R ati o n ale f or c h a n ge U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 4. 2. 2. 1 Descri pti o n of c h a n ge C h a n ge d “ M ” t o “ m ” i n first a n d t hir d b ullet. Re m o ve d “. ” i n first a n d t hir d b ullet. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 4. 2. 2. 2 Descri pti o n of c h a n ge Re m o ve d “) ” after N A C a n d “( ” after pirfe ni d o ne."
92,page_92,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 5. 1. 2. 1 Descri pti o n of c h a n ge C orrecte d: “As per i ncl usi o n criteri o n # 7, p atie nts m ust be p h ysic all y a ble t o perf or m a 6 M W T. ” t o “ As per i ncl usi o n criteri o n # 8, p atie nts m ust be p h ysic all y a ble t o perf or m a 6 M W T, as per t he i nstr ucti o ns. ” A d de d h y perli n k t o A p pe n di x 1 0. 1 R ati o n ale f or c h a n ge T y p o; a d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 5. 1. 2. 5 Descri pti o n of c h a n ge C orrecte d: “ T he m a xi m al w or k c a p acit y ( Wc a p) of e ac h p atie nt will be deter mi ne d d uri n g a n i ncre me nt al c ycle er g o metr y c o n d ucte d at Visit 2, acc or di n g t o t he met h o d ol o g y descri be d b y O’ D o n nell a n d We b b [ R 9 8 _ 1 4 8 8 ] (see A p pe n di x 1 0. 1 ). ” t o “ T he m a xi m al w or k c a p acit y ( Wc a p) of e ac h p atie nt will be deter mi ne d d uri n g a n i ncre me nt al c ycle er g o metr y c o n d ucte d at Visit 1, acc or di n g t o t he met h o d ol o g y descri be d b y O’ D o n nell a n d We b b [ R 9 8 _ 1 4 8 8 ] (see A p pe n di x 1 0. 1 ). ” Re pl ace d: “ A pr actice c o nst a n tw or k"
93,page_93,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 4 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 R ati o n ale f or c h a n ge T o c orrect as t o w he n i ncre me nt al c ycle er g o met r y will be c o n d ucte d a n d t o ali g n wit h fl o wc h art. Secti o n t o be c h a n ge d 5. 2. 1 Descri pti o n of c h a n ge C h a n ge d: “ Me as ure me nt of hei g ht a n d b o d y wei g ht will be perf or me d at t he ti me p oi nts s pecifie d i n t he fl o wc h art. ” t o “ Me as ure me nt of hei g ht a n d b o d y wei g ht will be perf or me d at Visit 1. ” R ati o n ale f or c h a n ge Cl arific ati o n as t o w he n t his will be perf or me d. Secti o n t o be c h a n ge d 5. 2. 3 Descri pti o n of c h a n ge C h a n ge d: “ A ser u m h u m a n c h ori o nic g o n a d otr o pi n ( H C G) test will be perf or me d o n all fe m ales of c hil d- be ari n g p ote nti al at Visit 1. Uri ne pre g n a nc y tests are t o be perf or me d at Visits 2 -7. ”t o “ A ser u m h u m a n c h ori o nic g o n a d otr o pi n
94,page_94,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 5 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 ( H C G) test will be perf or me d o n all fe m ales of c hil d -be ari n g p ote nti al at Visit 1. Uri ne pre g n a nc y tests are t o be perf or me d at Visits 2 - 7, as a n alter n ati ve, a ser u m pre g n a nc y test c a n be perf or me d at Visits 2 -7 if re q uire d b y site or et hics b o ar d . ” R ati o n ale f or c h a n ge Cl arific ati o n t h at a ser u m pre g n a nc y test c a n be perf or me d at Visits 2 -7 if re q uire d . Secti o n t o be c h a n ge d 6. 1 Descri pti o n of c h a n ge Re m o ve d “s ” i n w or d “ wee ks ” C orrecte d t y p o t o l oc al fr o m ce ntr al re g ar di n g l a b or at or y. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. O nl y l oc al l a b or at or y is bei n g use d. Secti o n t o be c h a n ge d 6. 2. 1 Descri pti o n of c h a n ge Visit 0 ore m o ve d “ d ” fr o m a n d u n der first b ullet oc h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs Visit 1 ob ullet 1 4, re pl ace d w or d “ C o nst a nt ” wit h “ I ncre me nt al a n d pr actice ” oc h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs R ati o n ale f or c h a n ge C orrecte d t y p o. T o be c o nsiste nt wit h t he fl o wc h art a n d t o cl arif y w he n t he i ncre me nt al a n d pr actice tests are perf or me d. U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 7. 1 Descri pti o n of c h a n ge C h a n ge d 1 8 m o nt hs t o 3 0 m o nt hs. R ati o n ale f or c h a n ge U p d ate d fr o m 1 8 m o nt hs t o 3 0 m o nt hs t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 7. 3 Descri pti o n of c h a n ge C h a n ge d: “ T he effic ac y will be c o n d ucte d o n t he R a n d o mize d Set. F or effic ac y a n al ysis, all me as ure me nt sperf or me d wit hi n t he first 3 0 wee ks will be use d. ” t o “T he effic ac y will be c o n d ucte d o n t he R a n d o mize d Set. F or effic ac y a n al ysis, all"
95,page_95,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 6 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 me as ure me nt sperf or me d wit hi n visits 2 -7 will be use d. ” R ati o n ale f or c h a n ge U p d ate d t o s pecif y tre at me nt peri o d. Secti o n t o be c h a n ge d 8. 7 Descri pti o n of c h a n ge C h a n ge d “ Tri al Cli nic al M o nit or ” t o Cli nic al Tri al Le a der ” C h a n ge d “ L oc al Cli nic al M o nit or ( C M L) ” t o Cli nic al Tri al M a n a ger ( C T M) ” R ati o n ale f or c h a n ge A d mi nistr ati ve Secti o n t o be c h a n ge d 1 0. 1 Descri pti o n of c h a n ge C h a n ge d: “ T o s u p ple me nt t he i nf or m ati o n o n t he Si x Mi n ute W al k Test descri be d i n t his secti o n, a M a n u al of pr oce d ures a n d i nstr ucti o n al vi de o h as bee n de vel o pe d. M ore det aile d i nf or m ati o n o n t he pr oce d ure, o n st affi n g, site a n d e q ui p me nt re q uire me nts, p atie nt pre p ar ati o n, I C me as ure me nts, a n d c alc ul ati o ns etc. c a n be f o u n d i n t his M a n u al, w hic h is file d i n t he I S F. t o “ T o s u p ple me nt t he i nf or m ati o n o n t he Si x Mi n ute W al k Test descri be d i n t his secti o n, i nstr ucti o ns a n d a n i nstr ucti o n al vi de o h as bee n de vel o pe d. M ore det aile d i nf or m ati o n o n t he pr oce d ure, o n st affi n g, site a n d e q ui p me nt re q uire me nts, p atie nt pre p ar ati o n, I C me as ure me nts, a n d c alc ul ati o ns etc. c a n be f o u n d i n t he i nstr ucti o ns, w hic h is file d i n t he I S F. ” R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ges. Secti o n t o be c h a n ge d 1 0. 1. 1 Descri pti o n of c h a n ge A d de d c ol o ns t hr o u g h o ut t o f or m at. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 1 0. 1. 2 Descri pti o n of c h a n ge C h a n ge d/ re m o ve d w or d “ m a n u al ” t o “i nstr ucti o ns ” t hr o u g h o ut secti o n. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge t o be i n li ne wit h t he w a y s u p p orti n g d oc u me nts are n a me d i n t he I S F. Secti o n t o be c h a n ge d 1 0. 1. 3"
96,page_96,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 7 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Descri pti o n of c h a n ge After fi g ure 1 0. 1. 3: 1, m ai n b ullet 4 – re m o ve d “ d ” pri or t o t he w or d “ d ys p ne a ”.  R ati o n ale f or c h a n ge Secti o n t o be c h a n ge d 1 0. 3 Descri pti o n of c h a n ge T he S T. G E O R G E’ S R E S PI R A T O R Y Q U E S TI O N N AI R E ( S G R Q) w as u p d ate d t o reflect t he m ost c urre nt versi o n. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 1 0. 5 Descri pti o n of c h a n ge T he Ki n g’s Brief I L D Q uesti o n n aire ( K -BI L D) w as u p d ate d t o reflect t he m ost c urre nt versi o n. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 1 0. 7 Descri pti o n of c h a n ge U p d ate d t o all o w use of hist oric d at a as per i ncl usi o n criteri o n 6 a n d c orrecti o n of t y p o gr a p hic al err or i n visit n u m ber. R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge."
97,page_97,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 8 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 1 1. 2 G L O B A L A M E N D M E N T 2 D ate of a m e n d me nt 1 6 Dec 2 0 1 9 E u dr a C T n u m ber E U n u m ber N ot a p plic a ble BI Tri al n u m ber 1 1 9 9- 0 3 2 4 BI I n vesti g ati o n al Pr o d uct(s) ni nte d a ni b Title of pr ot oc ol St u d y of P ul m o n ar y Re h a bilit ati o n I n Ni nte d a ni b Tre ate d P atie nts wit h I P F: I m pr o ve me nts i n Acti vit y, E xercise E n d ur a nce Ti me, a n d Q o L T o be i m ple me nte d o nl y after a p pr o v al of t he I R B / I E C / C o m pete nt A ut h orities X T o be i m ple me nte d i m me di atel y i n or der t o eli mi n ate h az ar d – I R B / I E C / C o m pete nt A ut h orit y t o be n otifie d of c h a n ge wit h re q uest f or a p pr o v al C a n be i m ple me nte d wit h o ut I R B / I E C / C o m pete nt A ut h orit y a p pr o v al as c h a n ges i n v ol ve l o gistic al or a d mi nistr ati ve as pects o nl y Secti o n t o be c h a n ge d Title P a ge Descri pti o n of c h a n ge U p d ate d t he f oll o wi n g: Versi o n D ate of Pr ot oc ol St at us R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ges Secti o n t o be c h a n ge d Cli nic al Tri al Pr ot oc ol S y n o psis Descri pti o n of c h a n ge U p d ate d t he f oll o wi n g: Re visi o n D ate C h a n ge d Incl usi o n C riteri a fr o m “ O n st a ble d ose of ni nte d a ni b f or u p t o 3 0 m o nt hs ” t o “ Tre ate d o n a st a ble d ose of ni nte d a ni b f or u p t o 3 0 m o nt hs .P atie nts w h o h a ve rece ntl y st arte d ni nte d a ni b 1 5 0 m g BI D a n d h a ve st arte d b y t he d a y of r a n d o miz ati o n m ust be o n ni nte d a ni b 1 5 0 m g BI D a mi ni m u m of 1 0 d a ys b y t he first d a y of p ul m o n ar y re h a bilit ati o n. ” C h a n ge d I ncl usi o n Criteri a F orce d Vit al C a p acit y ( F V C) fr o m ≥ 5 0 % of pre dicte d t o ≥ 4 5 % of pre dicte d C h a n ge d E xcl usi o n Criteri a fr o m “ P artici p ati o n i n a p ul m o n ar y re h a bilit ati o n pr o gr a m c o m plete d i n t he p ast 3 m o nt hs ” t o “ Pre vi o us"
98,page_98,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 9 9 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 p artici p ati o n i n p ul m o n ar y re h a bilit ati o n pr o gr a m wit hi n 4 5 d a ys pri or t o si g ni n g i nf or me d c o nse nt A d de d s u b b ullet p oi nt st o sec o n d ar y en d p oi nt b ullet # 3t o be c o nsiste nt wit h secti o n 5. 1. 1. 2 . R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ges. U p d ate t he I ncl usi o n a n d E xcl usi o n Criteri a t o f urt her i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d Fl o wc h art Descri pti o n of c h a n ge  U p d ate d F o ot n ote 6 t o “ 6 wee ks ” fr o m “ 4 wee ks ” R ati o n ale f or c h a n ge T o pr o vi de m ore cl arific ati o n as t o w he n i ncre me nt al c ycle er g o metr y will be c o n d ucte d. T o i ncre ase t he wi n d o w t o sc he d ule P R. Secti o n t o be c h a n ge d 1. 4 Descri pti o n of c h a n ge C h a n ge d “ n ot less t h a n t hree ” t o “ u p t o t hirt y ” A d de d “ g astr oi ntesti n al perf or ati o n ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities; t o ali g n wit h c urre nt A E SIs i n t he pr o gr a m. Secti o n t o be c h a n ge d 2. 1. 1 Descri pti o n of c h a n ge C h a n ge d “f or 3 -3 0 m os ” t o “ f or u p t o 3 0 m os ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 1 Descri pti o n of c h a n ge C h a n ge d “c urre ntl y t a ki n g ni nte d a ni b at a d ose of 1 5 0 m g bi d f or n ot less t h a n 3 m o nt hs or m o re t h a n 3 0 m o nt hs ” t o “ tre ate d wit h
99,page_99,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 0 0 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 ni nte d a ni b at a d ose of 1 5 0 m g bi d f or u p t o 3 0 m o nt hs. ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 2 Descri pti o n of c h a n ge U p d ate d w or di n g fr o m “ T he c o h ort i n t his st u d y is p atie nts t h at are o n a st a ble t her a p y wit h ni nte d a ni b f or 3 -3 0 m o nt hs. ” t o “ T he c o h ort i n t his st u d y is p atie nts t h at are tre ate d wit h ni nte d a ni b f or u p t o 3 0 m o nt hs. ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 3. 1 Descri pti o n of c h a n ge C h a n ge d “ bet wee n 3 a n d 3 0 m o nt hs ” t o “ u p t o 3 0 m o nt hs ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 3. 3. 2 Descri pti o n of c h a n ge C h a n ge d “ C urre ntl y t a ki n g ni nte d a ni b 1 5 0 m g BI D, at a st a ble d ose f or 3 -3 0 m o nt hs ” t o “ P atie nts bei n g tre ate d wit h a st a ble d ose of ni nte d a ni b 1 5 0 m g BI D f or u p t o 3 0 m o nt hs. P atie nts w h o h a ve rece ntl y st arte d ni nte d a ni b 1 5 0 m g BI D a n d h a ve st arte d b y t he d a y of r a n d o miz ati o n m ust be o n ni nte d a ni b 1 5 0 m g BI D a mi ni m u m of 1 0 d a ys b y t he f irst d a y of p ul m o n ar y re h a bilit ati o n. ” Re m o ve d f o ot n ote 2. C h a n ge d “ F V C fr o m ≥ 5 0 % of pre dicte d ” t o “ ≥ 4 5 % of pre dicte d ” C h a n ge “ P h ysic all y c a p a ble of perf or mi n g b ot h a 6 mi n ute w al k test m ust s uccessf ull y c o m plete t he pr actice tests f or b ot h, per t he i nstr ucti o ns. P ote nti al s u b -st u d y p atie nts t h at re q uire s u p ple me nt al o x y ge n or c a n n ot c o m plete t he i ncre me nt al or pr actice w or k r ate c ycle er g o metr y test will n ot p artici p ate i n t he s u b -st u d y, b ut will q u alif y f or t he m ai n st u d y. ” t o "" P h ysic all y c a p a ble of perf or mi n g b ot h a 6 mi n ute w al k test a n d w or k r ate c ycle er g o metr y (s u b -"
100,page_100,"B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 0 1 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 st u d y p atie nts), m ust s uccessf ull y c o m p lete t he pr actice tests f or t he 6 mi n ute w al k test , per t he i nstr ucti o ns. P ote nti al s u b -st u d y p atie nts t h at re q uire s u p ple me nt al o x y ge n or c a n n ot c o m p lete t he i ncre me nt al w or k r ate c ycle er g o metr y test will n ot p artici p ate i n t he s u b -st u d y, b ut will q u alif y f or t he m ai n st u d y. ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 3. 3. 3 Descri pti o n of c h a n ge C h a n ge d “ P artici p ati o n i n a p ul m o n ar y re h a bilit ati o n pr o gr a m c o m plete d i n t he p ast 3 m o nt hs. ” t o “ Pre vi o us p artici p ati o n i n p ul m o n ar y re h a bilit ati o n pr o gr a m wit hi n 4 5 d a ys pri or t o si g ni n g c o nse nt . ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 4. 1. 2 Descri pti o n of c h a n ge C h a n ge d “ f or 3 t o 3 0 m o nt hs ” t o “ f or u p t o 3 0 m o nt hs t o q u alif y f or t he tri al a n d t o c o nti n ue o n ni nte d a ni b f or t he d ur ati o n of t he tri al. P atie nts w h o h a ve rece ntl y st arte d ni nte d a ni b 1 5 0 m g BI D a n d h a ve st arte d b y t he d a y of r a n d o miz ati o n m ust be o n ni nte d a ni b 1 5 0 m g BI D a mi ni m u m of 1 0 d a ys b y t he first d a y of p ul m o n ar y re h a bilit ati o n. ” A d de d “ Te m p or ar y ” i n fr o nt of d ose . R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 4. 1. 4 Descri pti o n of c h a n ge C h a n ge d “ S u bj ects are re q uire d t o be o n a st a ble ( 3 t o 3 0 m o nt hs) d ose of ni nte d a ni b 1 5 0 m g BI D, a d mi nistere d per prescri bi n g i nstr ucti o ns ( R 1 8 -1 2 8 9), t o e nter t he tri al a n d t o c o nti n ue o n t his d ose t hr o u g h o ut t he tri al. ” t o “ S u bjects are re q uire d t o be tre ate d o n a st a ble ( u p t o 3 0 m o nt hs) d ose of ni nte d a ni b 1 5 0 m g BI D, a d mi nistere d per prescri bi n g i nstr ucti o ns ( R 1 8 -1 2 8 9), t o e nter t he tri al a n d t o c o nti n ue o n t his d ose t hr o u g h o ut t he tri al. P atie nts w h o"
101,page_101,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 0 2 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 h a ve rece ntl y st arte d ni nte d a ni b 1 5 0 m g BI D a n d h a ve st arte d b y t he d a y of r a n d o miz ati o n m ust be o n ni nte d a ni b 1 5 0 m g BI D a mi ni m u m of 1 0 d a ys b y t he first d a y of p ul m o n ar y re h a bilit ati o n. ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 5. 1. 2. 5 Descri pti o n of c h a n ge R ati o n ale f or c h a n ge A d mi nistr ati ve c h a n ge. Secti o n t o be c h a n ge d 5. 2. 6. 1 Descri pti o n of c h a n ge A d de d G astr oi ntesti n al perf or ati o n R ati o n ale f or c h a n ge T o ali g n wit h pr o gr a m A E SIs Secti o n t o be c h a n ge d 5. 2. 6. 2
102,page_102,B oe hri n ger I n gel hei m 1 6 Dec 2 0 1 9 BI Tri al N o.: 1 1 9 9- 0 3 2 4 c 1 9 5 5 8 8 0 8 - 0 6 Cli nic al Tri al Pr ot oc ol P a ge 1 0 3 of 1 0 3 Pr o prietar y c o nfi de ntial i nf or mati o n © 2 0 1 9 B oe hri n ger I n gel hei m I nter nati o nal G m b H or o ne or m ore of its affiliate d c o m pa nies 0 0 1- M C S - 4 0- 1 0 6- R D - 0 3 ( 1 4 . 0) / Sa ve d o n: 1 7 Oct o ber 2 0 1 6 Descri pti o n of c h a n ge C h a n ge d “f a x ” t o “s u b mit ” R ati o n ale f or c h a n ge A d mi nistr ati ve Secti o n t o be c h a n ge d 6. 2. 1 Descri pti o n of c h a n ge C h a n ge d Visit 0 a n d Vi sit 1 t o reflect u p d ate t o I N C 1 - “f or u p t o 3 0 m o nt hs ” a n d a d de d “ P atie nts w h o h a ve rece ntl y st arte d ni nte d a ni b 1 5 0 m g BI D a n d h a ve st arte d b y t he d a y of r a n d o miz ati o n m ust be o n ni nte d a ni b 1 5 0 m g BI D a mi ni m u m of 1 0 d a ys b y t he first d a y of p ul m o n ar y re h a bilit ati o n. ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 6. 2. 2 Descri pti o n of c h a n ge U p d ate “ 4 wee ks ” t o “ 6 wee ks ” R ati o n ale f or c h a n ge T o i ncre ase t he wi n d o w t o sc he d ule P R. Secti o n t o be c h a n ge d 7. 1 Descri pti o n of c h a n ge U p d ate d “ c urre ntl y t a ki n g ni nte d a ni b at a d ose of 1 5 0 m g bi d f or n ot less t h a n 3 m o nt hs or m o re t h a n 3 0 m o nt hs ” t o “ c urre ntl y tre ate d wit h ni nte d a ni b at a d ose of 1 5 0 m g bi d f or u p t o 3 0 m o nt hs ” R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities. Secti o n t o be c h a n ge d 1 0. 7 Descri pti o n of c h a n ge U p d ate d F V C t o 4 5 % R ati o n ale f or c h a n ge U p d ate d t o i m pr o ve recr uiti n g o p p ort u nities
103,page_103,"A P P R O V A L / SI G N A T U R E P A G E D oc u me nt N u m b er: Tec h nic al Versi o n N u m ber: D oc u me nt N a me: Title: Si g n at ures ( o bt ai ne d electr o nic all y) Me a ni n g of Si g n at ure Si g n e d b y D ate Si g ne d c 1 9 5 5 8 8 0 8 6. 0 cli nical-trial- pr ot oc ol- versi o n- 3. 0 St u d y of P ul m o nar y Re ha bilitati o n I n Ni nte da ni b Treate d Patie nts wit h I P F: I m pr o ve me nts i n Acti vit y, E xercise E n d ura nce Ti me, a n d Q o L A ut h or- Cli nical Trial Lea der 1 6 Dec 2 0 1 9 1 5: 3 0 C E T A ut h or- Trial Statisticia n 1 6 Dec 2 0 1 9 1 6: 4 2 C E T A p pr o val- Me dical 1 6 Dec 2 0 1 9 2 3: 1 0 C E T A p pr o val- T hera pe utic Area 1 6 Dec 2 0 1 9 2 3: 2 0 C E T A p pr o val- Tea m Me m ber Me dici ne 1 8 Dec 2 0 1 9 1 4: 0 2 C E T Verificati o n- Pa per Si g nat ure C o m pleti o n 1 8 Dec 2 0 1 9 1 4: 1 0 C E T"
104,page_104,B oe hri n ger I n gel h ei m P a ge 2 of 2 D oc u me nt N u m b er: Tec h nic al Versi o n N u m ber : ( C o nti n u e d) Si g n at ures ( o bt ai n e d electr o nic all y) Me a ni n g of Si g n at ure Si g ne d b y D ate Si g ne d c 1 9 5 5 8 8 0 8 6. 0
